<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD001257.pub2" GROUP_ID="SCHIZ" ID="913699072314500817" MERGED_FROM="" MODIFIED="2011-10-05 16:50:42 +0200" MODIFIED_BY="Claire Irving" NOTES="&lt;p&gt;Exported from Review Manager 4.2.7&lt;/p&gt;&lt;p&gt;&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2009-11-11 14:16:34 +0000" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="003" REVMAN_SUB_VERSION="5.0.22" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="11.0">
<COVER_SHEET MODIFIED="2011-10-05 16:50:42 +0200" MODIFIED_BY="Claire Irving">
<TITLE>Polyunsaturated fatty acid supplementation for schizophrenia</TITLE>
<CONTACT MODIFIED="2011-10-05 16:50:42 +0200" MODIFIED_BY="Claire Irving"><PERSON ID="7716" ROLE="AUTHOR"><PREFIX>Mrs</PREFIX><FIRST_NAME>Claire</FIRST_NAME><MIDDLE_INITIALS>B</MIDDLE_INITIALS><LAST_NAME>Irving</LAST_NAME><POSITION>Managing Editor</POSITION><EMAIL_1>Claire.Irving@nottingham.ac.uk</EMAIL_1><EMAIL_2>claireirving@btinternet.com</EMAIL_2><ADDRESS><DEPARTMENT>Cochrane Schizophrenia Group</DEPARTMENT><ORGANISATION>The University of Nottingham</ORGANISATION><ADDRESS_1>Institute of Mental Health, Sir Colin Campbell Building</ADDRESS_1><ADDRESS_2>University of Nottingham Innovation Park, Triumph Road</ADDRESS_2><CITY>Nottingham</CITY><ZIP>NG7 2TU</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 755 719 7471</PHONE_1><FAX_1>+44 115 823 1392</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2011-10-05 16:50:42 +0200" MODIFIED_BY="Claire Irving"><PERSON ID="7716" ROLE="AUTHOR"><PREFIX>Mrs</PREFIX><FIRST_NAME>Claire</FIRST_NAME><MIDDLE_INITIALS>B</MIDDLE_INITIALS><LAST_NAME>Irving</LAST_NAME><POSITION>Managing Editor</POSITION><EMAIL_1>Claire.Irving@nottingham.ac.uk</EMAIL_1><EMAIL_2>claireirving@btinternet.com</EMAIL_2><ADDRESS><DEPARTMENT>Cochrane Schizophrenia Group</DEPARTMENT><ORGANISATION>The University of Nottingham</ORGANISATION><ADDRESS_1>Institute of Mental Health, Sir Colin Campbell Building</ADDRESS_1><ADDRESS_2>University of Nottingham Innovation Park, Triumph Road</ADDRESS_2><CITY>Nottingham</CITY><ZIP>NG7 2TU</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 755 719 7471</PHONE_1><FAX_1>+44 115 823 1392</FAX_1></ADDRESS></PERSON><PERSON ID="1185207882E26AA201DC7B3ED0E7591D" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>Roger</FIRST_NAME><LAST_NAME>Mumby-Croft</LAST_NAME><POSITION>Lecturer</POSITION><EMAIL_1>Roger.Mumby-Croft@wbs.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Westminster College</DEPARTMENT><ORGANISATION/><ADDRESS_1>62 Harpes Road</ADDRESS_1><CITY>Oxford</CITY><ZIP>OX2 7QL</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 1865 485740</PHONE_1></ADDRESS></PERSON><PERSON ID="1185093782E26AA201DC7B3E8142B6D3" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>L A</FIRST_NAME><LAST_NAME>Joy</LAST_NAME><EMAIL_1>tony.joy@tesco.net</EMAIL_1><ADDRESS><ORGANISATION/><ADDRESS_1>Puckmill Barn</ADDRESS_1><CITY>Frampton Mansell</CITY><ZIP>GL5 6SX</ZIP><REGION>Gloucestershire</REGION><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2009-02-23 10:39:49 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Minor update: 24/05/06&lt;/p&gt;&lt;p&gt;New studies found and included or excluded: 12/11/05&lt;/p&gt;&lt;p&gt;Conclusions changed: 13/01/03&lt;/p&gt;&lt;p&gt;Reformatted: 10/09/99&lt;/p&gt;" NOTES_MODIFIED="2009-02-23 10:39:49 +0000" NOTES_MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="12" MONTH="2" YEAR="2009"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="8" MONTH="11" YEAR="2008"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="13" MONTH="5" YEAR="2010"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="1998"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="1999"/>
<LAST_CITATION_ISSUE ISSUE="3" YEAR="2006"/>
</DATES>
<WHATS_NEW MODIFIED="2011-10-05 16:50:42 +0200" MODIFIED_BY="Claire Irving" NOTES="&lt;p&gt;Update 2002&lt;br&gt;New title to reflect more specific classification of EFAs.&lt;br&gt;New search of databases carried out in July 2002.&lt;br&gt;New studies added to both excluded and included studies tables.&lt;br&gt;Clarification of types of EFA's and their specific components.&lt;br&gt;Reclassification of comparison and data tables.&lt;br&gt;New outcomes added.&lt;br&gt;New results.&lt;br&gt;Rewording of text to accomodate new data.&lt;br&gt;&lt;br&gt;Update 2005&lt;br&gt;Claire Joy new email address.&lt;br&gt;New search of CSG database in 2005.&lt;br&gt;New study (Emsley 2002) added to included studies table.&lt;br&gt;New data from this trial added (leaving study early and skewed PANSS data).&lt;br&gt;Rewording of text to accomodate new trial and data.&lt;br&gt;New references for Fenton trial.&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2009-11-11 14:16:34 +0000" NOTES_MODIFIED_BY="[Empty name]"><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2011-10-05 16:50:42 +0200" MODIFIED_BY="Claire Irving"><DATE DAY="5" MONTH="10" YEAR="2011"/><DESCRIPTION><P>Contact details updated.</P></DESCRIPTION></WHATS_NEW_ENTRY>


</WHATS_NEW>
<HISTORY MODIFIED="2011-10-05 16:50:42 +0200" MODIFIED_BY="Claire Irving"><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2011-10-05 16:50:42 +0200" MODIFIED_BY="Claire Irving"><DATE DAY="4" MONTH="8" YEAR="2010"/><DESCRIPTION><P>Contact details updated.</P></DESCRIPTION></WHATS_NEW_ENTRY><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-08-04 16:20:10 +0200" MODIFIED_BY="Claire Irving">
<DATE DAY="11" MONTH="11" YEAR="2009"/>
<DESCRIPTION>
<P>Plain language summary revised</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY><WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2010-08-04 16:20:10 +0200" MODIFIED_BY="Claire Irving">
<DATE DAY="23" MONTH="2" YEAR="2009"/>
<DESCRIPTION>
<P>New search carried out and two new included studies added.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-02-23 10:40:03 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="23" MONTH="4" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="24" MONTH="5" YEAR="2006"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Cochrane Schizophrenia Group General Fund</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>School of Business, Oxford Brookes University</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2009-11-11 14:15:24 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2009-11-11 14:15:24 +0000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2009-02-10 11:25:46 +0000" MODIFIED_BY="[Empty name]">Polyunsaturated fatty acid supplementation for schizophrenia</TITLE>
<SUMMARY_BODY MODIFIED="2009-11-11 14:15:24 +0000" MODIFIED_BY="[Empty name]">
<P>Schizophrenia is a serious mental health problem that affects about one percent of any population. For some people it can become an illness that they have to live with for their entire life. Early research has suggested that supplementing the diet with omega 3 or omega 6 fatty acids may have a positive effect on the symptoms of schizophrenia. This review looks at randomised control trials where omega 3 or omega 6 were used in combination with antipsychotic medication, or as a treatment in their own right for schizophrenia. Eight studies were found which included a total of 517 people who had a diagnosis of schizophrenia or schizoaffective disorder (combined symptoms of schizophrenia and a mood disorder). They ranged from six to 16 weeks in length and were in both hospital and community settings.</P>
<P>The majority of the trials compared two different types of omega 3 fatty acids, EPA (usually as E-EPA) and DHA with placebo, in people with schizophrenia who are stable on antipsychotic medication. Some of these trials show some improvement in general functioning and in mental state but not to a statistically significant degree. In the longest trial there was no difference between the two groups at the end of the study.  One trial compared E-EPA with DHA and found a suggestion that E-EPA works better than DHA, but again it was not statistically significant.  Where EPA was compared to placebo as a first line treatment for schizophrenia (30 people), those taking EPA had a better overall outcome and improvement in mental state.  However, this was a short trial with few people. Finally, one trial compared a type of omega 6 with placebo in men who had the movement disorder tardive dykinesia (16 people). There was no improvement in the symptoms of movement adverse effects in either group at the end of six weeks.       </P>
<P>These trials were both small and short.  In addition most of the data they reported were not able to be used, and half of the trials were funded by the group supplying the trial medication. Therefore it is still not clear whether taking manufactured omega 3 or 6 improves overall functioning or mental state in people with schizophrenia.</P>
<P>(Plain language summary prepared for this review by Janey Antoniou of RETHINK, UK <A HREF="http://www.rethink.org">www.rethink.org</A>)</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2009-05-11 14:23:07 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2009-02-18 13:36:13 +0000" MODIFIED_BY="[Empty name]">
<P>Limited evidence supports a hypothesis suggesting that the symptoms of schizophrenia may be the result of altered neuronal membrane structure and metabolism. The structure and metabolism is dependent on blood plasma levels of certain essential fatty acids and their metabolites.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2009-01-14 11:40:55 +0000" MODIFIED_BY="[Empty name]">
<P>To assess the effects of polyunsaturated fatty acids for people with schizophrenia.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2009-05-06 13:23:08 +0100" MODIFIED_BY="[Empty name]">
<P>We have updated the initial searches of 1998, 2002 and 2005 with a search of the Cochrane Schizophrenia Group's Register, November 2008, which is based on regular searches of CINAHL, EMBASE, MEDLINE and PsycINFO.</P>
<P>Where necessary, we contacted authors and relevant pharmaceutical companies for additional information.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2009-02-23 10:43:10 +0000" MODIFIED_BY="[Empty name]">
<P>We included all randomised controlled trials of polyunsaturated fatty acid treatment for schizophrenia.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2009-05-06 13:23:38 +0100" MODIFIED_BY="[Empty name]">
<P>Working independently, we selected studies for quality assessment and extracted relevant data. We analysed on an intention-to-treat basis. Where possible and appropriate we calculated the Relative Risk (RR) and their 95% confidence intervals (CI) and estimated the number needed to treat (NNT). For continuous data we calculated weighted mean differences (WMD) and their 95% confidence intervals. We also inspected the data for heterogeneity.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2009-05-11 14:23:07 +0100" MODIFIED_BY="[Empty name]">
<P>Eight studies are now included in this review. When any dose omega-3 (E-EPA or EPA) is compared with placebo, small short trials suggest that the need for neuroleptics appears to be reduced for people allocated omega-3 supplementation (n=30, 1 RCT, RR 0.73 CI 0.54 to 1.00) and mental state may improve (n=30, 1 RCT, RR not gaining 25% change in PANSS scores 0.54 CI 0.30 to 0.96, NNT 3 CI 2 to 29). There are no differences in the number of people leaving the study early (n=595, 6 RCTs, RR 0.86 CI 0.50 to 1.48). There are few data on the comparison of any dose omega-6 (GLA) with placebo. For movement disorder outcomes, the one small study we found does not show any difference for average short-term endpoint AIMS score (n=16, 1 RCT, WMD 1.30 CI -1.96 to 4.56). When any dose omega-3 (E-EPA or EPA) is compared with any dose omega-3 (DHA) there is no significant difference for mental state outcome of not gaining 25% change in PANSS scores (n=31, 1 RCT, RR 0.66 CI 0.39 to 1.11). When different doses of omega-3 (E-EPA) are compared with placebo there are no differences in measures of global and mental state between the studies. For the outcome of 'experiencing at least one adverse effect' no differences between groups are found for any dose (1 g/day E-EPA vs placebo n=63, 1 RCT, RR 0.97 CI 0.60 to 1.56; 2 g/day E-EPA vs placebo n=63, 1 RCT, RR 0.67 CI 0.37 to 1.20; 4 g/day E-EPA vs placebo n=58, 1 RCT, RR 1.15 CI 0.72 to 1.82).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2009-02-23 10:45:48 +0000" MODIFIED_BY="[Empty name]">
<P>Three updates of this review have resulted in more included studies and more people randomised but still relatively little useful additional data. The results remain inconclusive. The new trials all compare the omega-3 polyunsaturated fatty acids, in particular eicosapentaenoic acid and its ester, ethyl-eicosapentaenoic acid. The use of omega-3 polyunsaturated fatty acids for schizophrenia still remains experimental and this review highlights the need for large, well designed, conducted and reported studies.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2009-05-11 14:39:01 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2009-05-06 13:35:53 +0100" MODIFIED_BY="[Empty name]">
<P>
<BR/>
</P>
<CONDITION MODIFIED="2009-02-23 10:56:02 +0000" MODIFIED_BY="[Empty name]">
<P>Currently 45 million people worldwide suffer from schizophrenia (<LINK REF="REF-WHO-1998" TYPE="REFERENCE">WHO 1998</LINK>). The lifetime prevalence for this disabling mental illness is about one per cent, irrespective of race, gender, social class or country of origin (<LINK REF="REF-Jablensky-1992" TYPE="REFERENCE">Jablensky 1992</LINK>).</P>
<P>Abnormal neurotransmission has been found in those who suffer from schizophrenia (<LINK REF="REF-Heresco_x002d_Levy-1998" TYPE="REFERENCE">Heresco-Levy 1998</LINK>). Brain activity is the result of a highly complex transmission of an infinite amount of nervous impulses. Chemicals (neurotransmitters) conduct these impulses between the nerve cells (neurones), and any alteration in this neurotransmission ultimately has far-reaching consequences for brain function.</P>
<P>The mainstay of treatment for schizophrenia has been pharmacological; targeting neurotransmission within the brain. Most of the drugs used block various neurotransmitter sites within the brain. Although these compounds were first formulated in the 1950s, they are still in wide use today, and newer medications are refinements of the 'old generation' of drugs. Many people with schizophrenia have symptoms that are responsive to one or other of these drugs. Response, however, may often be partial, still leaving the sufferer disabled and unwell (<LINK REF="REF-Wiersma-1998" TYPE="REFERENCE">Wiersma 1998</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2009-02-23 11:09:13 +0000" MODIFIED_BY="[Empty name]">
<P>There is now some evidence that dietary influences, particularly levels of essential fatty acids (EFAs), can also affect the occurrence and course of schizophrenia (<LINK REF="REF-Christensen-1998" TYPE="REFERENCE">Christensen 1998</LINK>, <LINK REF="REF-Mellor-1995" TYPE="REFERENCE">Mellor 1995</LINK>, <LINK REF="REF-Mellor-1996" TYPE="REFERENCE">Mellor 1996</LINK>, <LINK REF="STD-Peet-2001a" TYPE="STUDY">Peet 2001a</LINK>, <LINK REF="REF-Puri-1997" TYPE="REFERENCE">Puri 1997</LINK>). Such evidence, albeit limited, gives added support to an innovative hypothesis suggesting that the symptoms of schizophrenia may be the result of altered neuronal membrane structure and metabolism (<LINK REF="REF-Horrobin-1994" TYPE="REFERENCE">Horrobin 1994</LINK>).</P>
<P>There are two types of EFAs, omega-6 and omega-3. Those of the omega-6 type are found in soft margarine and substances such as vegetable oil. The second type, omega-3, is abundant in oily fish such as mackerel and sardines. Other sources of EFAs are manufactured preparations such as fish oil and evening primrose oil capsules.<BR/>
</P>
</INTERVENTION>
<THEORY MODIFIED="2009-05-06 13:35:53 +0100" MODIFIED_BY="[Empty name]">
<P>Neurotransmission is dependent on the structure and metabolism of neurotransmitter sites located in the neuronal membrane. As brain activity is dependent on an immeasurable number of neurotransmissions occurring at neurotransmitter sites, even a slight change in neuronal cell membrane metabolism could profoundly alter brain functioning and promote symptoms such as those seen in schizophrenia (<LINK REF="REF-Horrobin-1994" TYPE="REFERENCE">Horrobin 1994</LINK>).</P>
<P>In turn, neuronal cell membrane structure and metabolism itself is dependent on blood plasma levels of certain essential fatty acids (EFAs) and their hydroxy-metabolites (<LINK REF="REF-Di-Marzo-1992" TYPE="REFERENCE">Di Marzo 1992</LINK>, <LINK REF="REF-Nunez-1993" TYPE="REFERENCE">Nunez 1993</LINK>). EFAs are polyunsaturated fatty acids that are not synthesised by the body and therefore they are only available through diet. Several studies have shown that people with schizophrenia often have low levels of the particular EFAs necessary for normal nerve cell membrane metabolism ( <LINK REF="REF-Glen-1994" TYPE="REFERENCE">Glen 1994</LINK>, <LINK REF="REF-Horrobin-1991" TYPE="REFERENCE">Horrobin 1991</LINK>). Dietary supplementation of these EFAs is possible, and early uncontrolled, open studies suggest such supplementation may have a direct, positive, effect on the symptoms of schizophrenia (<LINK REF="REF-Mellor-1995" TYPE="REFERENCE">Mellor 1995</LINK>, <LINK REF="REF-Mellor-1996" TYPE="REFERENCE">Mellor 1996</LINK>). In addition, if membrane functioning has significant effects upon nerve impulse transmission, EFA supplementation may enhance the efficacy of currently available antipsychotic drugs already known to have a beneficial affect on altered neurotransmission.</P>
</THEORY>
<IMPORTANCE MODIFIED="2009-01-14 11:16:22 +0000" MODIFIED_BY="[Empty name]">
<P>Recently, more trials investigating the effects of EFA supplementation for schizophrenia have been completed. As more data becomes available, hopefully more useful evidence for this relatively simple treatment can be provided.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2009-02-18 13:56:53 +0000" MODIFIED_BY="[Empty name]">
<P>To assess the effects of EFA supplementation of antipsychotic treatment for schizophrenia-like illnesses.</P>
<P>To investigate the evidence for a difference between the effects of omega-3 and omega-6 EFA supplementation of neuroleptic treatment for schizophrenia-like illnesses.</P>
<P>To investigate the effects of pure preparations of EFA such as the omega-3 eicosapentaenoic acid compared with a mixture of EFA's such as the 'fish oil' or 'evening primrose oil' preparations sold over the counter in pharmacies or drug stores.</P>
</OBJECTIVES>
<METHODS MODIFIED="2009-05-06 13:57:02 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2009-02-23 11:18:15 +0000" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2009-02-23 11:13:33 +0000" MODIFIED_BY="[Empty name]">
<P>All relevant randomised controlled trials. We excluded quasi-randomised trials, such as those where allocation is undertaken on surname. If a trial was described as double-blind, but it was implied it had been randomised, we included these trials in a sensitivity analysis.</P>
<P>Randomised cross-over studies will be eligible but only data up to the point of first cross-over because of the instability of the problem behaviours and the likely carry-over effects of all treatments.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>People with schizophrenia or similar chronic mental illnesses, diagnosed by any criteria, irrespective of gender, age or race.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>1. Any type of polyunsaturated fatty acid supplementation of a standard neuroleptic care: any dose. There are two types of relevance.</P>
<P>1.1 Omega-3 EFAs: these include eicosapentaenoic acid (EPA), its ester, ethyl-eicosapentaenoic acid (E-EPA) and docosahexanoic acid (DHA)<BR/>1.2 Omega-6 EFAs: for example, gamma-linolenic acid (GLA).</P>
<P>2. Standard neuroleptic care: the normal level of psychiatric care and medication provided in the area where the trial was conducted.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2009-02-23 11:18:15 +0000" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2009-02-23 11:14:55 +0000" MODIFIED_BY="[Empty name]">
<P>1. Global state<BR/>1.1 Relapse</P>
<P>2. General functioning<BR/>2.1 No clinically important change in general functioning</P>
<P>3. Satisfaction with treatment<BR/>3.1 Leaving the study early - general reason<BR/>3.2 Recipient of care not satisfied with treatment</P>
<P>4. Adverse effects<BR/>4.1 No clinically important general adverse effects</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2009-02-23 11:18:15 +0000" MODIFIED_BY="[Empty name]">
<P>1. Death - suicide and natural causes</P>
<P>2. Global state<BR/>2.1 Time to relapse<BR/>2.2 No clinically important change in global state<BR/>2.3 Not any change in global state<BR/>2.4 Average endpoint global state score<BR/>2.5 Average change in global state scores</P>
<P>3. Service outcomes<BR/>3.1 Hospitalisation<BR/>3.2 Time to hospitalisation</P>
<P>4. Mental state<BR/>4.1 No clinically important change in general mental state<BR/>4.2 Not any change in general mental state<BR/>4.3 Average endpoint general mental state score<BR/>4.4 Average change in general mental state scores<BR/>4.5 No clinically important change in specific symptoms<BR/>4.6 Not any change in specific symptoms<BR/>4.7 Average endpoint specific symptom score<BR/>4.8 Average change in specific symptom scores</P>
<P>5. Satisfaction with treatment<BR/>5.1 Leaving the study early: specific reason<BR/>5.2 Recipient of care not satisfied with treatment<BR/>5.3 Recipient of care average satisfaction score<BR/>5.4 Recipient of care average change in satisfaction scores<BR/>5.6 Carer not satisfied with treatment<BR/>5.7 Carer average satisfaction score<BR/>5.8 Carer average change in satisfaction scores</P>
<P>6. General functioning<BR/>6.1 Average endpoint general functioning score<BR/>6.2 Average change in general functioning scores<BR/>6.3 No clinically important change in specific aspects of functioning, such as social or life skills<BR/>6.4 Not any change in specific aspects of functioning, such as social or life skills<BR/>6.5 Average endpoint specific aspects of functioning, such as social or life skills<BR/>6.6 Average change in specific aspects of functioning, such as social or life skills</P>
<P>7. Behaviour<BR/>7.1 No clinically important change in general behaviour<BR/>7.2 Not any change in general behaviour<BR/>7.3 Average endpoint general behaviour score<BR/>7.4 Average change in general behaviour scores<BR/>7.5 No clinically important change in specific aspects of behaviour<BR/>7.6 Not any change in specific aspects of behaviour<BR/>7.7 Average endpoint specific aspects of behaviour<BR/>7.8 Average change in specific aspects of behaviour</P>
<P>8. Adverse effects<BR/>8.1 Not any general adverse effects<BR/>8.2 Average endpoint general adverse effect score<BR/>8.3 Average change in general adverse effect scores<BR/>8.4 No clinically important change in specific adverse effects<BR/>8.5 Not any change in specific adverse effects<BR/>8.6 Average endpoint specific adverse effects<BR/>8.7 Average change in specific adverse effects</P>
<P>9. Engagement with services<BR/>9.1 No clinically important engagement<BR/>9.2 Not any engagement<BR/>9.3 Average endpoint engagement score<BR/>9.4 Average change in engagement scores</P>
<P>10. Quality of life<BR/>10.1 No clinically important change in quality of life<BR/>10.2 Not any change in quality of life<BR/>10.3 Average endpoint quality of life score<BR/>10.4 Average change in quality of life scores<BR/>10.5 No clinically important change in specific aspects of quality of life<BR/>10.6 Not any change in specific aspects of quality of life<BR/>10.7 Average endpoint specific aspects of quality of life<BR/>10.8 Average change in specific aspects of quality of life</P>
<P>11. Economic outcomes<BR/>11.1 Direct costs<BR/>11.2 Indirect costs</P>
<P>We selected outcome measures which provided global estimations of functioning. We did not report highly specific outcomes, such as 'sense of safety'. Such specific outcomes are rarely reported in more than one study and it is difficult to assess their relevance to the effectiveness of the treatment. We also reported other outcomes not readily falling into these categories but they are not of pre-stated interest.</P>
<P>We divided outcomes into short term (less than three months) medium term (three to six months) and long term (over six months).</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2009-05-06 13:40:41 +0100" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2009-05-06 13:40:41 +0100" MODIFIED_BY="[Empty name]">
<P>1. Update of 2008<BR/>1.1 The Cochrane Schizophrenia Group Trials Register was searched (November 2008): for details of the search phrase see <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>.<BR/>
</P>
<P>2. Previous versions of this review<BR/>2.1 For details of the original search: see <A HREF="01">Appendix 1</A>.</P>
<P>2.2 For details of the searches in previous updates: see <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2009-01-14 12:59:14 +0000" MODIFIED_BY="[Empty name]">
<P>Where necessary, we contacted authors and relevant pharmaceutical companies for any missing information or data.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2009-05-06 13:57:02 +0100" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2009-01-22 13:05:23 +0000" MODIFIED_BY="[Empty name]">
<P>Authors CJ and RMC independently inspected citations identified from the search. We identified potentially relevant reports and ordered full papers for reassessment. Where difficulties or disputes arose we asked author LAJ for help and if it was impossible to decide, those full papers were ordered for assessment. This process was repeated for the full papers. If it was impossible to resolve disagreements these studies were added to those awaiting assessment and the authors of the papers contacted for clarification.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2009-05-06 13:44:03 +0100" MODIFIED_BY="[Empty name]">
<P>1. Extraction<BR/>Authors CJ and RMC independently extracted data from included studies. Again, any disagreement was discussed, decisions documented and, if necessary, authors of studies were contacted for clarification. With remaining problems LAJ helped clarify issues and those final decisions were documented.</P>
<P>2. Management<BR/>Data were extracted onto standard, simple forms.</P>
<P>3. Scale-derived data<BR/>A wide range of instruments are available to measure outcomes in mental health studies. These instruments vary in quality and many are not validated, or are even ad hoc. We included continuous data from rating scales only if the measuring instrument had been described in a peer-reviewed journal (<LINK REF="REF-Marshall-2000" TYPE="REFERENCE">Marshall 2000</LINK>) and the instrument is either a self-report or completed by an independent rater or relative (not the therapist).</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2009-02-23 11:22:54 +0000" MODIFIED_BY="[Empty name]">
<P>Again working independently, CJ and RMC assessed risk of bias using the tool described in the Cochrane Collaboration Handbook (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>). This tool encourages consideration of how the sequence was generated, how allocation was concealed, the integrity of blinding at outcome, the completeness of outcome data, selective reporting and other biases. We would not have included studies where sequence generation was at high risk of bias or where allocation was clearly not concealed.</P>
<P>If disputes arose as to which category a trial has to be allocated, again, resolution was made by discussion, after working with the third reviewer (LAJ).</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2009-02-23 11:24:57 +0000" MODIFIED_BY="[Empty name]">
<P>1. Binary data<BR/>For binary outcomes we calculated a standard estimation of the fixed-effect risk ratio (RR) and its 95% confidence interval (CI). For statistically significant results we calculated the number needed to treat/harm statistic (NNT/H), and its 95% confidence interval (CI) using Visual Rx (<A HREF="http://www.nntonline.net/">http://www.nntonline.net/</A>) taking account of the event rate in the control group.</P>
<P>2. Continuous data<BR/>2.1 Summary statistic<BR/>For continuous outcomes we estimated a fixed-effect weighted mean difference (WMD) between groups. We did not calculate effect size measures.</P>
<P>2.2 Endpoint versus change data<BR/>We preferred to use scale endpoint data, which typically cannot have negative values and is easier to interpret from a clinical point of view. Change data are often not ordinal and are very problematic to interpret. If endpoint data were unavailable, we used change data.</P>
<P>2.3 Skewed data<BR/>Continuous data on clinical and social outcomes are often not normally distributed. To avoid the pitfall of applying parametric tests to non-parametric data, we aimed to apply the following standards to all data before inclusion: (a) standard deviations and means are reported in the paper or obtainable from the authors; (b) when a scale starts from the finite number zero, the standard deviation, when multiplied by two, is less than the mean (as otherwise the mean is unlikely to be an appropriate measure of the centre of the distribution, (<LINK REF="REF-Altman-1996" TYPE="REFERENCE">Altman 1996</LINK>); (c) if a scale starts from a positive value (such as PANSS which can have values from 30 to 210) the calculation described above was modified to take the scale starting point into account. In these cases skew is present if 2SD&gt;(S-S min), where S is the mean score and S min is the minimum score. Endpoint scores on scales often have a finite start and end point and these rules can be applied. When continuous data are presented on a scale which includes a possibility of negative values (such as change data), it is difficult to tell whether data are skewed or not. Skewed data from studies of less than 200 participants were entered in additional tables rather than into an analysis. Skewed data pose less of a problem when looking at means if the sample size is large and were entered into syntheses.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2009-02-23 11:27:01 +0000" MODIFIED_BY="[Empty name]">
<P>1. Cluster trials<BR/>Studies increasingly employ 'cluster randomisation' (such as randomisation by clinician or practice) but analysis and pooling of clustered data poses problems. Firstly, authors often fail to account for intraclass correlation in clustered studies, leading to a 'unit of analysis' error (<LINK REF="REF-Divine-1992" TYPE="REFERENCE">Divine 1992</LINK>) whereby p values are spuriously low, confidence intervals unduly narrow and statistical significance overestimated. This causes type I errors (<LINK REF="REF-Bland-1997" TYPE="REFERENCE">Bland 1997</LINK>, <LINK REF="REF-Gulliford-1999" TYPE="REFERENCE">Gulliford 1999</LINK>).</P>
<P>Where clustering is not accounted for in primary studies, we presented data in a table, with a (*) symbol to indicate the presence of a probable unit of analysis error. In subsequent versions of this review we will seek to contact first authors of studies to obtain the intraclass correlation coefficient of their clustered data and to adjust for this by using accepted methods (<LINK REF="REF-Gulliford-1999" TYPE="REFERENCE">Gulliford 1999</LINK>). Where clustering had been incorporated into the analysis of primary studies, we present these data as if from a non-cluster randomised study, but adjusted for the clustering effect.</P>
<P>We have sought statistical advice and have been advised that the binary data as presented in a report should be divided by a 'design effect'. This is calculated using the mean number of participants per cluster (m) and the intraclass correlation coefficient (ICC) [Design effect = 1+(m-1)*ICC] (<LINK REF="REF-Donner-2002" TYPE="REFERENCE">Donner 2002</LINK>). If the ICC was not reported it was assumed to be 0.1 (<LINK REF="REF-Ukoumunne-1999" TYPE="REFERENCE">Ukoumunne 1999</LINK>).</P>
<P>If cluster studies has been appropriately analysed taking into account the intraclass correlation coefficient and relevant data documented in the report, synthesis with other studies would have been possible using the generic inverse variance technique.</P>
<P>2. Cross-over trials<BR/>A major concern of cross-over trials is the carry-over effect. It occurs if an effect (e.g. pharmacological, physiological or psychological) of the treatment in the first phase is carried over to the second phase. As a consequence on entry to the second phase the participants can differ systematically from their initial state despite a wash-out phase. For the same reason cross-over trials are not appropriate if the condition of interest is unstable (<LINK REF="REF-Elbourne-2002" TYPE="REFERENCE">Elbourne 2002</LINK>). As both effects are very likely in schizophrenia, we will only use data of the first phase of cross-over studies.</P>
<P>3. Studies with multiple treatment groups<BR/>Where a study involved more than two treatment groups, if relevant, the additional treatment arms were presented in comparisons. Where the additional treatment arms were not relevant, these data were not reproduced.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2009-05-06 13:55:58 +0100" MODIFIED_BY="[Empty name]">
<P>1. Overall loss of credibility<BR/>At some degree of loss of follow up data must lose credibility (<LINK REF="REF-Xia-2007" TYPE="REFERENCE">Xia 2007</LINK>). We are forced to make a judgment where this is for the short-term trials likely to be included in this review. Should more than 30% of data be unaccounted for by the first follow up we did not reproduce these data or use them within analyses.</P>
<P>2. Binary<BR/>In the case where attrition for a binary outcome is between 0 and 30% and outcomes of these people are described, we included these data as reported. Where these data were not clearly described, we assumed the worst primary outcome, and rates of adverse effects similar to those who did continue to have their data recorded.</P>
<P>3. Continuous<BR/>In the case where attrition for a continuous outcome is between 0 and 30% and completer-only data were reported, we have reproduced these.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2009-02-23 11:29:49 +0000" MODIFIED_BY="[Empty name]">
<P>1. Clinical heterogeneity<BR/>We considered all included studies without any comparison to judge clinical heterogeneity.</P>
<P>2. Statistical<BR/>2.1 Visual inspection<BR/>We visually inspected graphs to investigate the possibility of statistical heterogeneity.</P>
<P>2.2 Employing the I-squared statistic<BR/>This provided an estimate of the percentage of inconsistency thought to be due to chance. I-squared estimate greater than or equal to 50% was interpreted as evidence of high levels of heterogeneity (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>).</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2009-05-06 13:57:02 +0100" MODIFIED_BY="[Empty name]">
<P>Reporting biases arise when the dissemination of research findings is influenced by the nature and direction of results (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>). These are described in section 10.1 of the Cochrane Handbook for Systematic Reviews of Interventions (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>). We are aware that funnel plots may be useful in investigating reporting biases but are of limited power to detect small-study effects. We did not use funnel plots for outcomes where there were ten or fewer studies, or where all studies were of similar sizes. In other cases, where funnel plots were possible, we sought statistical advice in their interpretation.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2009-02-23 11:31:06 +0000" MODIFIED_BY="[Empty name]">
<P>Where possible we employed a fixed-effect model for analyses. We understand that there is no closed argument for preference for use of fixed or random-effects models. The random-effects method incorporates an assumption that the different studies are estimating different, yet related, intervention effects. This does seem true to us, however, random-effects does put added weight onto the smaller of the studies - those trials that are most vulnerable to bias. For this reason we favour using fixed-effect models employing random-effects only when investigating heterogeneity.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2009-02-23 11:31:54 +0000" MODIFIED_BY="[Empty name]">
<P>If data are clearly heterogeneous we checked that data are correctly extracted and entered and that we had made no unit of analysis errors. If the high levels of heterogeneity remained we did not undertake a meta-analysis at this point for if there is considerable variation in results, and particularly if there is inconsistency in the direction of effect, it may be misleading to quote an average value for the intervention effect. We would have wanted to explore heterogeneity. We pre-specified no characteristics of studies that may be associated with heterogeneity except quality of trial method. If no clear association could be shown by sorting studies by quality of methods a random-effects meta-analysis was performed. Should another characteristic of the studies be highlighted by the investigation of heterogeneity, perhaps some clinical heterogeneity not hitherto predicted but plausible causes of heterogeneity, these post-hoc reasons will be discussed and the data analysed and presented. However, should the heterogeneity be substantially unaffected by use of random-effects meta-analysis and no other reasons for the heterogeneity be clear, the final data were presented without a meta-analysis.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2009-02-18 13:40:57 +0000" MODIFIED_BY="[Empty name]">
<P>If necessary, we analysed the effect of including studies with high attrition rates in a sensitivity analysis. We aimed to include trials in a sensitivity analysis if they are described as 'double-blind' but only implied randomisation. If we found no substantive differences within primary outcome when these high attrition and 'implied randomisation' studies were added to the overall results, we included them in the final analysis. However, if there was a substantive difference we only used clearly randomised trials and those with attrition lower than 30%.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2009-05-11 14:39:01 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2009-05-11 14:39:01 +0100" MODIFIED_BY="[Empty name]">
<P>For substantive descriptions of studies please see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> and <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> tables.</P>
<SEARCH_RESULTS MODIFIED="2009-05-11 14:39:01 +0100" MODIFIED_BY="[Empty name]">
<P>The original search in 1998 produced a list of 16 references. Further inspection of abstracts and collation of references into individual studies reduced the list to seven, of which only two could be included. A new search, using a new electronic search term (see search strategy in <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>), was carried out in 2002; this produced a list of 35 possible new references. From this list, we found eight new studies to add to the review. We eventually excluded four of these, making the total number of excluded studies nine. Three studies were added to the included studies table. The 2005 search found six new references; two were additional references for <LINK REF="STD-Fenton-2001" TYPE="STUDY">Fenton 2001</LINK> - a study already included, and two were not relevant to the review. The final two references were for <LINK REF="STD-Emsley-2002" TYPE="STUDY">Emsley 2002</LINK> a study previously classed as 'ongoing'. Our 2008 update found 151 references from 42 studies, 21 of these references relating to nine studies were relevant to the review. One of these studies (<LINK REF="STD-Peet-2001a" TYPE="STUDY">Peet 2001a</LINK>) was already included in the review, five others (<LINK REF="STD-Bentsen-2007" TYPE="STUDY">Bentsen 2007</LINK>, <LINK REF="STD-Blanchet-2008" TYPE="STUDY">Blanchet 2008</LINK>, <LINK REF="STD-Korbanic-2005" TYPE="STUDY">Korbanic 2005</LINK>, <LINK REF="STD-Murck-2001" TYPE="STUDY">Murck 2001</LINK> and <LINK REF="STD-Richtand-2007" TYPE="STUDY">Richtand 2007</LINK>) are ongoing. One further study (<LINK REF="STD-Amminger-2007" TYPE="STUDY">Amminger 2007</LINK> ) was excluded leaving two new trials (<LINK REF="STD-Berger-2007" TYPE="STUDY">Berger 2007</LINK> and <LINK REF="STD-Emsley-2006" TYPE="STUDY">Emsley 2006</LINK>) for inclusion. This review now includes eight studies.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2009-05-06 14:17:29 +0100" MODIFIED_BY="[Empty name]">
<P>For the 2008 update we included two new studies, <LINK REF="STD-Berger-2007" TYPE="STUDY">Berger 2007</LINK> and <LINK REF="STD-Emsley-2006" TYPE="STUDY">Emsley 2006</LINK>. We now have eight included studies in this review with a total of 517 people randomised (further details can be found in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table).</P>
<P>1. Length of studies<BR/>Study duration ranged from six (<LINK REF="STD-Wolkin-1986" TYPE="STUDY">Wolkin 1986</LINK>) to 16 weeks (<LINK REF="STD-Fenton-2001" TYPE="STUDY">Fenton 2001</LINK>).</P>
<P>2. Setting<BR/>Studies take place in a mixture of hospital and community settings.</P>
<P>3. Participants<BR/>All included studies involved people with DSM-IV schizophrenia although <LINK REF="STD-Wolkin-1986" TYPE="STUDY">Wolkin 1986</LINK> (n=16) does include one person with bipolar affective disorder and does not use any diagnostic criteria. <LINK REF="STD-Fenton-2001" TYPE="STUDY">Fenton 2001</LINK> also includes people with schizo-affective disorder. Most participants are chronically ill, and are still symptomatic despite exposure to antipsychotic drugs. <LINK REF="STD-Peet-2001b" TYPE="STUDY">Peet 2001b</LINK>, however, specifically includes only people who are recently ill and have no previous exposure to neuroleptics. <LINK REF="STD-Berger-2007" TYPE="STUDY">Berger 2007</LINK> also only randomises relatively young people experiencing their first psychotic episode. All participants in <LINK REF="STD-Emsley-2006" TYPE="STUDY">Emsley 2006</LINK> have established neuroleptic induced tardive dyskinesia. All studies are mixed sex apart from <LINK REF="STD-Wolkin-1986" TYPE="STUDY">Wolkin 1986</LINK>. <LINK REF="STD-Wolkin-1986" TYPE="STUDY">Wolkin 1986</LINK> includes men suffering not only from serious mental illness but also neuroleptic-induced mild tardive dyskinesia. <LINK REF="STD-Emsley-2002" TYPE="STUDY">Emsley 2002</LINK> does not state the sex of participants. The overall age range of participants is 18-65 years.</P>
<P>4. Study size<BR/>Overall, sample size is small. <LINK REF="STD-Peet-2002" TYPE="STUDY">Peet 2002</LINK>, the largest study includes 122 people. The size of the other trials ranges from 16 (<LINK REF="STD-Wolkin-1986" TYPE="STUDY">Wolkin 1986</LINK>) to 90 (<LINK REF="STD-Fenton-2001" TYPE="STUDY">Fenton 2001</LINK>).</P>
<P>5. Interventions<BR/>All included studies give people polyunsaturated fatty acids not synthesised by the body. The majority of trials compare EFA supplementation with placebo supplementation and use omega-3 EFAs, either eicosapentaenoic acid (EPA), its ester, ethyl-eicosapentaenoic acid (E-EPA) or docosahexanoic acid (DHA). <LINK REF="STD-Peet-2001a" TYPE="STUDY">Peet 2001a</LINK> also compares EPA supplementation with DHA supplementation. <LINK REF="STD-Wolkin-1986" TYPE="STUDY">Wolkin 1986</LINK> is the only trial to compare an omega-6 EFA, gamma-linolenic acid (GLA) with placebo. <LINK REF="STD-Peet-2001b" TYPE="STUDY">Peet 2001b</LINK> is the only trial not to supplement neuroleptic treatment. In this study participants are allocated eicosapentaenoic acid or placebo as sole treatment unless it becomes necessary to prescribe standard antipsychotic drugs during the trial. Some trials use specific doses of E-EPA supplementation. <LINK REF="STD-Fenton-2001" TYPE="STUDY">Fenton 2001</LINK> compares 2 g/day E-EPA with placebo but also give all participants an additional supplement of Vitamin E. <LINK REF="STD-Peet-2002" TYPE="STUDY">Peet 2002</LINK> compares different doses (1 g/day, 2 g/day or 4 g/day) of E-EPA with placebo. <LINK REF="STD-Berger-2007" TYPE="STUDY">Berger 2007</LINK> and <LINK REF="STD-Emsley-2006" TYPE="STUDY">Emsley 2006</LINK> compare a single dose of 2 g/day E-EPA with placebo while <LINK REF="STD-Emsley-2002" TYPE="STUDY">Emsley 2002</LINK> compares 3 g/day E-EPA with placebo.</P>
<P>6. Outcomes<BR/>6.1 Missing outcomes<BR/>Only four main treatment effects are evaluated: global state; mental state; adverse events and leaving the study early. None of the studies reported on mortality, direct measures of compliance, relapse, patient and carer satisfaction, social functioning or cost of treatment.</P>
<P>6.2 Scales<BR/>Nine rating scales are used to collect scale data, only four of these provide useful, non skewed continuous data - the Positive and Negative Syndrome Scale (PANSS), the Abnormal Involuntary Movement Scale (AIMS), the Simpson and Angus Scale (SAS) and the MADRS. All are validated and peer-reviewed. Scale details are provided below:</P>
<P>6.2.1. Abnormal Involuntary Movement Scale - AIMS (<LINK REF="REF-Guy-1976" TYPE="REFERENCE">Guy 1976</LINK>).<BR/>A 12-item scale designed to record the occurrence of dyskinetic movements. Each item is rated from zero (none) to four (severe). Low score indicates low levels of dyskinetic movements. This scale was used in <LINK REF="STD-Wolkin-1986" TYPE="STUDY">Wolkin 1986</LINK>.</P>
<P>6.2.2 Positive and Negative Syndrome Scale - PANSS (<LINK REF="REF-Kay-1986" TYPE="REFERENCE">Kay 1986</LINK>).<BR/>A brief clinician-rated scale used to assess mental state and severity of psychopathology. There are 30 items, each item is scored on a scale of one (absent) to seven (extreme). The PANSS can be divided into three sub-scales measuring severity of (i) general psychopathology, (ii) positive symptoms (PANSS-P), and (iii) negative symptoms (PANSS-N). A low score indicates low levels of psychopathology. This scale was used in <LINK REF="STD-Peet-2001a" TYPE="STUDY">Peet 2001a</LINK>.</P>
<P>6.2.3 Montgomery Asberg Depression Rating Scale - MADRS (<LINK REF="REF-Montgomery-1979" TYPE="REFERENCE">Montgomery 1979</LINK>)<BR/>A 65-item comprehensive psychopathology scale was used to identify the 17 most commonly occurring symptoms in primary depressive illness. Ratings are based on ten items, with higher scores indicating more symptoms.</P>
<P>6.2.4 Simpson Angus Scale - SAS (<LINK REF="REF-Simpson-1970" TYPE="REFERENCE">Simpson 1970</LINK>)<BR/>This 10-item scale, with a scoring system of zero to four for each item, measures drug-induced parkinsonism, a short-term drug-induced movement disorder. A low score indicates low levels of parkinsonism.</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2009-05-06 14:22:40 +0100" MODIFIED_BY="[Empty name]">
<P>The review now contains ten excluded studies. Only one, <LINK REF="STD-Peet-1996" TYPE="STUDY">Peet 1996</LINK>, was not randomised. <LINK REF="STD-Heresco_x002d_Levy-1996" TYPE="STUDY">Heresco-Levy 1996</LINK>, <LINK REF="STD-Maurer-2002" TYPE="STUDY">Maurer 2002</LINK>, <LINK REF="STD-Silbergeld-1973" TYPE="STUDY">Silbergeld 1973</LINK> and <LINK REF="STD-Vaddadi-1986" TYPE="STUDY">Vaddadi 1986</LINK> are randomised but all use interventions not specifically relevant to this review. <LINK REF="STD-Heresco_x002d_Levy-1996" TYPE="STUDY">Heresco-Levy 1996</LINK> uses glycine (an amino acid) to supplement standard antipsychotic treatments, <LINK REF="STD-Maurer-2002" TYPE="STUDY">Maurer 2002</LINK> compares olanzapine with haloperidol and <LINK REF="STD-Silbergeld-1973" TYPE="STUDY">Silbergeld 1973</LINK> compares dexamethasone with placebo. <LINK REF="STD-Vaddadi-1986" TYPE="STUDY">Vaddadi 1986</LINK> investigates whether depot antipsychotic withdrawal could take place while all study participants took EFA supplementation. <LINK REF="STD-Glen-1996" TYPE="STUDY">Glen 1996</LINK>, <LINK REF="STD-Holman-1983" TYPE="STUDY">Holman 1983</LINK> and <LINK REF="STD-Vaddadi-1989" TYPE="STUDY">Vaddadi 1989</LINK>, are relevant trials of EFA supplementation they do not report any usable data. In addition, <LINK REF="STD-Holman-1983" TYPE="STUDY">Holman 1983</LINK> is not explicit about allocation; it is, however, a double-blind trial. We have contacted the authors of these trials and if the required data is supplied, we will include these trials in a future update. <LINK REF="STD-Amminger-2007" TYPE="STUDY">Amminger 2007</LINK> compares E-EPA with placebo but randomised people at high risk of psychosis. <LINK REF="STD-Puri-2001" TYPE="STUDY">Puri 2001</LINK> does randomise people with schizophrenia but those with Huntington's disease. Details of all excluded trials can be found in the '<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>' table.</P>
<SUBSECTION>
<HEADING LEVEL="4">Awaiting assessment</HEADING>
<P>No studies are awaiting assessment.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Ongoing studies</HEADING>
<P>There are now five ongoing studies in this review (<LINK REF="STD-Bentsen-2007" TYPE="STUDY">Bentsen 2007</LINK>, <LINK REF="STD-Blanchet-2008" TYPE="STUDY">Blanchet 2008</LINK>, <LINK REF="STD-Korbanic-2005" TYPE="STUDY">Korbanic 2005</LINK>, <LINK REF="STD-Murck-2001" TYPE="STUDY">Murck 2001</LINK> and <LINK REF="STD-Richtand-2007" TYPE="STUDY">Richtand 2007</LINK> ).</P>
</SUBSECTION>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2009-02-23 15:54:02 +0000" MODIFIED_BY="[Empty name]">
<P>A summary of risk of bias can be found in <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> and <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>.<BR/>
</P>
<ALLOCATION MODIFIED="2009-02-23 15:27:26 +0000" MODIFIED_BY="[Empty name]">
<P>All studies stated they were randomised but <LINK REF="STD-Emsley-2002" TYPE="STUDY">Emsley 2002</LINK>, <LINK REF="STD-Fenton-2001" TYPE="STUDY">Fenton 2001</LINK> and <LINK REF="STD-Wolkin-1986" TYPE="STUDY">Wolkin 1986</LINK> did not describe the randomisation techniques and we have to classify them as unclear quality with moderate risk of selection bias. <LINK REF="STD-Berger-2007" TYPE="STUDY">Berger 2007</LINK>, <LINK REF="STD-Emsley-2006" TYPE="STUDY">Emsley 2006</LINK>, <LINK REF="STD-Peet-2001a" TYPE="STUDY">Peet 2001a</LINK>, <LINK REF="STD-Peet-2001b" TYPE="STUDY">Peet 2001b</LINK> and <LINK REF="STD-Peet-2002" TYPE="STUDY">Peet 2002</LINK> all describe how allocation is concealed via pre-coded packages, each with a unique randomisation number generated by a company independent to the trial. These trials therefore are classified as clear quality with a low risk of selection bias and low risk of overestimate of positive effect.</P>
</ALLOCATION>
<BLINDING MODIFIED="2009-02-23 15:27:32 +0000" MODIFIED_BY="[Empty name]">
<P>All trials stated that they were double-blind and all but <LINK REF="STD-Emsley-2002" TYPE="STUDY">Emsley 2002</LINK> and <LINK REF="STD-Wolkin-1986" TYPE="STUDY">Wolkin 1986</LINK> described how this was attempted. <LINK REF="STD-Berger-2007" TYPE="STUDY">Berger 2007</LINK>, <LINK REF="STD-Emsley-2006" TYPE="STUDY">Emsley 2006</LINK>, <LINK REF="STD-Fenton-2001" TYPE="STUDY">Fenton 2001</LINK>, <LINK REF="STD-Peet-2001a" TYPE="STUDY">Peet 2001a</LINK>, <LINK REF="STD-Peet-2001b" TYPE="STUDY">Peet 2001b</LINK> and <LINK REF="STD-Peet-2002" TYPE="STUDY">Peet 2002</LINK> used capsules that were identical in both appearance and taste. No trial, however, tested whether their attempts at blinding were successful. We have to rate the risk of observer bias in <LINK REF="STD-Emsley-2002" TYPE="STUDY">Emsley 2002</LINK> and <LINK REF="STD-Wolkin-1986" TYPE="STUDY">Wolkin 1986</LINK> as unclear, which adds to their potential for overestimate of positive effects. The other trials all have a low risk of observer bias.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2009-02-23 15:28:27 +0000" MODIFIED_BY="[Empty name]">
<P>All of the studies that had people leaving early (<LINK REF="STD-Peet-2001a" TYPE="STUDY">Peet 2001a</LINK> and <LINK REF="STD-Peet-2002" TYPE="STUDY">Peet 2002</LINK> had no loss) present data on loss and give descriptions. <LINK REF="STD-Wolkin-1986" TYPE="STUDY">Wolkin 1986</LINK>, however, has 37% loss to follow up for both groups. This is greater than the pre-stated limit of 30% and the data reported in this study for mental state could not be presented in this review as bias could be introduced to the final analysis if only conducted on those completing the study. Of the other five studies that had low attrition rates, one (<LINK REF="STD-Peet-2001b" TYPE="STUDY">Peet 2001b</LINK>) did not describe how they dealt with missing data, three (<LINK REF="STD-Emsley-2002" TYPE="STUDY">Emsley 2002</LINK>; <LINK REF="STD-Emsley-2006" TYPE="STUDY">Emsley 2006</LINK> and <LINK REF="STD-Fenton-2001" TYPE="STUDY">Fenton 2001</LINK>) undertook an 'intention-to-treat' (ITT) analysis and one trial (<LINK REF="STD-Berger-2007" TYPE="STUDY">Berger 2007</LINK>) uses multiple imputation to deal with lost data. Based on this information we assigned most trials a low risk of attrition bias but had to rate <LINK REF="STD-Wolkin-1986" TYPE="STUDY">Wolkin 1986</LINK> as a high risk trial.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2009-03-05 11:39:15 +0000" MODIFIED_BY="[Empty name]">
<P>Compared to the trials used in the first version of this review, the quality of data reporting has fallen. This is mainly due to the larger new trials <LINK REF="STD-Berger-2007" TYPE="STUDY">Berger 2007,</LINK> <LINK REF="STD-Emsley-2006" TYPE="STUDY">Emsley 2006</LINK>, and <LINK REF="STD-Peet-2002" TYPE="STUDY">Peet 2002</LINK> who report more outcomes, and in particular use more scales to collect continuous data but do not present data useful to this review, and for some outcomes no data are presented. These trials had a high risk of selective reporting bias. The other trials present data for all outcomes and for most outcomes the data reporting is above average with use of use valid scales and presentation of variances with mean total scores. </P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2009-02-23 15:54:02 +0000" MODIFIED_BY="[Empty name]">
<P>In half of the trials there is a high risk of other sources of bias, mainly author subjectivity. For four trials (<LINK REF="STD-Peet-2001a" TYPE="STUDY">Peet 2001a</LINK>; <LINK REF="STD-Peet-2001b" TYPE="STUDY">Peet 2001b</LINK>, <LINK REF="STD-Peet-2002" TYPE="STUDY">Peet 2002</LINK> and <LINK REF="STD-Wolkin-1986" TYPE="STUDY">Wolkin 1986</LINK>) funding comes from the drug companies supplying trial medication and in <LINK REF="STD-Peet-2002" TYPE="STUDY">Peet 2002</LINK> one of the main authors, Professor Horrobin, was an employee of the sponsoring drug company at the time of the trial. Another trial with a potential risk of bias is <LINK REF="STD-Berger-2007" TYPE="STUDY">Berger 2007</LINK>. This is a grant sponsored study, the main author however, is a consultant for several pharmaceutical companies. These sources of bias in these trials combined with their tendency to selectively report outcomes gave us reason to judge the risk of bias in the studies to be high, with these authors likely to be overestimating any true positive effect, and underestimating negative effects.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2009-05-11 14:27:26 +0100" MODIFIED_BY="[Empty name]">
<P>1. COMPARISON 1. ANY DOSE OMEGA-3 (E-EPA OR EPA) versus PLACEBO<BR/>1.1 Global State<BR/>
<LINK REF="STD-Peet-2001b" TYPE="STUDY">Peet 2001b</LINK> (short term, up to 12 weeks) and <LINK REF="STD-Fenton-2001" TYPE="STUDY">Fenton 2001</LINK> (medium term, 13-26 weeks) report data for global state. <LINK REF="STD-Peet-2001b" TYPE="STUDY">Peet 2001b</LINK> is an unusual study as people are unmedicated prior to randomisation. The need for neuroleptics during the trial appears to favour omega-3 supplementation with fewer people requiring neuroleptic drugs in this group but the result is not quite statistically significant (n=30, 1 RCT, RR 0.73 CI 0.54 to 1.00). <LINK REF="STD-Peet-2001b" TYPE="STUDY">Peet 2001b</LINK> also reports on the number of days that people in the study are free of standard antipsychotics. This is considerably less for those allocated to the omega-3 group, but data are skewed so are presented in a table. <LINK REF="STD-Fenton-2001" TYPE="STUDY">Fenton 2001</LINK> reported scale data from Clinical Global Impression endpoint scores. There is no difference between groups (n=87, 1 RCT, MD 0.00 CI -0.29 to 0.29). <LINK REF="STD-Berger-2007" TYPE="STUDY">Berger 2007</LINK> presents numbers achieving a symptomatic response by 12 weeks and there are no significant differences between groups for this outcome for all participants (n=69, 1 RCT, RR 0.90 CI 0.5 to 1.63) or for nonaffective participants (n=53, 1 RCT, RR 0.56 CI 0.25 to 1.25).</P>
<P>1.2 Mental State<BR/>
<LINK REF="STD-Peet-2001b" TYPE="STUDY">Peet 2001b</LINK> judges that an improvement of greater than 25% on the PANSS scale is clinically meaningful for this group of patients. Results show a significant improvement in PANSS scores, favouring the omega-3 EFA group for people who are unmedicated when included in the study (n=30, 1 RCT, RR 0.54 CI 0.30 to 0.96, NNT3 CI 2 to 29). In <LINK REF="STD-Peet-2001a" TYPE="STUDY">Peet 2001a</LINK>, there is a suggestion that people already on antipsychotic drugs when randomised to receive omega-3 EFA, did show higher level of improvement compared with those receiving placebo but the statistical significance is borderline (n=29, 1 RCT, RR 0.62 CI 0.37 to 1.05). Similar results are found for the average endpoint scores on the PANSS scale. <LINK REF="STD-Peet-2001b" TYPE="STUDY">Peet 2001b</LINK> found unmedicated participants receiving omega-3 have significantly lower endpoint scores than those receiving placebo for the short term (n=30, 1 RCT, MD -12.5 CI -22.38 to -2.62). Medicated participants receiving omega-3 supplementation in <LINK REF="STD-Peet-2001a" TYPE="STUDY">Peet 2001a</LINK> also have significantly lower endpoint scores, again for the short term, but the difference is borderline (n=29, 1 RCT, MD -10.4 CI -20.35 to -0.45). Medium-term data, reported by <LINK REF="STD-Fenton-2001" TYPE="STUDY">Fenton 2001</LINK>, does not favour either group (n=87, 1 RCT, MD -1.0 CI -8.15 to 6.15). <LINK REF="STD-Fenton-2001" TYPE="STUDY">Fenton 2001</LINK> reports data for depression as measured on the MADRS. Skewed data, presented in this review in '<LINK TAG="ADDITIONAL_TABLES" TYPE="SECTION">Additional tables</LINK>' suggests no effect for the medium term.</P>
<P>1.3 Adverse effects<BR/>
<LINK REF="STD-Fenton-2001" TYPE="STUDY">Fenton 2001</LINK> reports usable data for movement disorders as measured by the AIMS and Simpson and Angus scales. Their skewed data are presented in a table but do not suggest any effect of omega-3 supplementation.</P>
<P>1.4 Leaving the study early<BR/>Seven studies have low or no attrition (&lt;10% total). Combining data from those with low attrition, <LINK REF="STD-Berger-2007" TYPE="STUDY">Berger 2007</LINK>, <LINK REF="STD-Emsley-2006" TYPE="STUDY">Emsley 2006</LINK>, <LINK REF="STD-Fenton-2001" TYPE="STUDY">Fenton 2001</LINK>, <LINK REF="STD-Peet-2001a" TYPE="STUDY">Peet 2001a</LINK>, <LINK REF="STD-Peet-2001b" TYPE="STUDY">Peet 2001b</LINK> and <LINK REF="STD-Peet-2002" TYPE="STUDY">Peet 2002</LINK>, and suggests that there are no differences in numbers between groups leaving the study early (n=679, 6 RCTs, RR 0.85 CI 0.51 to 1.40).</P>
<P>2. COMPARISON 2. ANY DOSE OMEGA-6 (GLA) versus PLACEBO<BR/>2.1 Tardive dyskinesia<BR/>One small study (<LINK REF="STD-Wolkin-1986" TYPE="STUDY">Wolkin 1986</LINK>) finds no significant difference between groups for the average short-term endpoint AIMS score by the end of trial (n=16, 1 RCT, MD 1.30 CI -1.96 to 4.56).</P>
<P>2.2 Leaving the study early<BR/>Three people in each of the groups left one small study early (n=16, 1 RCT, RR 1.0 CI 0.28 to 3.54).</P>
<P>3. COMPARISON 3. ANY DOSE OMEGA 3 (E-EPA or EPA) versus ANY DOSE OMEGA-3 (DHA)<BR/>3.1 Mental state<BR/>One small (n=31) study compares the effects of different omega-3 EFAs (<LINK REF="STD-Peet-2001a" TYPE="STUDY">Peet 2001a</LINK>). For the outcome of no clinically important improvement in mental state in the short term (&gt;25% improvement in PANSS scores), E-EPA is no different to DHA (n=31, 1 RCT, RR 0.66 CI 0.39 to 1.11). Measuring improvement in mental state by the difference in change of PANSS scores also shows no difference between groups (n=31, WMD -9.80 CI -20.97 to 1.37).</P>
<P>3.2 Leaving the study early<BR/>There is no loss from either group for this comparison (n=31, study duration 12 weeks).</P>
<P>4. COMPARISON 4. SPECIFIC DOSE OMEGA-3 (E-EPA) versus PLACEBO<BR/>4.1 Global state<BR/>
<LINK REF="STD-Fenton-2001" TYPE="STUDY">Fenton 2001</LINK> compares supplementation with less than 1 g/day E-EPA with antipsychotic supplementation with placebo and finds no difference between groups on the CGI scale in the medium term (n=87, 1 RCT, MD 0.00 CI -0.29 to 0.29).</P>
<P>4.2 Mental State<BR/>Again <LINK REF="STD-Fenton-2001" TYPE="STUDY">Fenton 2001</LINK> reports usable data for medium-term endpoint PANSS scores. There is no difference between people allocated less than 1 g/day E-EPA supplementation and those receiving placebo (n=78, 1 RCT, MD -1.00 CI -8.15 to 6.15). <LINK REF="STD-Emsley-2002" TYPE="STUDY">Emsley 2002</LINK> presents skewed data for percentage change in PANSS scores from baseline and results suggest a positive effect for those receiving 3 g/day E-EPA supplementation compared with those receiving placebo; this data can be found in '<LINK TAG="ADDITIONAL_TABLES" TYPE="SECTION">Additional tables</LINK>'.</P>
<P>4.3 Adverse effects<BR/>Unless stated, all data for adverse effects are provided by <LINK REF="STD-Peet-2002" TYPE="STUDY">Peet 2002</LINK>, a short-term study. For the outcome of 'experiencing at least one adverse effect' no differences between groups are found for any dose (1 g/day E-EPA vs placebo n=63 , 1 RCT, RR 0.97 CI 0.60 to 1.56; 2 g/day E-EPA vs placebo n=63, 1 RCT, RR 0.67 CI 0.37 to 1.20; 4 g/day E-EPA vs placebo n=58, 1 RCT, RR 1.15 CI 0.72 to 1.82).</P>
<P>Short-term use of E-EPA supplementation is not clearly associated with gastrointestinal problems such as diarrhoea and nausea but most data comes from one small study with few events (<LINK REF="STD-Peet-2002" TYPE="STUDY">Peet 2002</LINK>). Data from two studies, the short-term <LINK REF="STD-Peet-2002" TYPE="STUDY">Peet 2002</LINK> and medium-term <LINK REF="STD-Fenton-2001" TYPE="STUDY">Fenton 2001</LINK> do not show that people receiving less than 1 g/day of E-EPA are more likely to experience diarrhoea than those on placebo (n=150, 2 RCTs, RR 2.04 CI 0.91 to 4.54). However, these data are heterogeneous and the results of the medium-term <LINK REF="STD-Fenton-2001" TYPE="STUDY">Fenton 2001</LINK> do suggest that there may be a link with the use of low dose E-EPA supplementation and diarrhoea (n=87, 1 RCT, RR 17.39 CI 1.03 to 292).</P>
<P>
<LINK REF="STD-Peet-2002" TYPE="STUDY">Peet 2002</LINK> records how many people have experienced liver and bilary tract problems, metabolic and nutritional difficulties (for example weight gain), and musculoskeletal adverse effects. No differences are apparent for any dose of E-EPA supplementation compared with placebo. The same study looked for any psychiatric sequelae of giving different doses of E-EPA supplementation, psychosexual difficulties and adverse effects such as infections. Again although it appears as though there is an effect, no statistically significant differences are apparent. Finally, rashes, urinary problems and 'any other' adverse effects are rare and not different for any doses.</P>
<P>4.4 Leaving the study early<BR/>Overall there are no significant differences in loss between groups. <LINK REF="STD-Fenton-2001" TYPE="STUDY">Fenton 2001</LINK> (medium term) and <LINK REF="STD-Peet-2002" TYPE="STUDY">Peet 2002</LINK> (short term) report data for &lt;1 g/day E-EPA compared with placebo supplementation. No differences in numbers leaving the study early are found between groups (n=150, 2 RCTs, RR 1.61 CI 0.71 to 3.67). Results from data provided by <LINK REF="STD-Berger-2007" TYPE="STUDY">Berger 2007</LINK>, <LINK REF="STD-Emsley-2006" TYPE="STUDY">Emsley 2006</LINK> and <LINK REF="STD-Peet-2002" TYPE="STUDY">Peet 2002</LINK> also show no difference between groups for the 2 g/day E-EPA comparison (n=307, 3 RCTs, RR 1.17 CI 0.54 to 2.55) and the 4 g/day E-EPA comparison with placebo (n=58, 1 RCT, RR 2.30 CI 0.22 to 23.94). <LINK REF="STD-Emsley-2002" TYPE="STUDY">Emsley 2002</LINK> also finds no short-term differences in loss between groups for a 3 g/day dose of E-EPA compared with placebo (n=40, 1 RCT, RR 3.00 CI 0.13 to 69.52)</P>
<P>5. Heterogeneity and publication bias<BR/>Both the possibility of heterogeneity and publication bias are impossible to test on such a small number of studies.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2009-05-06 15:02:32 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2009-05-06 14:54:27 +0100" MODIFIED_BY="[Empty name]">
<P>1. COMPARISON 1: ANY DOSE OMEGA-3 (E-EPA or EPA) versus PLACEBO<BR/>1.1 Global state<BR/>
<LINK REF="STD-Peet-2001b" TYPE="STUDY">Peet 2001b</LINK> investigates the short-term effects of omega-3 compared with placebo for people with schizophrenia not medicated at the start of the study. Global outcomes tend to favour the EPA group although none are statistically significant and expecting a clear result from a study of only 30 people is ambitious. The <LINK REF="STD-Peet-2001b" TYPE="STUDY">Peet 2001b</LINK> trial generates important hypotheses for future studies. <LINK REF="STD-Fenton-2001" TYPE="STUDY">Fenton 2001</LINK>, a generally less favourable study for EPA supplementation of antipsychotic drugs, at least in the medium term, uses the CGI to measure global state and also finds no effect. <LINK REF="STD-Berger-2007" TYPE="STUDY">Berger 2007</LINK> found no effect for numbers achieving symptomatic response when assessing all participants. When the nonaffective participants were separated out a positive affect of EPA supplementation seems to appear but this difference fails to make significance. The numbers in this study, again are small. No firm conclusions can be made from any of these results but they certainly do not support the use of EPA outside of the experimental situation.</P>
<P>1.2 Mental state<BR/>Overall the mental state of both medicated and unmedicated people, if measured by a 25% improvement on the PANSS scale, is significantly better for those receiving omega-3 EFA compared with placebo (NNT 3 CI 2 to 8). The trialist judged that an improvement of greater than 25% on the PANSS scale is clinically meaningful for this group of patients. We feel this to be unlikely, and are in keeping with other reviewers in this field (<LINK REF="REF-Hunter-2003" TYPE="REFERENCE">Hunter 2003</LINK>), but leave the final judgement to the reader. Short-term PANSS scores from <LINK REF="STD-Peet-2001a" TYPE="STUDY">Peet 2001a</LINK> and <LINK REF="STD-Peet-2001b" TYPE="STUDY">Peet 2001b</LINK> concur and are favourable for the EPA group but again the mean differences may not be very clinically meaningful and the longer-term study (<LINK REF="STD-Fenton-2001" TYPE="STUDY">Fenton 2001</LINK>) finds no effect. Whether clinically significant or not, omega-3 EPAs may be having an effect worthy of more research. These are drugs working in quite a different way to standard antipsychotics and, therefore, may teach us much about the pathology of schizophrenia.</P>
<P>1.3 Adverse effects<BR/>In keeping with the complete lack of a suggestion of a global clinical effect in <LINK REF="STD-Fenton-2001" TYPE="STUDY">Fenton 2001</LINK>, this study finds that EPA supplementation does not result in any movement disorders as measured by the AIMS and Simpson and Angus scales. If EPA did have some clinical effect, an issue that is still debatable, this apparent lack of adverse effects would become more important.</P>
<P>1.4 Leaving the study early<BR/>Considering that some drug treatments gain a licence using data from studies with over 50% loss to follow up over similar time periods, it is good to see such low attrition (&lt;10% total) in these trials. There is nothing to suggest that EPAs encourage loss to follow up.</P>
<P>2. COMPARISON 2: ANY DOSE OMEGA-6 (GLA) versus PLACEBO<BR/>2.1 Tardive dyskinesia<BR/>
<LINK REF="STD-Wolkin-1986" TYPE="STUDY">Wolkin 1986</LINK> investigates omega-6 EFA supplementation for the chronic condition of tardive dyskinesia, a complication of long-term use of antipsychotic drugs, and records AIMS ratings on 16 people after six weeks of treatment. No differences are found between treatment groups. This same small (n=16), short study finds no difference between groups for leaving before the end of trial. Nothing is proved or disproved by investigation in such a small short trial. The effects of omega-6 EPAs for people with tardive dyskinesia are unproven.</P>
<P>3. COMPARISON 3: ANY DOSE OMEGA -3 (E-EPA or EPA) versus ANY DOSE OMEGA -3 (DHA)<BR/>3.1 Mental state<BR/>When comparing different types of omega-3 supplementation it does appear as though E-EPA is more effective at producing a greater than 25% change on the PANSS compared to DHA. This result, however, comes from one small (n=31) study (<LINK REF="STD-Peet-2001a" TYPE="STUDY">Peet 2001a</LINK>) and therefore no firm conclusions should be made.</P>
<P>4. COMPARISON 4: SPECIFIC DOSES of OMEGA-3 (E-EPA) versus PLACEBO<BR/>4.1 Global and mental state<BR/>Very low dose E-EPA (&lt;1 g/day) does not seem to have any clear effect on global or mental state when compared with placebo over 16 weeks, but numbers are very small and, as for all results in this review, inconclusive.</P>
<P>4.2 Adverse effects<BR/>Most adverse effect data was derived from <LINK REF="STD-Peet-2002" TYPE="STUDY">Peet 2002</LINK> (n=122, short term), and all events are rare and results are inconclusive. Any doses of E-EPA, when compared with placebo, are not associated with frequent adverse effects. Adding the few data from the one medium-term study (<LINK REF="STD-Fenton-2001" TYPE="STUDY">Fenton 2001</LINK>) results in the synthesised results becoming heterogeneous, and this one study does suggest that there may be a link with the use of low dose E-EPA supplementation and diarrhoea (n=87, 1 RCT, RR 17.39 CI 1.03 to 292).</P>
<P>4.3 Leaving the study early<BR/>Within these studies, all doses of E-EPA seem acceptable to people with schizophrenia.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2009-02-23 16:12:32 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised studies investigating the effects of polyunsaturated acids for those with schizophrenia have been carried out for over 20 years now, but the majority randomise relatively small numbers of people and none so far have been longer than 16 weeks. While assessing the short-term effects of supplementation is important for the acute symptoms of schizophrenia such as mental state, the chronic symptoms of schizophrenia such as impaired global and social functioning may take longer to improve and such short-term studies can not adequately address these problems.</P>
<P>Another issue with applicability is that all trials used manufactured enriched oils as supplements to antipsychotic medication rather than dietary supplementation with foods rich in EFAs. It was not possible to assess the effects of manufactured oils compared to oils obtained naturally from the diet. Access to these specific enriched supplements may be too difficult and expensive for many people.</P>
<P>Outcome reporting was mainly symptom and physician-oriented. Patient-oriented global and functional outcomes, such as social functioning, ability to work, patient and carer satisfaction and family burden were not reported. There is clearly a need for studies focusing not only on symptoms, but also on general and social functioning, family burden and patient acceptability.</P>
<P>The setting of trials were a mixture of hospital and community, reflecting the situation most people with schizophrenia experience.</P>
<P>Overall the completeness and applicability of evidence for those suffering from schizophrenia is poor. Despite realistic settings, many useful outcomes were not investigated and the important long-term effects were also overlooked. It is also disappointing that recent trials are concentrating on investigating the effects of highly-refined enriched oils rather than the possible effects simple dietary supplementation may have.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2009-05-06 15:02:32 +0100" MODIFIED_BY="[Empty name]">
<P>Overall, the methodological quality of the eight included studies is good. The process of randomisation is, in the main, described and blindness is also described but remained untested. The studies are, however, small and short. Only <LINK REF="STD-Peet-2002" TYPE="STUDY">Peet 2002</LINK> randomises over 100 people and only <LINK REF="STD-Fenton-2001" TYPE="STUDY">Fenton 2001</LINK> is over three months in duration. Despite good methodological quality, data reporting is poor, and the quality of evidence suffers. It is unfortunate that the largest study (<LINK REF="STD-Peet-2002" TYPE="STUDY">Peet 2002</LINK>) fails to report variances with the average scores thus rendering most of the scale-derived data useless. It is also disappointing that the more recent studies, <LINK REF="STD-Berger-2007" TYPE="STUDY">Berger 2007</LINK>, <LINK REF="STD-Emsley-2002" TYPE="STUDY">Emsley 2002</LINK> and <LINK REF="STD-Emsley-2006" TYPE="STUDY">Emsley 2006</LINK>, have no overall effect on the results of this review. Their main effect is to lower the quality of evidence and increase risk of bias with higher rates of selective outcome reporting and poor presentation of unusable data. With so few good quality data, all findings can still only be considered as hypothesis generating.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2009-02-23 16:13:28 +0000" MODIFIED_BY="[Empty name]">
<P>We have only worked with published reports and by doing this we may be perpetuating a reporting and publishing bias.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2009-02-10 11:45:19 +0000" MODIFIED_BY="[Empty name]">
<P>This review substantially updates past work in that two new studies are included. The findings of this review are similar to previous versions, but this is due to a lack of new data rather than new data confirming previous results. Although the conclusions remain the same, the positive findings of previous versions are now more questionable because of the new Risk of Bias table function (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> and <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>) of this version of RevMan. This table highlights more potential bias in the included trials and their likelihood of overestimating positive effects.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2009-02-23 16:14:40 +0000" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2009-02-23 16:14:40 +0000" MODIFIED_BY="[Empty name]">
<P>1. For people with schizophrenia<BR/>Those suffering from serious mental illnesses should find data on the effects of EFA supplementation inconclusive. Volunteering to be involved in ongoing studies may help resolve the issue, but it is important that the researchers record and release all clinically relevant data.</P>
<P>2. For clinicians<BR/>Despite two new studies there is very little useful new data and there is currently still no reason for clinicians to either encourage or discourage the use of polyunsaturated fatty acids. If a person with schizophrenia wishes to use one then, perhaps, an omega-3 preparation should be the preferred option. Clinicians should be able to prescribe an omega-3 preparation as part of a well-designed randomised trial.</P>
<P>3. For policy makers<BR/>This review provides no evidence to support change in policy.</P>
<P>4. For funders<BR/>The value of polyunsaturated fatty acids for treating schizophrenia is still unproven. The intriguing theory behind their use and even the possibility of a clinical effect could create a whole new path of research. Support of a substantial study would seem warranted.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>1. General<BR/>By not fully implementing the CONSORT recommendations (<LINK REF="REF-Begg-1996" TYPE="REFERENCE">Begg 1996</LINK>, <LINK REF="REF-Moher-2001" TYPE="REFERENCE">Moher 2001</LINK>), trialists and editors have done a disservice to people with schizophrenia.</P>
<P>2. Specific<BR/>There are still too few data on the role that essential fatty acid supplementation plays in the treatment of people with schizophrenia. Its use is based on relatively new theoretical hypotheses. The data in this review neither refute nor strongly support the need for further trials. Certainly future trials should be large (probably &gt;150 per treatment arm), and their duration over one year (please see suggested study design <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). In addition, unless clinically relevant outcomes are measured, the real value of omega-3 or omega-6 EFA supplementation will remain in doubt.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2009-05-06 15:08:12 +0100" MODIFIED_BY="[Empty name]">
<P>The reviewers would like to thank Clive Adams and the Cochrane Schizophrenia Group editorial base staff past and present for advice and administrative support, Crispin Bennett for list of current research and clarification of types of EFA's, David Horrobin for advice and information about types of EFA's and Oliver Gillie for pointing out the lack of clarity in description of types of EFA's used in studies.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2009-02-10 11:01:45 +0000" MODIFIED_BY="[Empty name]">
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2009-05-06 15:07:56 +0100" MODIFIED_BY="[Empty name]">
<P>Claire Irving: protocol writing, searching, trial selection, data extraction, completion of report. Completion of 2002, 2005, 2008 update.<BR/>Roger Mumby-Croft: protocol writing, trial agreement, data agreement, help with completion of report. Advice and confirmation of trial status for the 2002 update.<BR/>Tony Joy: protocol writing, trial agreement, help (as lay reader) with completion of report. Advice and confirmation of trial status for the 2002 update.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2009-02-10 11:02:18 +0000" MODIFIED_BY="[Empty name]">
<P>We have substantially reformatted this review in light of changes to software (RevMan 5).</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2009-05-06 15:08:29 +0100" MODIFIED_BY="[Empty name]">
<P>Previously published under the title of 'Polyunsaturated fatty acid (fish or evening primrose oil) for schizophrenia'.<BR/>
</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2009-07-14 15:36:19 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2009-07-14 15:36:19 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2009-07-14 15:36:19 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Berger-2007" MODIFIED="2009-07-14 15:36:19 +0100" MODIFIED_BY="[Empty name]" NAME="Berger 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-01-27 12:58:25 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Berger G, Wood S, Proffitt T, McConchie M, Khan A, O'Donnell C, Yuen H, Smith D, Horrobin D, McGorry P</AU>
<TI>Ethyl-eicosapentaenoic acid (E-EPA) supplementation in early psychosis. A double-blind add on standard therapy in 80 drug naive or early treated first episode psychosis patients</TI>
<SO>Schizophrenia Research</SO>
<YR>2004</YR>
<VL>70</VL>
<NO>1</NO>
<PG>41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-01-28 11:05:53 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Berger GE, Proffitt TM, McConchie M, Yuen H, Wood SJ, Amminger GP, Brewer W, McGorry PD</AU>
<TI>Ethyl-eicosapentaenoic acid in first-episode psychosis: a randomised placebo-controlled trial</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2007</YR>
<VL>68</VL>
<NO>12</NO>
<PG>1867-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-01-27 13:12:49 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Berger GE, Proffitt TM, McConchie MA, Wood SJ, Yuen HP, McGorry PD</AU>
<TI>Ethyl-Eicosapentaenoic acid (E-EPA) supplementation in early psychosis. A double-blind, randomised, placebo controlled trial (RCT) comparing 2g E-EPA versus placebo add on therapy in 80 drug naive or early treated first episode psychosis</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>2005</YR>
<VL>31</VL>
<PG>475</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-07-14 15:36:19 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>McConchie MA, Berger GE, Proffitt TM, Yuen HP, Wood S, smith D, Horrobin D, McGorry PD</AU>
<TI>Effect of diagnostic heterogeneity on response to ethyl-eicosapentaenoic acid (EPA) in first episode psychosis (FEP)</TI>
<SO>Proceedings of the 12th Biennial Winter Workshop on Schizophrenia; 2004 Feb 7-13, Davos, Switzerland</SO>
<YR>2004</YR>
<CY>Davos</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-01-27 13:08:12 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Proffitt T, Wood S, Yuen H, McConchie M, Brewer W, Horrobin D, McGorry P, Berger G</AU>
<TI>Ethyl-Eicosapentaenoic acid (E-EPA) supplementation in first-episode psychosis: effects on cognition mediated by lipid metabolic status</TI>
<SO>Schizophrenia Research</SO>
<YR>2004</YR>
<VL>70</VL>
<NO>1</NO>
<PG>40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Emsley-2002" NAME="Emsley 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Emsley R, Myburgh C, Oosthuizen P, van Rensburg SJ</AU>
<TI>Randomised, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2002</YR>
<VL>159</VL>
<PG>1596-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Emsley-2006" MODIFIED="2009-02-26 09:53:04 +0000" MODIFIED_BY="[Empty name]" NAME="Emsley 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-02-26 09:52:55 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Emsley R, Niehaus DJH, Koen L, Oosthuizen PP, Turner HJ, Carey P, Van Rensburg SJ, Maritz JS, Murck H</AU>
<TI>The effects of eicosapentaenoic acid in tardive dyskinesia: a randomised placebo-controlled trial</TI>
<SO>Schizophrenia Research</SO>
<YR>2006</YR>
<VL>84</VL>
<NO>1</NO>
<PG>112-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-02-26 09:53:04 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Emsley R</AU>
<TI>A double-blind, randomised, parallel-group comparison of ethyl-eicosapentaenoic acid (e-epa) versus placebo as add-on medication in patients with established tardive dyskinesia</TI>
<SO>www.clinicaltrials.gov</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fenton-2001" MODIFIED="2009-05-06 15:22:36 +0100" MODIFIED_BY="[Empty name]" NAME="Fenton 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-02-10 12:02:48 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Conducted by Stanley Research Foundation, USA.&lt;br&gt;Allocation: randomised.&lt;br&gt;Participants: ~80 people with serious mental illness.&lt;br&gt;Site: USA&lt;br&gt;Interventions: continued neuroleptics + 3g EFA (ethyl EPA) supplementation vs continued neuroleptics + placebo.&lt;br&gt;Recruitment: due to start January 1999.&lt;/p&gt;" NOTES_MODIFIED="2009-02-10 12:02:48 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fenton W, Dickerson F, Boronow JJ, Hibbeln JR, Knable MB</AU>
<TI>A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2001</YR>
<VL>158</VL>
<NO>12</NO>
<PG>2071-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-05-06 15:22:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fenton WS, Boronow J, Dickerson F, Hibbein J, Knable MB</AU>
<TI>Randomised trial of supplemental EPA for residual symptoms of schizophrenia</TI>
<SO>Biological Psychiatry</SO>
<YR>2000</YR>
<VL>47</VL>
<PG>S159-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-02-26 09:56:06 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Fenton WS, Dickerson F, Boronow JJ, Hibbein JR, Knable MB</AU>
<TI>Placebo-controlled trial of omega-3 fatty acid</TI>
<SO>Proceedings of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia,USA</SO>
<YR>2002</YR>
<CY>Philadelphia</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Peet-2001a" MODIFIED="2009-02-26 09:56:36 +0000" MODIFIED_BY="[Empty name]" NAME="Peet 2001a" YEAR="2001">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Peet M, Brind J, Ramchand CN, Shah S, Vankar GK</AU>
<TI>Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia</TI>
<SO>Schizophrenia Research</SO>
<YR>2001</YR>
<VL>49</VL>
<PG>243-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Peet M, De Laugharne J, Mellor J</AU>
<TI>Double-blind trial of N3 fatty acid supplementation in the treatment of schizophrenia</TI>
<SO>Schizophrenia Research</SO>
<YR>1997</YR>
<VL>24</VL>
<PG>209</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Peet M, Mellor J</AU>
<TI>Double-blind, placebo controlled trial of N-3 polyunsaturated fatty acids as an adjunct to neuroleptics</TI>
<SO>Schizophrenia Research</SO>
<YR>1998</YR>
<VL>29</VL>
<PG>160</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-02-26 09:56:36 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Peet M</AU>
<TI>International multi-centre, double-blind, placebo controlled trial of EPA as an adjunct to existing neuroleptic treated schizophrenic patients</TI>
<SO>National Research Register</SO>
<YR>2001</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shah S, Vankar GK, Telang SD, Ramchand CN, Peet M</AU>
<TI>Eicosapentaenoic acid (EPA) as an adjunct in the treatment of schizophrenia</TI>
<SO>Schizophrenia Research</SO>
<YR>1998</YR>
<VL>29</VL>
<PG>158</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Peet-2001b" MODIFIED="2009-02-26 09:56:54 +0000" MODIFIED_BY="[Empty name]" NAME="Peet 2001b" YEAR="2001">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Peet M, Brind J, Ramchand CN, Sha S, Vankar GK</AU>
<TI>Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia</TI>
<SO>Schizophrenia Research</SO>
<YR>2001</YR>
<VL>49</VL>
<PG>243-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Peet-2002" MODIFIED="2009-02-26 09:59:06 +0000" MODIFIED_BY="[Empty name]" NAME="Peet 2002" YEAR="1998">
<REFERENCE MODIFIED="2009-02-25 16:56:54 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Horrobin DF, Bennett CN, Peet M</AU>
<TI>Correlation between clinical improvement and red cell fatty acid changes when treating schizophrenia with eicosapentaenoic acid</TI>
<SO>Proceedings of the 8th International Congress on Schizophrenia Research; 2001 April 28- May 2; British Columbia, Canada</SO>
<YR>2001</YR>
<PG>232</PG>
<CY>British Columbia</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-02-26 09:58:39 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Horrobin DF</AU>
<TI>The role of phospholipids in schizophrenia</TI>
<SO>Proceedings of the 7th World Congress of Biological Psychiatry; 2001 July 1-6; Berlin, Germany</SO>
<YR>2001</YR>
<CY>Berlin</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Horrobin Df, Jenkins K, Bennett CN, Christie WW</AU>
<TI>Eicosapentaenoic acid and arachidonic acid: collaboration and not antagonism is the key to biological understanding</TI>
<SO>Prostaglandins, Leukotrienes and Essential Fatty Acids</SO>
<YR>2002</YR>
<VL>66</VL>
<NO>1</NO>
<PG>83-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-02-25 16:58:16 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Peet M, Horrobin DF, Rowlands P, Murray R, De Wet C, Kendall K, Abed R, Lloyd G, Barber M, Hellewell J, Stirling J, Hay A, Roberts S, Puri B, Lekh S</AU>
<TI>A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms</TI>
<SO>Journal of Psychiatric Research</SO>
<YR>2002</YR>
<VL>36</VL>
<PG>7-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-02-26 09:59:06 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Peet M</AU>
<TI>A multi-centre, double-blind, randomised, parallel group, placebo controlled, dose ranging pilot study of ethyl eicosapentaenoate (ethly EPA) in patients with schizophrenia</TI>
<SO>National Research Register</SO>
<YR>2001</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-02-25 16:59:41 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Peet M</AU>
<TI>Eicosapentaenoic acid (EPA) is effective in relieving schizophrenic symptoms in patients on clozapine</TI>
<SO>Proceedings of the 8th International Congress on Schizophrenia Research; 2001 April 28 - May 2; British Columbia, Canada</SO>
<YR>2001</YR>
<PG>241-2</PG>
<CY>British Columbia</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-02-26 09:56:54 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shah S, Ramchand CN, Peet M</AU>
<TI>Double blind pilot study of eicosapentaenoic acid (EPA) as the sole treatment for schizophrenia</TI>
<SO>Schizophrenia Research</SO>
<YR>2000</YR>
<VL>41</VL>
<NO>1</NO>
<PG>27</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wolkin-1986" NAME="Wolkin 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wolkin A, Jordan B, Peselow E, Rubinstein M, Rotrosen J</AU>
<TI>Essential fatty acid supplementation in tardive dyskinesia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1986</YR>
<VL>143</VL>
<PG>912-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2009-05-06 15:23:32 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Amminger-2007" MODIFIED="2009-02-26 10:01:12 +0000" MODIFIED_BY="[Empty name]" NAME="Amminger 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-02-25 17:00:54 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Amminger GP Schafer MR</AU>
<TI>Is it feasible to conduct a RCT in ultra-high risk individuals at a child and adolescent psychiatric service?</TI>
<SO>Proceedings of the 5th International Conference on Early Psychosis; 2006 Oct 4-6; Birmingham, UK</SO>
<YR>2006</YR>
<CY>Birmingham</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-02-25 17:01:37 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Amminger GP, Schafer MR</AU>
<TI>Indicated prevention with omega-3 fatty acids in adolescents at ultra-high risk for psychosis - rationale, methods and 3-months outcome</TI>
<SO>Proceedings of the 5th International Conference on Early Psychosis; 2006 Oct 4-6, Birmingham, UK</SO>
<YR>2006</YR>
<CY>Birmingham</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-02-26 10:01:12 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Amminger GP</AU>
<TI>Indicated prevention with omega-3 fatty acids in adolescents with 'at-risk-mental-state' for psychosis: a randomised, double blind, placebo-controlled treatment trial</TI>
<SO>www.clinicaltrials.gov</SO>
<YR>2006</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-02-10 12:05:57 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>AmmingerG, Schaefer MR, Papageorgiou K, Becker J, Mossaheb N, Harrigan SM, McGorry PD, Berger GE</AU>
<TI>Omega-3 fatty acids reduce the risk of early transition to psychosis in ultra-high risk individuals: a double-blind randomised, placebo-controlled treatment study</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>2007</YR>
<VL>33</VL>
<NO>2</NO>
<PG>418-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-02-25 17:02:29 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Klier C, Hollmann M, Schlogelhofer M, Mossaheb N, Friedrich M, Amminger PG</AU>
<TI>Indicated prevention with omega-3 fatty acids (epa/dha) in adolescents with "at-risk-mental-state" for psychosis</TI>
<SO>Proceedings of the XIII World Congress of Psychiatry; 2005 Sept 10-15; Cairo, Egypt</SO>
<YR>2005</YR>
<CY>Cairo</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Glen-1996" NAME="Glen 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Glen AIM, Cooper SJ, Rybakowski J, Vaddadi K, Brayshaw N, Horrobin DF</AU>
<TI>Membrane fatty acids, niacin flushing and clinical parameters</TI>
<SO>Prostaglandins, Leukotrienes and Essential Fatty Acids</SO>
<YR>1996</YR>
<VL>55</VL>
<PG>9-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Heresco_x002d_Levy-1996" NAME="Heresco-Levy 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Heresco Levy U, Javitt DC, Ermilov M, Mordel C, Horowitz A, Kelly D</AU>
<TI>Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1996</YR>
<VL>169</VL>
<PG>610-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Holman-1983" NAME="Holman 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Holman CP, Bell AFJ</AU>
<TI>A trial of evening primrose oil in the treatment of chronic schizophrenia</TI>
<SO>Journal of Orthomolecular Psychiatry</SO>
<YR>1983</YR>
<VL>12</VL>
<PG>302-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Maurer-2002" MODIFIED="2009-02-26 10:04:15 +0000" MODIFIED_BY="[Empty name]" NAME="Maurer 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-02-26 10:04:15 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Maurer I, Volz HP, Czekalla J, Holstein W, Streck S, Winnefel K</AU>
<TI>Reduction of arachidonic acid levels by haloperidol in patients with schizophrenia</TI>
<SO>Schizophrenia Research</SO>
<YR>2002</YR>
<VL>53</VL>
<NO>3 suppl 1</NO>
<PG>209</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Peet-1996" MODIFIED="2009-05-06 15:23:20 +0100" MODIFIED_BY="[Empty name]" NAME="Peet 1996" YEAR="1996">
<REFERENCE MODIFIED="2009-02-10 12:06:39 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Laugharne JDE, Mellor JE, Peet M</AU>
<TI>Fatty acids and schizophrenia</TI>
<SO>Lipids</SO>
<YR>1996</YR>
<VL>31</VL>
<PG>163-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mellor JE, Laugharne JDE, Peet M</AU>
<TI>Omega-3 fatty acid supplementation in schizophrenic patients</TI>
<SO>Human Psychopharmacology</SO>
<YR>1996</YR>
<VL>11</VL>
<PG>39-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mellor JE, Laugharne JDE, Peet M</AU>
<TI>Schizophrenic symptoms and dietary intake of n-3 fatty acids</TI>
<SO>Schizophrenia Research</SO>
<YR>1995</YR>
<VL>18</VL>
<PG>85-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-05-06 15:23:20 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Peet M, Laugharne JDE, Mellor J, Ramchand CN</AU>
<TI>Essential fatty acid deficiency in erythrocyte membranes from chronic schizophrenic patients, and the clinical effects of dietary supplementation</TI>
<SO>Prostaglandins, Leukotrienes and Essential Fatty Acids</SO>
<YR>1996</YR>
<VL>55</VL>
<PG>71-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Puri-2001" MODIFIED="2009-02-26 10:05:02 +0000" MODIFIED_BY="[Empty name]" NAME="Puri 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-02-26 10:05:02 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Puri BK, Bydder GM, Counsell SJ, Corridan BJ, Richardson AJ, Hajnal JV, Appel C, McKee HM, Vaddadi KS, Horrobin DF</AU>
<TI>MRI and neuropsychological improvement in huntington disease following ethyl-EPA treatment</TI>
<SO>Clinical Neuroscience</SO>
<YR>2002</YR>
<VL>13</VL>
<NO>1</NO>
<PG>123-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Silbergeld-1973" MODIFIED="2009-05-06 15:23:32 +0100" MODIFIED_BY="[Empty name]" NAME="Silbergeld 1973" YEAR="1973">
<REFERENCE MODIFIED="2009-05-06 15:23:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Silbergeld S, Noble E</AU>
<TI>Corticosteroids in psychiatric patients: Subacute and diurnal effects on free fatty acid and catecholamine metabolism</TI>
<SO>Journal of Psychiatric Research</SO>
<YR>1973</YR>
<VL>10</VL>
<PG>59-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vaddadi-1986" NAME="Vaddadi 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vaddadi KS, Gilleard CJ, Mindham RH, Butler R</AU>
<TI>A controlled trial of prostaglandin E1 precursor in chronic neuroleptic resistant schizophrenic patients</TI>
<SO>Psychopharmacology Berlin</SO>
<YR>1986</YR>
<VL>88</VL>
<PG>362-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vaddadi-1989" MODIFIED="2009-02-26 10:07:03 +0000" MODIFIED_BY="[Empty name]" NAME="Vaddadi 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vaddadi KS, Courtney P, Gilleard CJ, Manku MS, Horrobin DF</AU>
<TI>A double-blind trial of essential fatty acid supplementation in patients with tardive dyskinesia</TI>
<SO>Psychiatry Research</SO>
<YR>1989</YR>
<VL>27</VL>
<PG>313-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-02-26 10:07:03 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Vaddadi KS, Gilleard CJ</AU>
<TI>Essential fatty acids, tardive dyskinesia and schizophrenia</TI>
<SO>Omega-6 Essential Fatty acids: Pathophysiology and Roles in Clinical Medicine</SO>
<YR>1990</YR>
<PG>333-43</PG>
<PB>Alan R, Liss. Inc</PB>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2009-02-03 12:01:50 +0000" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES MODIFIED="2009-05-06 15:23:48 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Bentsen-2007" MODIFIED="2009-05-06 15:23:48 +0100" MODIFIED_BY="[Empty name]" NAME="Bentsen 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-02-26 10:08:17 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Bentsen H, Lingjaerde O</AU>
<TI>A multicentre, placebo-controlled trial of eicosapentaenoic acid (EPA) and antioxidant supplementation in the treatment of schizophrenia and related disorders</TI>
<SO>www.clinicaltrials.gov</SO>
<YR>2007</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-05-06 15:23:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Landro NI, Bentsen H</AU>
<TI>The effects of a fatty acid and antioxidants on neuropsychological functioning in schizophrenia and related psychoses</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>2007</YR>
<VL>33</VL>
<PG>529-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Blanchet-2008" MODIFIED="2009-02-26 10:08:36 +0000" MODIFIED_BY="[Empty name]" NAME="Blanchet 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-02-26 10:08:36 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Blanchet PJ, Stip E</AU>
<TI>Efficacy of docosahexaenoic acid on tardive dyskinesia</TI>
<SO>www.clinicaltrials.gov</SO>
<YR>2008</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Korbanic-2005" MODIFIED="2009-02-26 10:08:48 +0000" MODIFIED_BY="[Empty name]" NAME="Korbanic 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-02-26 10:08:48 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Korbanic CJ, Yao JK</AU>
<TI>CAD risk in schizophrenia: effect of omega-3 fatty acid supplementation</TI>
<SO>www.clinicaltrials.gov</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Murck-2001" MODIFIED="2009-02-26 10:09:05 +0000" MODIFIED_BY="[Empty name]" NAME="Murck 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-02-26 10:09:05 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Murck H</AU>
<TI>A multicentre, double blind, randomised, parallel group, placebo controlled dose ranging pilot study of ethyl-eicosapentaenoate (ethyl-epa) in patients with schizophrenia</TI>
<SO>Current Controlled Trials</SO>
<YR>2001</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Richtand-2007" MODIFIED="2009-02-26 10:09:17 +0000" MODIFIED_BY="[Empty name]" NAME="Richtand 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-02-26 10:09:17 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Richtand N</AU>
<TI>Omega-3 fatty acid deficiency replacement in early schizophrenia</TI>
<SO>www.clinicaltrials.gov</SO>
<YR>2007</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2009-05-06 15:38:42 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2009-05-06 15:38:42 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Altman-1996" MODIFIED="2009-02-10 12:08:20 +0000" MODIFIED_BY="[Empty name]" NAME="Altman 1996" TYPE="JOURNAL_ARTICLE">
<AU>Altman DG, Bland JM</AU>
<TI>Detecting skewness from summary information</TI>
<SO>BMJ</SO>
<YR>1996</YR>
<VL>313</VL>
<PG>1200</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Begg-1996" MODIFIED="2009-02-10 12:08:44 +0000" MODIFIED_BY="[Empty name]" NAME="Begg 1996" TYPE="JOURNAL_ARTICLE">
<AU>Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, Pitkin R, Rennie D, Schulz KF, Simel D, Stroup DFSO</AU>
<TI>Improving the quality of reporting of randomised controlled trials. The CONSORT statement [comment]</TI>
<SO>JAMA</SO>
<YR>1996</YR>
<VL>276</VL>
<PG>637-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bland-1997" MODIFIED="2009-02-10 12:07:52 +0000" MODIFIED_BY="[Empty name]" NAME="Bland 1997" TYPE="JOURNAL_ARTICLE">
<AU>Bland JM</AU>
<TI>Statistics notes. Trials randomised in clusters</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<PG>600</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Christensen-1998" MODIFIED="2009-02-10 12:07:51 +0000" MODIFIED_BY="[Empty name]" NAME="Christensen 1998" TYPE="JOURNAL_ARTICLE">
<AU>Christensen O, Christensen E</AU>
<TI>Fat consumption and schizophrenia</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1998</YR>
<VL>78</VL>
<PG>587-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Di-Marzo-1992" MODIFIED="2009-02-10 12:07:51 +0000" MODIFIED_BY="[Empty name]" NAME="Di Marzo 1992" TYPE="JOURNAL_ARTICLE">
<AU>Di Marzo V, Piomelli D</AU>
<TI>Participation of prostaglandin E2 in dopamine D2 receptor-dependent potentiation of arachidonic response</TI>
<SO>Journal of Neurochemisty</SO>
<YR>1992</YR>
<VL>59</VL>
<PG>379-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Divine-1992" MODIFIED="2009-02-10 12:07:52 +0000" MODIFIED_BY="[Empty name]" NAME="Divine 1992" TYPE="JOURNAL_ARTICLE">
<AU>Divine GW, Brown JT, Frazier LM</AU>
<TI>The unit of analysis error in studies about physicians' patient care behaviour</TI>
<SO>Journal of Internal Medicine</SO>
<YR>1992</YR>
<VL>7</VL>
<NO>6</NO>
<PG>623-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Donner-2002" MODIFIED="2009-02-10 12:08:58 +0000" MODIFIED_BY="[Empty name]" NAME="Donner 2002" TYPE="JOURNAL_ARTICLE">
<AU>Donner A, Klar N</AU>
<TI>Issues in the meta-analysis of cluster randomised trials</TI>
<SO>Statistics in Medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<PG>2971-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" MODIFIED="2009-02-10 12:07:52 +0000" MODIFIED_BY="[Empty name]" NAME="Egger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Davey-smith G, Schneider M, Minder C</AU>
<TI>Bias in meta-analysis, detected by a simple graphical test</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<PG>629-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Elbourne-2002" MODIFIED="2009-02-10 12:07:52 +0000" MODIFIED_BY="[Empty name]" NAME="Elbourne 2002" TYPE="JOURNAL_ARTICLE">
<AU>Elbourne D, Altman DG, Higgins JPT, Curtina F, Worthingtond HV, Vaile A</AU>
<TI>Meta-analyses involving cross-over trials: methodological issues</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2002</YR>
<VL>31</VL>
<NO>1</NO>
<PG>140-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Glen-1994" MODIFIED="2009-02-10 12:07:51 +0000" MODIFIED_BY="[Empty name]" NAME="Glen 1994" TYPE="JOURNAL_ARTICLE">
<AU>Glen AIM, Glen EMT, Horrobin D, Vaddadi KS, Spellman M, Morse-Fisher N, Ellisk, Skinner FS</AU>
<TI>A red cell membrane abnormality in a subgroup of schizophrenic patients: evidence for two diseases</TI>
<SO>Schizophrenia Research</SO>
<YR>1994</YR>
<VL>12</VL>
<PG>53-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gulliford-1999" MODIFIED="2009-02-10 12:07:52 +0000" MODIFIED_BY="[Empty name]" NAME="Gulliford 1999" TYPE="JOURNAL_ARTICLE">
<AU>Gulliford MC, Ukoumunne OC, Chinn S</AU>
<TI>Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from Health Survey for England 1994</TI>
<SO>American Journal of Epidemiology</SO>
<YR>1999</YR>
<VL>149</VL>
<PG>876-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guy-1976" MODIFIED="2009-02-26 10:11:32 +0000" MODIFIED_BY="[Empty name]" NAME="Guy 1976" TYPE="BOOK">
<AU>Guy Q</AU>
<SO>ECDEU assessment manual for psychopharmacology</SO>
<YR>1976</YR>
<EN>ADM 76-338</EN>
<PB>US Department of Health, Education and Welfare</PB>
<CY>Rockville, MD</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Heresco_x002d_Levy-1998" MODIFIED="2009-02-10 12:07:51 +0000" MODIFIED_BY="[Empty name]" NAME="Heresco-Levy 1998" TYPE="JOURNAL_ARTICLE">
<AU>Heresco-Levy U, Javitt DCAD</AU>
<TI>The role of N-methyl-D-aspartate (NMDA) receptor-mediated neurotransmission in the pathophysiology and therapeutics of psychiatric syndromes</TI>
<SO>European Neuropsychopharmacology</SO>
<YR>1998</YR>
<VL>8</VL>
<PG>141-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2009-02-23 11:29:24 +0000" MODIFIED_BY="[Empty name]" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2008" MODIFIED="2009-02-23 11:22:42 +0000" MODIFIED_BY="[Empty name]" NAME="Higgins 2008" TYPE="BOOK">
<AU>Higgins, JPT, Green S (editors)</AU>
<SO>Cochrane Handbook for systematic reviews of interventions 5.0.1 [updated September 2008]</SO>
<YR>2008</YR>
<PB>The Cochrane Collaboration</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Horrobin-1991" MODIFIED="2009-02-10 12:07:51 +0000" MODIFIED_BY="[Empty name]" NAME="Horrobin 1991" TYPE="JOURNAL_ARTICLE">
<AU>Horrobin DF, Manku MS, Hillman H, Iain A, Glen M</AU>
<TI>Fatty acid levels in the brains of schizophrenics and normal controls</TI>
<SO>Biological Psychiatry</SO>
<YR>1991</YR>
<VL>30</VL>
<PG>795-805</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Horrobin-1994" MODIFIED="2009-02-10 12:07:51 +0000" MODIFIED_BY="[Empty name]" NAME="Horrobin 1994" TYPE="JOURNAL_ARTICLE">
<AU>Horrobin DF, Glen AIM, Vaddadi KSO</AU>
<TI>The membrane hypothesis of schizophrenia</TI>
<SO>Schizophrenia Research</SO>
<YR>1994</YR>
<VL>13</VL>
<PG>195-207</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hunter-2003" MODIFIED="2009-02-26 10:14:48 +0000" MODIFIED_BY="[Empty name]" NAME="Hunter 2003" TYPE="COCHRANE_REVIEW">
<AU>Hunter RH, Gilbody SM, Joy CB, Kennedy E, Song F</AU>
<TI>Risperidone versus typical antipsychotic medication for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>1</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS MODIFIED="2009-02-26 10:14:48 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-26 10:14:48 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000440"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Jablensky-1992" MODIFIED="2009-02-10 12:07:51 +0000" MODIFIED_BY="[Empty name]" NAME="Jablensky 1992" TYPE="JOURNAL_ARTICLE">
<AU>Jablensky A, Sartorius N, Ernberg G, Anker M, Korten A, Cooper JE, Day R, Bertelsen A</AU>
<TI>Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study</TI>
<SO>Psychological Medicine Monograph Supplement</SO>
<YR>1992</YR>
<VL>20</VL>
<PG>1-97</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kay-1986" MODIFIED="2009-02-23 15:19:30 +0000" MODIFIED_BY="[Empty name]" NAME="Kay 1986" TYPE="BOOK">
<AU>Kay SR, Opler LA, Fiszbein A</AU>
<SO>Positive and Negative Syndrome Scale(PANSS) manual</SO>
<YR>1986</YR>
<PB>Multi-Health Systems</PB>
<CY>North Tonawanda (NY)</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marshall-2000" MODIFIED="2009-02-10 12:07:52 +0000" MODIFIED_BY="[Empty name]" NAME="Marshall 2000" TYPE="JOURNAL_ARTICLE">
<AU>Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M</AU>
<TI>Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2000</YR>
<VL>176</VL>
<PG>249-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mellor-1995" MODIFIED="2009-02-10 12:07:51 +0000" MODIFIED_BY="[Empty name]" NAME="Mellor 1995" TYPE="JOURNAL_ARTICLE">
<AU>Mellor J, Laugharne JDE, Peet M</AU>
<TI>Schizophrenic symptoms and dietary intake of n-3 fatty acids</TI>
<SO>Schizophrenia Research</SO>
<YR>1995</YR>
<VL>18</VL>
<PG>85-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mellor-1996" MODIFIED="2009-02-10 12:09:21 +0000" MODIFIED_BY="[Empty name]" NAME="Mellor 1996" TYPE="JOURNAL_ARTICLE">
<AU>Mellor JE, Laugharne JDE, Peet M</AU>
<TI>Omega-3 fatty acid supplementation in schizophrenic patients</TI>
<SO>Human Psychopharmacology</SO>
<YR>1996</YR>
<VL>11</VL>
<PG>39-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moher-2001" MODIFIED="2009-02-10 12:09:31 +0000" MODIFIED_BY="[Empty name]" NAME="Moher 2001" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Schulz KF, Altman D</AU>
<TI>The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials</TI>
<SO>JAMA</SO>
<YR>2001</YR>
<VL>285</VL>
<PG>1987-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Montgomery-1979" MODIFIED="2009-02-10 12:07:52 +0000" MODIFIED_BY="[Empty name]" NAME="Montgomery 1979" TYPE="JOURNAL_ARTICLE">
<AU>Montgomery SA, Asberg M</AU>
<TI>A new depression scale designed to be sensitive to change</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1979</YR>
<VL>134</VL>
<PG>382-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nunez-1993" MODIFIED="2009-02-26 10:15:58 +0000" MODIFIED_BY="[Empty name]" NAME="Nunez 1993" TYPE="JOURNAL_ARTICLE">
<AU>Nunez EA, editor</AU>
<TI>Fatty acids and cell signalling</TI>
<SO>Prostaglandins Leukotrienes EFAs</SO>
<YR>1993</YR>
<VL>12</VL>
<PG>53-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Puri-1997" MODIFIED="2009-02-10 12:07:51 +0000" MODIFIED_BY="[Empty name]" NAME="Puri 1997" TYPE="JOURNAL_ARTICLE">
<AU>Puri BK, Easton T, Richardson AJ</AU>
<TI>Normalisation of positive and negative symptoms of schizophrenia following dietary supplementation with essential fatty acids: a case study</TI>
<SO>Biological Psychiatry</SO>
<YR>1997</YR>
<VL>42</VL>
<PG>S189</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Simpson-1970" MODIFIED="2009-02-10 12:07:52 +0000" MODIFIED_BY="[Empty name]" NAME="Simpson 1970" TYPE="JOURNAL_ARTICLE">
<AU>Simpson GM, Angus JWS</AU>
<TI>A rating scale for extra-pyramidal side-effects</TI>
<SO>Acta Psychiatrica Scandinavica Supplementum</SO>
<YR>1970</YR>
<VL>212</VL>
<PG>11-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ukoumunne-1999" MODIFIED="2009-02-10 12:09:47 +0000" MODIFIED_BY="[Empty name]" NAME="Ukoumunne 1999" TYPE="JOURNAL_ARTICLE">
<AU>Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ</AU>
<TI>Methods for evaluating area-wide and organisation-based intervention in health and health care: a systematic review</TI>
<SO>Health Technology Assessment</SO>
<YR>1999</YR>
<VL>3</VL>
<NO>5</NO>
<PG>1-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-1998" MODIFIED="2009-02-10 12:07:51 +0000" MODIFIED_BY="[Empty name]" NAME="WHO 1998" TYPE="OTHER">
<AU>WHO</AU>
<TI>Global Health Statistics Online</TI>
<SO>Available: http//www.who.ch/msa/mnh/ems/rates/schizo.htm.</SO>
<YR>24th July 1998</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wiersma-1998" MODIFIED="2009-02-10 12:07:51 +0000" MODIFIED_BY="[Empty name]" NAME="Wiersma 1998" TYPE="JOURNAL_ARTICLE">
<AU>Wiersma D, Nienhuis FJ, Slooff CJ, Giel R</AU>
<TI>Natural course of schizophrenic disorders: a 15-year follow-up of a Dutch incidence cohort</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>1998</YR>
<VL>24</VL>
<PG>75-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Xia-2007" MODIFIED="2009-05-06 15:38:42 +0100" MODIFIED_BY="[Empty name]" NAME="Xia 2007" TYPE="CONFERENCE_PROC">
<AU>Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El-Sayeh H, Pinfold V, Takriti Y</AU>
<TI>The Leeds Outcomes Stakeholders Survey (LOSS) Study</TI>
<SO>Proceedings of the 15th Cochrane Colloquium; 2007 Oct 23-27; Sao Paulo</SO>
<YR>2007</YR>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES>
<REFERENCE ID="REF-Joy-2000" NAME="Joy 2000" TYPE="JOURNAL_ARTICLE">
<AU>Joy CB, Mumby-Croft R, Joy LA</AU>
<TI>Polyunsaturated fatty acid supplementation (fish or evening primrose oil) for schizophrenia: a Cochrane review</TI>
<SO>Schizophrenia Research</SO>
<YR>2000</YR>
<VL>41</VL>
<NO>1</NO>
<PG>27</PG>
<IDENTIFIERS/>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2009-02-10 12:07:59 +0000" MODIFIED_BY="[Empty name]"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2009-05-06 15:21:23 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2009-05-06 15:13:23 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2009-05-06 15:09:43 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Berger-2007">
<CHAR_METHODS MODIFIED="2009-02-25 12:00:57 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: double.<BR/>Duration: 12 weeks.<BR/>Setting: inpatient and outpatient.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-02-25 12:01:37 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: DSM-IV first episode psychosis.<BR/>N=80.<BR/>Sex: 54M, 15F (NOTE only 69 participants analysed - see risk of bias table).<BR/>Age: 15-29 years.<BR/>Exclusions: drug induced psychosis, other organic brain disorders, history of intellectual disability, history of head injury.<BR/>History: first episode psychosis, currently psychotic.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-05-06 15:09:43 +0100" MODIFIED_BY="[Empty name]">
<P>1. 2 g ( 2 X 500 mg capsules, twice a day) purified E-EPA (ethyl eicosapentaenoic acid) plus current antipsychotic medication. N=35.<BR/>2. 2 g (2 X 500 mg capsules, twice a day) placebo oil. N=34.</P>
<P>Benzodiazepines, chlorpromazine, zuclopenthixol acetate (allowed for behaviour control)<BR/>Zolpidem tartrate (allowed for insomnia)<BR/>Selective serotonin reuptake inhibitors (allowed for depression)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-02-25 12:03:01 +0000" MODIFIED_BY="[Empty name]">
<P>Leaving the study early.</P>
<P>Unable to use:<BR/>Global state: time to first response, CGI, GAF scores (no mean, SD presented).<BR/>Mental state: BPRS, SANS, CDSS scores (no usable data presented).<BR/>Social functioning: SOFAS score (no usable data presented).<BR/>Adverse effects: SAS, EPS, BAS UKU scores (no usable data presented).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-05-06 15:10:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Emsley-2002">
<CHAR_METHODS MODIFIED="2009-02-02 10:23:19 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: double.<BR/>Duration: 12 weeks.<BR/>Setting: unclear.<BR/>Consent: written.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-05-06 15:10:17 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia (DSM-IV).<BR/>N=40.<BR/>Sex: not given.<BR/>Age: 18 - 55 years, mean ~ 46 years.<BR/>Exclusions: substance abuse, significant medical conditions.<BR/>History: chronic, mean duration of illness~23 years, Positive and Negative Syndrome Scale total score &gt;50.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-05-06 15:10:24 +0100" MODIFIED_BY="[Empty name]">
<P>1. Ethyl-eicosapentaenoic acid: 3 g/day (three 500 mg capsules twice daily). N=20.<BR/>2. Placebo (liquid paraffin). N=20.</P>
<P>Previous neuroleptic treatment remained constant throughout the trial. No other medication apart from analgesics for headaches and lorazepam for insomnia if required.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mental state: PANSS scores.<BR/>Leaving the study early.</P>
<P>Unable to use:<BR/>Mental state: PANSS subscale scores (no mean, no SD).<BR/>Adverse events: EPRS scores (no mean, no SD).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-05-06 15:10:44 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Emsley-2006">
<CHAR_METHODS MODIFIED="2009-02-25 12:12:50 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: double.<BR/>Duration: 12 weeks.<BR/>Setting: inpatient and outpatient from single site.<BR/>Consent: written.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-02-25 12:13:57 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: DSM-IV schizophrenia or schizoaffective disorder with established TD.<BR/>N= 84.<BR/>Age: 18-60 years.<BR/>Sex: 51M, 26F*<BR/>Exclusions: substance abuse, significant other medical or neurological illness, pregnancy, breastfeeding, receiving clozapine.<BR/>History: stable, received fixed dose antipsychotic medication for at least 6 weeks prior to trial entry.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-05-06 15:10:44 +0100" MODIFIED_BY="[Empty name]">
<P>1. 2 g/day E-EPA: 2 X 500 mg capsules twice a day plus current antipsychotic medication. N=39.<BR/>2. Placebo: 2 X 500 mg capsules twice a day plus current antipsychotic medication. N=38.</P>
<P>Allowed anticholinergic medication for treatment emergent EPS, anxiolytic or hypnotic medication for insomnia or anxiety, medication for any physical conditions.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-02-25 12:21:01 +0000" MODIFIED_BY="[Empty name]">
<P>Adverse effects: time to first response (TD).<BR/>Leaving the study early.</P>
<P>Unable to use:<BR/>Mental state: numbers with significant improvement, change in score on PANSS (no usable data presented).<BR/>Adverse effects: numbers with significant improvement on CGI subscore for TD (no usable data presented), change in scores on ESRS (skewed data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-01-30 11:55:48 +0000" MODIFIED_BY="[Empty name]">
<P>84 randomised, 77 analysed*</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-05-06 15:12:13 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fenton-2001">
<CHAR_METHODS MODIFIED="2009-02-02 12:34:44 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: double.<BR/>Duration: 16 weeks.<BR/>Setting: outpatient clinic.<BR/>Consent: given.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-05-06 15:12:03 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia or schizoaffective disorder (DSM-IV).<BR/>N=90.<BR/>History: residual symptoms despite neuroleptic treatment.<BR/>Sex: 70 men, 20 women.<BR/>Age: 18-65 years, mean~40 years.<BR/>Exclusions: substance abuse, bleeding disorder, mental deficiency, already taking fish oil supplements, anticoagulants, cholestyramine or clofibrate antilipaemic agents.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-05-06 15:12:13 +0100" MODIFIED_BY="[Empty name]">
<P>1. Ethyl-eicosapentaenoic acid: dose 500 mg/day + vitamin E. N=43.<BR/>2. Mineral oil placebo + vitamin E. N=44.*</P>
<P>Previous neuroleptic treatment remained constant throughout trial.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Global state: CGI score.<BR/>Mental state: PANSS, MADRS scores.<BR/>Adverse events: AIMS, SAS scores, other observed events.<BR/>Leaving the study early.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>* data for 87 participants only.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-05-06 15:12:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Peet-2001a">
<CHAR_METHODS MODIFIED="2009-02-02 12:55:45 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: double.<BR/>Duration: 12 weeks.<BR/>Setting: outpatient clinic.<BR/>Consent: given.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-05-06 15:12:34 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia (DSM-IV).<BR/>N=55.<BR/>History: symptomatic despite neuroleptic treatment.<BR/>Sex: 30 men, 15 women*.<BR/>Age:~30-56 years.<BR/>Exclusions: other significant physical or psychiatric illness.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-05-06 15:12:42 +0100" MODIFIED_BY="[Empty name]">
<P>1. Eicosapentaenoic acid enriched oil (containing 2 g of EPA). N=15.<BR/>2. Docosahexanoic acid oil (containing DHA)*. N=16.<BR/>3. Placebo (corn oil) N=14.</P>
<P>Previous neuroleptic treatment remained constant throughout trail.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-02-25 12:20:48 +0000" MODIFIED_BY="[Empty name]">
<P>Mental state: PANSS improved, not improved.<BR/>Leaving the study early.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-02-10 11:57:58 +0000" MODIFIED_BY="[Empty name]">
<P>* only 45 participants analysed.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-05-06 15:13:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Peet-2001b">
<CHAR_METHODS MODIFIED="2009-02-02 13:03:40 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random assignment.<BR/>Blindness: double.<BR/>Duration: 12 weeks.<BR/>Setting: psychiatric clinic.<BR/>Consent: given.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (DSM-IV ).<BR/>N=30.<BR/>History: either first episode or newly relapsed, all currently unmedicated.<BR/>Sex: 18 men, 12 women.<BR/>Age: ~25-45 years.<BR/>Exclusions: not described.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-05-06 15:13:05 +0100" MODIFIED_BY="[Empty name]">
<P>1. Eicosapentaenoic acid enriched oil (oil containing 2 g of EPA). N=15.<BR/>2. Placebo (corn oil). N=15.</P>
<P>Aim of study was to keep participants unmedicated but if neuroleptics were required after randomisation, they were given.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Global state: need for neuroleptics.<BR/>Mental state: PANSS score.<BR/>Leaving the study early.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-05-06 15:13:23 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Peet-2002">
<CHAR_METHODS MODIFIED="2009-02-02 13:07:33 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random assignment.<BR/>Blindness: double.<BR/>Duration: 12 weeks.<BR/>Setting: outpatient clinic.<BR/>Consent: given.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-02-25 12:23:05 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia (DSM-IV).<BR/>N=122.<BR/>History: symptomatic despite neuroleptic treatment.<BR/>Sex: 66M, 39F*.<BR/>Age: ~18 - 65 years.<BR/>Exclusions: suffered from schizophrenia for over 20 years, other significant medical or neurological disorder, substance abuse, risk of self harm, taking of concurrent co comitant medication, pregnancy, participation in other study within 90 days of trial, abnormal lab results.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-05-06 15:13:23 +0100" MODIFIED_BY="[Empty name]">
<P>1. Ethyl-eicosapentenoic acid: dose 1 g/day. N=32.<BR/>2. Ethyl-eicosapentaenoic acid: dose 2 g/day. N=32.<BR/>3. Ethyl-eicosapentaenoic acid: dose 4 g/day. N=27.<BR/>4. Placebo. N=31.</P>
<P>Previous neuroleptic treatment remained constant throughout trial.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-02-25 12:23:47 +0000" MODIFIED_BY="[Empty name]">
<P>Adverse effects: observed events.<BR/>Leaving the study early.</P>
<P>Unable to use:<BR/>Global state: CGI (no data).<BR/>Mental state: MADRS, PANSS, (no SD).<BR/>Compliance with medication (no data).<BR/>Adverse effects: AIMS, BAS, LUNSERS, SAS, (no SD).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>* only 115 participants analysed.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-02-25 12:50:29 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wolkin-1986">
<CHAR_METHODS>
<P>Allocation: random assignment.<BR/>Blindness: double.<BR/>Duration: 6 weeks.<BR/>Setting: hospital and community.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-02-25 12:50:17 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia (15), bipolar affective disorder (1).<BR/>N=16.<BR/>History: chronically ill, long exposure to antipsychotic drugs, mild TD over 1 yr.<BR/>Sex: men.<BR/>Age: average~55 years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-02-25 12:50:21 +0000" MODIFIED_BY="[Empty name]">
<P>1. Omega-6 EFA (gamma-linolenic acid): dose 600 mg/day. N=8.<BR/>2. Placebo. N=8.</P>
<P>Previous neuroleptic treatment remained constant throughout trial.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-02-25 12:50:29 +0000" MODIFIED_BY="[Empty name]">
<P>Adverse effects: AIMS.</P>
<P>Unable to use:<BR/>Leaving the study early (loss &gt; 30%)<BR/>Mental state: BPRS score (loss &gt; 30%).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2009-05-06 15:18:34 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2009-02-25 12:51:12 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Amminger-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-25 12:51:12 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Participants: young adolescents at risk of schizophrenia or psychosis.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-06 15:14:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Glen-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-06 15:14:34 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Participants: people with DSM-III-R schizophrenia.<BR/>Intervention: 500 mg/day oil of evening primrose vs placebo.<BR/>Outcomes: all data unusable.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Heresco_x002d_Levy-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with treatment-resistant chronic schizophrenia.<BR/>Intervention: continued antipsychotic drugs + glycine vs continued antipsychotic drugs + placebo, no EFA.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-06 15:14:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Holman-1983">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-06 15:14:54 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not stated, double-blind.<BR/>Participants: people with chronic schizophrenia.<BR/>Intervention: continued antipsychotic drugs + EFA vs continued antipsychotic drugs + placebo.<BR/>Outcomes: unable to use - loss to follow up (&gt; 50% &amp; original group not reported); mental state (BPRS - EFA group data only); and behaviour (MACC - EFA group data only).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Maurer-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with DSM-IV schizophrenia.<BR/>Intervention: haloperidol vs olanzapine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Peet-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Puri-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with Huntington's disease.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-06 15:16:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Silbergeld-1973">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-06 15:16:05 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia, depression, anxiety.<BR/>Intervention: dexamethasone (1 mg/day) vs placebo.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-06 15:17:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vaddadi-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-06 15:17:21 +0100" MODIFIED_BY="[Empty name]">
<P>Two studies.</P>
<P>Allocation: randomised.<BR/>Participants: people with treatment-resistant chronic schizophrenia.<BR/>Intervention: <BR/>Study 1. Continued antipsychotic drugs + EFA vs placebo depot injections + EFA.<BR/>Study 2. Continued antipsychotic drugs + EFA vs placebo depot injections + placebo, not evaluating EFA supplementation.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-10 11:59:36 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vaddadi-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-10 11:59:36 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia, mild neuroleptic-induced TD.<BR/>Intervention: continued antipsychotic drugs + EFA + vitamin E vs continued antipsychotic drugs + placebo + vitamin E.<BR/>Outcomes: unable to use - loss to follow up (numbers not reported by group); mental state (CPRS - no SD); movement disorders (AIMS - no SD); and cognitive function (WMS - no SD).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>Clinical Scales<BR/>AIMS - Abnormal Involuntary Movements Scale<BR/>BPRS - British Psychiatric Rating Scale<BR/>CPRS - Comprehensive Psychopathological Rating Scale<BR/>MACC - Motility Affect Cooperation Communication Scale<BR/>WMS - Wechsler Memory Scale</P>
<P>Miscellaneous<BR/>EFA - Essential fatty acid/s<BR/>SD - Standard deviation</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2009-02-03 12:01:50 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2009-05-06 15:21:23 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2009-02-25 12:57:10 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bentsen-2007">
<CHAR_STUDY_NAME MODIFIED="2009-02-25 12:53:32 +0000" MODIFIED_BY="[Empty name]">
<P>A multicentre, placebo-controlled trial of eicosapentaenoic acid (EPA) and antioxidant supplementation in the treatment of schizophrenia and related disorders.</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2009-02-25 12:53:46 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: double.<BR/>Duration: 16 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-02-25 12:56:00 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia or related psychoses.<BR/>N=99.<BR/>Age: 18-40 years.<BR/>Sex: male and female.<BR/>History: admitted within 21 days of trial, less than 15 years since first diagnosis.<BR/>Exclusions: substance abuse, allergy to medication.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-02-25 12:56:22 +0000" MODIFIED_BY="[Empty name]">
<P>1. E-EPA and/or Vitamins E+C plus regular medication.<BR/>2. Placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-02-25 12:56:57 +0000" MODIFIED_BY="[Empty name]">
<P>Mental state: PANSS.<BR/>Adverse effects: UKURS, lab results.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2009-01-27 23:33:47 +0000" MODIFIED_BY="[Empty name]">
<P>2007</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION/>
<CHAR_NOTES MODIFIED="2009-02-25 12:57:10 +0000" MODIFIED_BY="[Empty name]">
<P>Has been finished, no data yet.</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2009-05-06 15:21:06 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Blanchet-2008">
<CHAR_STUDY_NAME MODIFIED="2009-02-25 12:57:34 +0000" MODIFIED_BY="[Empty name]">
<P>Efficacy of docosahexaenoic acid on tardive dyskinesia.</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2009-02-25 12:57:45 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: double.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-02-25 12:57:49 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: people with tardive dyskinesia.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-02-25 12:57:59 +0000" MODIFIED_BY="[Empty name]">
<P>1. Omega-3 fish oil capsules (including DHA).<BR/>2. Placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-06 15:21:06 +0100" MODIFIED_BY="[Empty name]">
<P>Unknown.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2009-02-25 12:58:26 +0000" MODIFIED_BY="[Empty name]">
<P>February 2008.</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION/>
<CHAR_NOTES/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2009-05-06 15:21:16 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Korbanic-2005">
<CHAR_STUDY_NAME MODIFIED="2009-02-25 12:58:21 +0000" MODIFIED_BY="[Empty name]">
<P>CAD (coronary artery disease) risk in schizophrenia: effect of omega-3 fatty acid supplementation.</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2009-05-06 15:21:02 +0100" MODIFIED_BY="[Empty name]">
<P>Unknown.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-02-25 12:58:21 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: people with clinically stable schizophrenia.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-02-25 12:58:30 +0000" MODIFIED_BY="[Empty name]">
<P>1. Omega-3 polyunsaturated fatty acid administration, lipid lowering drug administration.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-02-25 12:58:33 +0000" MODIFIED_BY="[Empty name]">
<P>Mental state: reduction of illness severity.</P>
<P>Physical: reduction of coronary artery disease.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2009-05-06 15:21:16 +0100" MODIFIED_BY="[Empty name]">
<P>Unknown.</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION/>
<CHAR_NOTES/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2009-05-06 15:21:23 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Murck-2001">
<CHAR_STUDY_NAME MODIFIED="2009-02-25 12:58:44 +0000" MODIFIED_BY="[Empty name]">
<P>A multicentre, double-blind, randomised, parallel group, placebo-controlled, dose-ranging pilot study of ethyl-eicosapentaenoate (ethyl-EPA) in patients with schizophrenia.</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2009-05-06 15:21:23 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: double.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-02-25 12:58:54 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-02-25 12:59:06 +0000" MODIFIED_BY="[Empty name]">
<P>1. Varied doses of E-EPA.<BR/>2. Placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-02-03 12:01:42 +0000" MODIFIED_BY="[Empty name]"/>
<CHAR_STARTING_DATE/>
<CHAR_CONTACT_INFORMATION/>
<CHAR_NOTES MODIFIED="2009-02-03 12:01:42 +0000" MODIFIED_BY="[Empty name]"/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2009-02-25 13:02:11 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Richtand-2007">
<CHAR_STUDY_NAME MODIFIED="2009-02-25 12:59:11 +0000" MODIFIED_BY="[Empty name]">
<P>Omega-3 fatty acid deficiency replacement in early schizophrenia.</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2009-02-25 12:59:17 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: double.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-02-25 13:02:02 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-02-25 13:02:07 +0000" MODIFIED_BY="[Empty name]">
<P>1. Dietary supplementation with omega-3 fatty acids.<BR/>2. Placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES/>
<CHAR_STARTING_DATE MODIFIED="2009-02-25 13:02:11 +0000" MODIFIED_BY="[Empty name]">
<P>January 2008.</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION/>
<CHAR_NOTES/>
</ONGOING_CHAR>
<FOOTNOTES>
<P>
<BR/>EPA: Eicosapentaenoic acid.<BR/>PANSS: Positive and negative syndrome scale.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2009-02-25 12:50:55 +0000" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2009-02-25 12:50:34 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-25 12:03:36 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Berger-2007">
<DESCRIPTION>
<P>Randomised code list.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-02 13:14:18 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Emsley-2002">
<DESCRIPTION>
<P>No description given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-25 12:18:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Emsley-2006">
<DESCRIPTION>
<P>Assignment of numbers by independent clinical trials company but not described how achieved.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-25 12:19:35 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fenton-2001">
<DESCRIPTION>
<P>No description given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-25 12:21:16 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Peet-2001a">
<DESCRIPTION>
<P>Unique randomisation number generated by a company independent to the trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-25 12:22:31 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Peet-2001b">
<DESCRIPTION>
<P>Unique randomisation number generated by a company independent to the trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-25 12:24:16 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Peet-2002">
<DESCRIPTION>
<P>Unique randomisation number generated by a company independent to the trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-25 12:50:34 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wolkin-1986">
<DESCRIPTION>
<P>No description given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2009-02-25 12:50:37 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-25 12:03:37 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Berger-2007">
<DESCRIPTION>
<P>Sealed envelopes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-02 13:14:17 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Emsley-2002">
<DESCRIPTION>
<P>No description given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-25 12:18:09 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Emsley-2006">
<DESCRIPTION>
<P>Identical sealed packs.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-25 12:19:38 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fenton-2001">
<DESCRIPTION>
<P>No description given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-25 12:21:20 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Peet-2001a">
<DESCRIPTION>
<P>Pre-coded packages, code kept from researchers.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-25 12:22:35 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Peet-2001b">
<DESCRIPTION>
<P>Pre-coded packages, code kept from researchers.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-25 12:24:22 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Peet-2002">
<DESCRIPTION>
<P>Pre-coded packages, code kept from researchers.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-25 12:50:37 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wolkin-1986">
<DESCRIPTION>
<P>No description given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2009-02-25 12:50:41 +0000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-02-25 12:03:39 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Berger-2007">
<DESCRIPTION>
<P>Both interventions in identical tasteless capsules.</P>
<P>Key to allocation code kept from participants and researchers until end of data entry.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-02-02 13:14:14 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Emsley-2002">
<DESCRIPTION>
<P>No description given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-02-25 12:18:17 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Emsley-2006">
<DESCRIPTION>
<P>Identical sealed packs, identical capsules, code not broken until after trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-02-25 12:19:46 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fenton-2001">
<DESCRIPTION>
<P>Identical capsules used, raters blind to treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-02-25 12:21:24 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Peet-2001a">
<DESCRIPTION>
<P>Identical capsules in appearance and taste, raters blind to allocation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-02-25 12:22:39 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Peet-2001b">
<DESCRIPTION>
<P>Identical capsules in appearance and taste, raters blind to allocation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-02-25 12:24:26 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Peet-2002">
<DESCRIPTION>
<P>Identical capsules in appearance and taste, raters blind to allocation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-02-25 12:50:41 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wolkin-1986">
<DESCRIPTION>
<P>No description given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2009-02-25 12:50:46 +0000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-01-27 12:51:59 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Berger-2007">
<DESCRIPTION>
<P>Numbers leaving study early described and explained - all left before first analysis and code breaking.</P>
<P>Analysis available for all remaining participants. </P>
<P>Missing data from those who left early dealt with by multiple imputation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-06 10:35:46 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Emsley-2002">
<DESCRIPTION>
<P>LOCF, ITT.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-06 10:42:05 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Emsley-2006">
<DESCRIPTION>
<P>LOCF, ITT.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-25 12:19:48 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fenton-2001">
<DESCRIPTION>
<P>LOCF, ITT.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-25 12:21:28 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Peet-2001a">
<DESCRIPTION>
<P>Loss to follow up described but how this data was dealt with not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-25 12:22:43 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Peet-2001b">
<DESCRIPTION>
<P>Loss to follow up described but how this data was dealt with not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-25 12:24:33 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Peet-2002">
<DESCRIPTION>
<P>Loss to follow up described but how this data was dealt with not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-25 12:50:46 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wolkin-1986">
<DESCRIPTION>
<P>Significant loss occurred but not addressed in text.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2009-02-25 12:50:50 +0000" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-25 12:03:55 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Berger-2007">
<DESCRIPTION>
<P>Several outcomes not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-25 12:12:26 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Emsley-2002">
<DESCRIPTION>
<P>All outcomes reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-25 12:18:21 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Emsley-2006">
<DESCRIPTION>
<P>All outcomes reported but most data presentation unusable.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-25 12:19:53 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fenton-2001">
<DESCRIPTION>
<P>All outcomes reported and presented with means and SD.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-25 12:21:33 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Peet-2001a">
<DESCRIPTION>
<P>All outcomes reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-25 12:22:47 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Peet-2001b">
<DESCRIPTION>
<P>All outcomes reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-25 12:24:37 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Peet-2002">
<DESCRIPTION>
<P>Some outcomes had no data presentation in results.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-25 12:50:50 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wolkin-1986">
<DESCRIPTION>
<P>All outcomes reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2009-02-25 12:50:55 +0000" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-25 12:03:58 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Berger-2007">
<DESCRIPTION>
<P>Main author consultant for several major antipsychotic drug companies.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-25 12:49:33 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Emsley-2002">
<DESCRIPTION>
<P>Grant sponsored, medication supplied by Laxdale Ltd.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-25 12:18:39 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Emsley-2006">
<DESCRIPTION>
<P>Supported by grant from Stanley Medical/Alliance Research Institute, medication supplied by Amarin Neuroscience Ltd.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-25 12:19:59 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fenton-2001">
<DESCRIPTION>
<P>Supported by grant from Stanley Medical/Alliance Research Institute.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-10 11:58:00 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Peet-2001a">
<DESCRIPTION>
<P>Laxdale Ltd supplied trial medication and some financial support.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-10 11:58:35 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Peet-2001b">
<DESCRIPTION>
<P>Laxdale Ltd supplied trial medication and some financial support.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-25 12:29:51 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Peet-2002">
<DESCRIPTION>
<P>Main author Dr. Malcolm Peet received research funding from Laxdale, Prof. Horrobin was an employee of Laxdale at the time and other members of the E-E Multicentre Study Group received remuneration from Laxdale for the time spent on the study. Laxdale supplied medication for trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-25 12:50:55 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wolkin-1986">
<DESCRIPTION>
<P>Supported in part by Efamol ltd.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2009-05-06 15:21:45 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2009-05-06 15:21:45 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE>Suggested design of study</TITLE>
<TABLE COLS="5" ROWS="2">
<TR>
<TH>
<P>Type of study</P>
</TH>
<TH>
<P>Patient</P>
</TH>
<TH>
<P>Intervention</P>
</TH>
<TH>
<P>Outcomes</P>
</TH>
<TH>
<P>Notes</P>
</TH>
</TR>
<TR>
<TD>
<P>Allocation: randomised, with sequence generation and concealment of allocation clearly described.<BR/>Blindness: double, tested.<BR/>Design: parallel group.<BR/>Duration: 2, 6 and 12 months.</P>
</TD>
<TD>
<P>Diagnosis: any person with schizophrenia<BR/>History: stable on antipsychotic medication.<BR/>N=300.*<BR/>Age: any.<BR/>Sex: both.</P>
</TD>
<TD>
<P>1. Neuroleptic medication + ethyl-eicosapentaenoic acid: dose 3 g/day. N=150.<BR/>2. Neuroleptic medication alone. N=150.</P>
</TD>
<TD>
<P>Service use: readmission/relapse**, time in hospital, use of other psychotropic medications.<BR/>Global response: CGI (binary).**<BR/>Mental state: CGI (binary).<BR/>Serious adverse effects: any**, list.<BR/>Acceptability of treatment to patient, staff and carers (binary outcome).<BR/>Economic outcomes.</P>
</TD>
<TD>
<P>* Size of study with sufficient power to highlight ~10% difference between groups for primary outcome.<BR/>** Primary outcome.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2009-02-13 11:00:37 +0000" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2009-02-13 11:00:37 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>ANY DOSE OMEGA-3 (E-EPA or EPA ) versus PLACEBO</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.020610877852942" CI_START="0.5393517492042281" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7419354838709677" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.008860192809001107" LOG_CI_START="-0.26812790844236073" LOG_EFFECT_SIZE="-0.1296338578166798" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.06656871829147858" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="1.834574780287097">
<NAME>Global state: 1. Needing standard neuroleptics by end of trial (short term)</NAME>
<GROUP_LABEL_1>E-EPA or EPA</GROUP_LABEL_1>
<GROUP_LABEL_2>PLACEBO</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Omega 3</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placbeo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.020610877852942" CI_START="0.5393517492042281" DF="0" EFFECT_SIZE="0.7419354838709677" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="15" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="0.008860192809001107" LOG_CI_START="-0.26812790844236073" LOG_EFFECT_SIZE="-0.1296338578166798" NO="1" P_CHI2="1.0" P_Z="0.06656871829147858" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="1.834574780287097">
<NAME>untreated when included in study</NAME>
<DICH_DATA CI_END="1.020610877852942" CI_START="0.5393517492042281" EFFECT_SIZE="0.7419354838709677" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="15" LOG_CI_END="0.008860192809001107" LOG_CI_START="-0.26812790844236073" LOG_EFFECT_SIZE="-0.1296338578166798" ORDER="213" O_E="0.0" SE="0.16270418178826412" STUDY_ID="STD-Peet-2001b" TOTAL_1="15" TOTAL_2="15" VAR="0.026472650771388495" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.02" MODIFIED="2009-02-13 10:59:00 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="43" TOTAL_2="44" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Global state: 2. Average scale score by end of trial (CGI, medium term, high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Omega 3</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.29420170908230736" CI_START="-0.29420170908230736" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="3.5" MEAN_2="3.5" ORDER="214" SD_1="0.7" SD_2="0.7" SE="0.1501056710240254" STUDY_ID="STD-Fenton-2001" TOTAL_1="43" TOTAL_2="44" WEIGHT="0.0"/>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-001.03" NO="3" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Global state: 3. Average number of days on neuroleptics during trial (short term, skewed data)</NAME>
<TR>
<TH>
<P>Interventions</P>
</TH>
<TH>
<P>N</P>
</TH>
<TH>
<P>Mean</P>
</TH>
<TH>
<P>SD</P>
</TH>
</TR>
<OTHER_DATA ORDER="76" STUDY_ID="STD-Peet-2001b">
<TR>
<TD>
<P>EPA<BR/>
</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>35.1</P>
</TD>
<TD>
<P>34.7</P>
</TD>
</TR>
<TR>
<TD>
<P>Placebo</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>65.3</P>
</TD>
<TD>
<P>18.9</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.6259561695679605" CI_START="0.5004302388638431" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9020408163265307" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.21110883426460741" LOG_CI_START="-0.3006564556234509" LOG_EFFECT_SIZE="-0.044773810679421745" METHOD="MH" MODIFIED="2009-02-03 12:24:03 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="0.0" P_Z="0.7316357725462055" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="35" TOTAL_2="34" WEIGHT="100.0" Z="0.3429504036957126">
<NAME>Global state: 4. Not achieving symptomatic response by 12 weeks - all participants</NAME>
<GROUP_LABEL_1>E-EPA</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6259561695679605" CI_START="0.5004302388638431" EFFECT_SIZE="0.9020408163265307" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="14" LOG_CI_END="0.21110883426460741" LOG_CI_START="-0.3006564556234509" LOG_EFFECT_SIZE="-0.044773810679421745" MODIFIED="2009-02-03 12:24:03 +0000" MODIFIED_BY="[Empty name]" ORDER="488" O_E="0.0" SE="0.30061346455928656" STUDY_ID="STD-Berger-2007" TOTAL_1="35" TOTAL_2="34" VAR="0.09036845507433744" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.2436604711384986" CI_START="0.25008490442286896" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5576923076923077" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.09470183080704343" LOG_CI_START="-0.6019125222787296" LOG_EFFECT_SIZE="-0.25360534573584304" METHOD="MH" MODIFIED="2009-02-03 12:20:33 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="0.0" P_Z="0.15356085938448438" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="24" TOTAL_2="29" WEIGHT="100.0" Z="1.4270660422866113">
<NAME>Global state: 5. Not achieving symptomatic response by 12 weeks - nonaffective participants</NAME>
<GROUP_LABEL_1>E-EPA</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2436604711384986" CI_START="0.25008490442286896" EFFECT_SIZE="0.5576923076923077" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="13" LOG_CI_END="0.09470183080704343" LOG_CI_START="-0.6019125222787296" LOG_EFFECT_SIZE="-0.25360534573584304" MODIFIED="2009-02-03 12:17:38 +0000" MODIFIED_BY="[Empty name]" ORDER="487" O_E="0.0" SE="0.4091947192992442" STUDY_ID="STD-Berger-2007" TOTAL_1="24" TOTAL_2="29" VAR="0.16744031830238726" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.1345140521812289" CI_END="0.8533053208107452" CI_START="0.39338366361587823" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5793758480325645" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="25" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="-0.06889554630273996" LOG_CI_START="-0.40518367936531524" LOG_EFFECT_SIZE="-0.2370396128340276" METHOD="MH" MODIFIED="2009-02-03 12:18:25 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.7137969686368122" P_Q="0.0" P_Z="0.005726541158359645" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="30" TOTAL_2="29" WEIGHT="200.0" Z="2.763041917851817">
<NAME>Mental state: 1. Not improved by end of trial (&lt;25% improvement on PANSS scale, short term)</NAME>
<GROUP_LABEL_1>E-EPA OR EPA</GROUP_LABEL_1>
<GROUP_LABEL_2>PLACEBO</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Omega 3</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.958128371409792" CI_START="0.3026116719367649" DF="0" EFFECT_SIZE="0.5384615384615384" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="13" I2="0.0" ID="CMP-001.06.01" LOG_CI_END="-0.018576299627153937" LOG_CI_START="-0.519114324958006" LOG_EFFECT_SIZE="-0.26884531229257996" NO="1" P_CHI2="1.0" P_Z="0.03525276802929711" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="2.105442954738894">
<NAME>untreated when included in study</NAME>
<DICH_DATA CI_END="0.958128371409792" CI_START="0.3026116719367649" EFFECT_SIZE="0.5384615384615384" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="13" LOG_CI_END="-0.018576299627153937" LOG_CI_START="-0.519114324958006" LOG_EFFECT_SIZE="-0.26884531229257996" ORDER="216" O_E="0.0" SE="0.29401851378252775" STUDY_ID="STD-Peet-2001b" TOTAL_1="15" TOTAL_2="15" VAR="0.08644688644688646" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0460078818394423" CI_START="0.3701315263000934" DF="0" EFFECT_SIZE="0.6222222222222222" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" I2="0.0" ID="CMP-001.06.02" LOG_CI_END="0.019534957023110512" LOG_CI_START="-0.4316439218893594" LOG_EFFECT_SIZE="-0.20605448243312444" NO="2" P_CHI2="1.0" P_Z="0.0734152472459499" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="14" WEIGHT="100.0" Z="1.7902405599988873">
<NAME>receiving neuroleptics when included in study</NAME>
<DICH_DATA CI_END="1.0460078818394423" CI_START="0.3701315263000934" EFFECT_SIZE="0.6222222222222222" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" LOG_CI_END="0.019534957023110512" LOG_CI_START="-0.4316439218893594" LOG_EFFECT_SIZE="-0.20605448243312444" ORDER="217" O_E="0.0" SE="0.26502470684465484" STUDY_ID="STD-Peet-2001a" TOTAL_1="15" TOTAL_2="14" VAR="0.07023809523809524" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="4.272964354167453" CI_END="-1.3245353193397307" CI_START="-11.339217923030473" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-6.331876621185102" ESTIMABLE="YES" I2="53.19408648823888" I2_Q="53.19408648823888" ID="CMP-001.07" MODIFIED="2009-02-13 11:00:37 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.11806952586576769" P_Q="0.11806952586576769" P_Z="0.013196900317256711" Q="4.272964354167453" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="72" TOTAL_2="70" UNITS="" WEIGHT="300.0" Z="2.4784110736570684">
<NAME>Mental state: 2. Average scale score by end of trial (PANSS, high=poor)</NAME>
<GROUP_LABEL_1>E-EPA OR EPA</GROUP_LABEL_1>
<GROUP_LABEL_2>PLACEBO</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours E-EPA OR EPA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-2.61679305437009" CI_START="-22.383206945629908" DF="0" EFFECT_SIZE="-12.5" ESTIMABLE="YES" I2="0.0" ID="CMP-001.07.01" NO="1" P_CHI2="1.0" P_Z="0.01317857026433009" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="12" WEIGHT="100.0" Z="2.4789068914097485">
<NAME>untreated when included in study (short term)</NAME>
<CONT_DATA CI_END="-2.6167930543700884" CI_START="-22.38320694562991" EFFECT_SIZE="-12.5" ESTIMABLE="YES" MEAN_1="44.6" MEAN_2="57.1" ORDER="218" SD_1="8.7" SD_2="15.5" SE="5.042545181231588" STUDY_ID="STD-Peet-2001b" TOTAL_1="14" TOTAL_2="12" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.4483759822725393" CI_START="-20.351624017727474" DF="0" EFFECT_SIZE="-10.400000000000006" ESTIMABLE="YES" I2="0.0" ID="CMP-001.07.02" NO="2" P_CHI2="1.0" P_Z="0.04053342769713465" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="14" WEIGHT="100.0" Z="2.0482712573250272">
<NAME>receiving neuroleptics when included in study (short term)</NAME>
<CONT_DATA CI_END="-0.4483759822725393" CI_START="-20.351624017727474" EFFECT_SIZE="-10.400000000000006" ESTIMABLE="YES" MEAN_1="55.5" MEAN_2="65.9" ORDER="219" SD_1="12.2" SD_2="14.9" SE="5.077452492099144" STUDY_ID="STD-Peet-2001a" TOTAL_1="15" TOTAL_2="14" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="6.152425202849142" CI_START="-8.152425202849141" DF="0" EFFECT_SIZE="-1.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.07.03" NO="3" P_CHI2="1.0" P_Z="0.7840631891350407" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="44" WEIGHT="100.0" Z="0.27402788969527564">
<NAME>receiving neuroleptics when included in study (medium term)</NAME>
<CONT_DATA CI_END="6.152425202849142" CI_START="-8.152425202849141" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="69.0" MEAN_2="70.0" ORDER="220" SD_1="16.0" SD_2="18.0" SE="3.6492635881406796" STUDY_ID="STD-Fenton-2001" TOTAL_1="43" TOTAL_2="44" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-001.08" MODIFIED="2009-02-03 12:18:16 +0000" MODIFIED_BY="[Empty name]" NO="8" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Mental state: 3. Average scale score by end of trial (MADRS, medium term, high=poor, skewed data)</NAME>
<TR>
<TH>
<P>Interventions</P>
</TH>
<TH>
<P>N</P>
</TH>
<TH>
<P>Mean</P>
</TH>
<TH>
<P>SD</P>
</TH>
</TR>
<OTHER_DATA ORDER="84" STUDY_ID="STD-Fenton-2001">
<TR>
<TD>
<P>EPA<BR/>
</P>
</TD>
<TD>
<P>43</P>
</TD>
<TD>
<P>6.2</P>
</TD>
<TD>
<P>4.2</P>
</TD>
</TR>
<TR>
<TD>
<P>Placebo</P>
</TD>
<TD>
<P>44</P>
</TD>
<TD>
<P>6.6</P>
</TD>
<TD>
<P>4.7</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="5" ID="CMP-001.09" MODIFIED="2009-02-03 12:18:13 +0000" MODIFIED_BY="[Empty name]" NO="9" ROWS_PER_STUDY="4" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Adverse events: Average scale score by end of trial (medium term, high=poor, skewed data)</NAME>
<TR>
<TH>
<P>Scale</P>
</TH>
<TH>
<P>Interventions</P>
</TH>
<TH>
<P>N</P>
</TH>
<TH>
<P>Mean</P>
</TH>
<TH>
<P>SD</P>
</TH>
</TR>
<OTHER_DATA ORDER="85" STUDY_ID="STD-Fenton-2001">
<TR>
<TD>
<P>AIMS</P>
</TD>
<TD>
<P>EPA</P>
</TD>
<TD>
<P>43</P>
</TD>
<TD>
<P>2.7</P>
</TD>
<TD>
<P>5.3</P>
</TD>
</TR>
<TR>
<TD/>
<TD>
<P>Placebo</P>
</TD>
<TD>
<P>44</P>
</TD>
<TD>
<P>3.2</P>
</TD>
<TD>
<P>5.4</P>
</TD>
</TR>
<TR>
<TD>
<P>SAS</P>
</TD>
<TD>
<P>EPA</P>
</TD>
<TD>
<P>43</P>
</TD>
<TD>
<P>2.4</P>
</TD>
<TD>
<P>3.1</P>
</TD>
</TR>
<TR>
<TD/>
<TD>
<P>Placebo</P>
</TD>
<TD>
<P>44</P>
</TD>
<TD>
<P>2.7</P>
</TD>
<TD>
<P>3.8</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.1411762634878047" CI_START="-1.9411762634878036" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.39999999999999947" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.10" MODIFIED="2009-02-03 12:18:10 +0000" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="1.0" P_Q="1.0" P_Z="0.6109674240617824" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="39" TOTAL_2="38" UNITS="" WEIGHT="100.0" Z="0.5086930109096017">
<NAME>Adverse events: Average time to first tardive dyskinesia response</NAME>
<GROUP_LABEL_1>E-EPA</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.1411762634878047" CI_START="-1.9411762634878036" EFFECT_SIZE="-0.39999999999999947" ESTIMABLE="YES" MEAN_1="7.7" MEAN_2="8.1" MODIFIED="2009-01-30 11:56:45 +0000" MODIFIED_BY="[Empty name]" ORDER="72" SD_1="3.5" SD_2="3.4" SE="0.7863288691243338" STUDY_ID="STD-Emsley-2006" TOTAL_1="39" TOTAL_2="38" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="1.187642081721744" CI_END="1.4029567011974882" CI_START="0.5120834099055368" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8476030034745234" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="30" I2="0.0" I2_Q="0.0" ID="CMP-001.11" LOG_CI_END="0.14704426780585303" LOG_CI_START="-0.2906592938847784" LOG_EFFECT_SIZE="-0.0718075130394627" METHOD="MH" MODIFIED="2009-02-03 12:18:08 +0000" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.946057435751481" P_Q="0.0" P_Z="0.5201694196679537" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="370" TOTAL_2="309" WEIGHT="100.0" Z="0.6430842775559235">
<NAME>Leaving the study early</NAME>
<GROUP_LABEL_1>E-EPA OR EPA</GROUP_LABEL_1>
<GROUP_LABEL_2>PLACEBO</GROUP_LABEL_2>
<GRAPH_LABEL_1>FAVOURS Omega 3</GRAPH_LABEL_1>
<GRAPH_LABEL_2>FAVOURS Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.5656738126532549" CI_END="1.5897133934922683" CI_START="0.31472862209115554" DF="2" EFFECT_SIZE="0.7073388903868334" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="13" I2="0.0" ID="CMP-001.11.01" LOG_CI_END="0.201318833223287" LOG_CI_START="-0.5020637596256803" LOG_EFFECT_SIZE="-0.15037246320119657" MODIFIED="2009-02-02 10:04:05 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7536427146337752" P_Z="0.4020190450112747" STUDIES="5" TAU2="0.0" TOTAL_1="203" TOTAL_2="142" WEIGHT="38.72370728178994" Z="0.8380207731532654">
<NAME>short term</NAME>
<DICH_DATA CI_END="2.510826009765055" CI_START="0.2765800743435127" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.39981661887899633" LOG_CI_START="-0.558179110974246" LOG_EFFECT_SIZE="-0.07918124604762482" MODIFIED="2009-01-30 11:59:00 +0000" MODIFIED_BY="[Empty name]" ORDER="69" O_E="0.0" SE="0.5627314338711378" STUDY_ID="STD-Berger-2007" TOTAL_1="40" TOTAL_2="40" VAR="0.31666666666666665" WEIGHT="20.87531389853905"/>
<DICH_DATA CI_END="3.148306452599371" CI_START="0.1786674863038117" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.49807699947966155" LOG_CI_START="-0.7479544726962613" LOG_EFFECT_SIZE="-0.12493873660829993" ORDER="76" O_E="0.0" SE="0.7319250547113998" STUDY_ID="STD-Emsley-2006" TOTAL_1="42" TOTAL_2="42" VAR="0.5357142857142856" WEIGHT="12.339629993358642"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="223" O_E="0.0" SE="0.0" STUDY_ID="STD-Peet-2001a" TOTAL_1="15" TOTAL_2="14" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.8531415452949767" CI_START="0.03894342756823292" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.45532331768430767" LOG_CI_START="-1.4095658271236327" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="224" O_E="0.0" SE="1.0954451150103321" STUDY_ID="STD-Peet-2001b" TOTAL_1="15" TOTAL_2="15" VAR="1.2" WEIGHT="5.50876338989225"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="225" O_E="0.0" SE="0.0" STUDY_ID="STD-Peet-2002" TOTAL_1="91" TOTAL_2="31" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.3083135200375963" CI_END="1.8089241299588605" CI_START="0.4991869894027294" DF="2" EFFECT_SIZE="0.9502585913803228" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="17" I2="0.0" ID="CMP-001.11.02" LOG_CI_END="0.25742035202775543" LOG_CI_START="-0.30173674244469384" LOG_EFFECT_SIZE="-0.022158195208469206" MODIFIED="2009-01-30 11:59:19 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8571376619016375" P_Z="0.8765545995959031" STUDIES="3" TAU2="0.0" TOTAL_1="167" TOTAL_2="167" WEIGHT="61.27629271821006" Z="0.1553383297836258">
<NAME>medium term</NAME>
<DICH_DATA CI_END="2.6203861225065315" CI_START="0.2650160747226723" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.41836529075425605" LOG_CI_START="-0.5767277828495057" LOG_EFFECT_SIZE="-0.07918124604762482" MODIFIED="2009-01-29 11:00:14 +0000" MODIFIED_BY="[Empty name]" ORDER="70" O_E="0.0" SE="0.5845225972250061" STUDY_ID="STD-Berger-2007" TOTAL_1="80" TOTAL_2="80" VAR="0.3416666666666667" WEIGHT="19.347851905963022"/>
<DICH_DATA CI_END="3.148306452599371" CI_START="0.1786674863038117" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.49807699947966155" LOG_CI_START="-0.7479544726962613" LOG_EFFECT_SIZE="-0.12493873660829993" MODIFIED="2009-01-30 11:59:19 +0000" MODIFIED_BY="[Empty name]" ORDER="75" O_E="0.0" SE="0.7319250547113998" STUDY_ID="STD-Emsley-2006" TOTAL_1="42" TOTAL_2="42" VAR="0.5357142857142856" WEIGHT="12.339629993358642"/>
<DICH_DATA CI_END="2.886194343367041" CI_START="0.4525414069850424" EFFECT_SIZE="1.1428571428571428" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.46032557118235495" LOG_CI_START="-0.34434167722698156" LOG_EFFECT_SIZE="0.05799194697768673" ORDER="226" O_E="0.0" SE="0.4726655248827636" STUDY_ID="STD-Fenton-2001" TOTAL_1="45" TOTAL_2="45" VAR="0.2234126984126984" WEIGHT="29.58881081888839"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<OTHER_OUTCOME COLS="5" ID="CMP-001.12" MODIFIED="2009-02-03 12:18:05 +0000" MODIFIED_BY="[Empty name]" NO="12" ROWS_PER_STUDY="6" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Adverse events: Scale change score by end of trial (ESRS) (skewed data)</NAME>
<TR>
<TH>
<P>Subscale</P>
</TH>
<TH>
<P>Intervention</P>
</TH>
<TH>
<P>Mean score change</P>
</TH>
<TH>
<P>SD</P>
</TH>
<TH>
<P>Total</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2009-01-30 11:57:03 +0000" MODIFIED_BY="[Empty name]" ORDER="95" STUDY_ID="STD-Emsley-2006">
<TR>
<TD>
<P>Parkinson</P>
</TD>
<TD>
<P>E-EPA</P>
</TD>
<TD>
<P>-0.8</P>
</TD>
<TD>
<P>3.2</P>
</TD>
<TD>
<P>39</P>
</TD>
</TR>
<TR>
<TD/>
<TD>
<P>Placebo</P>
</TD>
<TD>
<P>-1.1</P>
</TD>
<TD>
<P>3.3</P>
</TD>
<TD>
<P>38</P>
</TD>
</TR>
<TR>
<TD>
<P>Dystonia</P>
</TD>
<TD>
<P>E-EPA</P>
</TD>
<TD>
<P>0.05</P>
</TD>
<TD>
<P>0.5</P>
</TD>
<TD>
<P>39</P>
</TD>
</TR>
<TR>
<TD/>
<TD>
<P>Placebo</P>
</TD>
<TD>
<P>0.4</P>
</TD>
<TD>
<P>0.5</P>
</TD>
<TD>
<P>38</P>
</TD>
</TR>
<TR>
<TD>
<P>Akathisia</P>
</TD>
<TD>
<P>E-EPA</P>
</TD>
<TD>
<P>-0.1</P>
</TD>
<TD>
<P>0.4</P>
</TD>
<TD>
<P>39</P>
</TD>
</TR>
<TR>
<TD/>
<TD>
<P>Placebo</P>
</TD>
<TD>
<P>-0.06</P>
</TD>
<TD>
<P>0.7</P>
</TD>
<TD>
<P>38</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>ANY DOSE OMEGA-6 (GLA) versus PLACEBO</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="4.5576110866964346" CI_START="-1.957611086696435" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="1.2999999999999998" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.01" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.43412414663725585" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="8" TOTAL_2="8" UNITS="" WEIGHT="100.0" Z="0.7821538888750427">
<NAME>Tardive dyskinesia: Average scale score by end of trial (AIMS, short term, high=poor)</NAME>
<GROUP_LABEL_1>GLA</GROUP_LABEL_1>
<GROUP_LABEL_2>PLACEBO</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Omega 6</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="4.5576110866964346" CI_START="-1.957611086696435" EFFECT_SIZE="1.2999999999999998" ESTIMABLE="YES" MEAN_1="7.3" MEAN_2="6.0" ORDER="227" SD_1="2.9" SD_2="3.7" SE="1.6620770138594663" STUDY_ID="STD-Wolkin-1986" TOTAL_1="8" TOTAL_2="8" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.543628888699885" CI_START="0.2821965932123575" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.549448233522865" LOG_CI_START="-0.549448233522865" LOG_EFFECT_SIZE="0.0" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="1.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="8" TOTAL_2="8" WEIGHT="99.99999999999999" Z="0.0">
<NAME>Leaving the study early (short term)</NAME>
<GROUP_LABEL_1>GLA</GROUP_LABEL_1>
<GROUP_LABEL_2>PLACEBO</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours omega 6</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.543628888699885" CI_START="0.2821965932123575" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.549448233522865" LOG_CI_START="-0.549448233522865" LOG_EFFECT_SIZE="0.0" ORDER="228" O_E="0.0" SE="0.6454972243679028" STUDY_ID="STD-Wolkin-1986" TOTAL_1="8" TOTAL_2="8" VAR="0.41666666666666663" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" NO="3">
<NAME>ANY DOSE OMEGA-3 (EPA or E-EPA) versus ANY DOSE OMEGA-3 (DHA)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="8" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="15" TOTAL_2="16" WEIGHT="0.0" Z="0.0">
<NAME>Mental state: 1. Not improved by end of trial (&lt;25% improvement on PANSS scale, short term)</NAME>
<GROUP_LABEL_1>E-EPA OR EPA</GROUP_LABEL_1>
<GROUP_LABEL_2>DHA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours E-EPA / EPA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DHA</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1137130870174128" CI_START="0.38688099272900245" EFFECT_SIZE="0.6564102564102564" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="13" LOG_CI_END="0.04677332299751186" LOG_CI_START="-0.41242260642681117" LOG_EFFECT_SIZE="-0.18282464171464963" ORDER="229" O_E="0.0" SE="0.26973396200035743" STUDY_ID="STD-Peet-2001a" TOTAL_1="15" TOTAL_2="16" VAR="0.07275641025641028" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.370963702088801" CI_START="-20.970963702088795" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-9.799999999999997" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.02" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.08553680506062429" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="16" UNITS="" WEIGHT="100.0" Z="1.7194261444875156">
<NAME>Mental state: 2. Percentage change in scale score by end of trial (PANSS, short term, high=good)</NAME>
<GROUP_LABEL_1>E-EPA OR EPA</GROUP_LABEL_1>
<GROUP_LABEL_2>DHA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours E-EPA / EPA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DHA</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.370963702088801" CI_START="-20.970963702088795" EFFECT_SIZE="-9.799999999999997" ESTIMABLE="YES" MEAN_1="55.5" MEAN_2="65.3" ORDER="230" SD_1="12.2" SD_2="19.0" SE="5.6995760076225555" STUDY_ID="STD-Peet-2001a" TOTAL_1="15" TOTAL_2="16" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="14" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>Leaving the study early (short term)</NAME>
<GROUP_LABEL_1>E-EPA OR EPA</GROUP_LABEL_1>
<GROUP_LABEL_2>DHA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours E-EPA / EPA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DHA</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="231" O_E="0.0" SE="0.0" STUDY_ID="STD-Peet-2001a" TOTAL_1="14" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2009-02-02 10:04:21 +0000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>SPECIFIC DOSES OF E-EPA versus PLACEBO</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.29420170908230736" CI_START="-0.29420170908230736" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.01" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="43" TOTAL_2="44" UNITS="" WEIGHT="100.0" Z="0.0">
<NAME>Global state: Average scale score by end of trial (CGI, medium term, high=poor)</NAME>
<GROUP_LABEL_1>E-EPA (&lt;1g/day)</GROUP_LABEL_1>
<GROUP_LABEL_2>PLACEBO</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours E-EPA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.29420170908230736" CI_START="-0.29420170908230736" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-004.01.01" NO="1" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="44" WEIGHT="100.0" Z="0.0">
<NAME>E-EPA (&lt;1g/day)</NAME>
<CONT_DATA CI_END="0.29420170908230736" CI_START="-0.29420170908230736" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="3.5" MEAN_2="3.5" ORDER="232" SD_1="0.7" SD_2="0.7" SE="0.1501056710240254" STUDY_ID="STD-Fenton-2001" TOTAL_1="43" TOTAL_2="44" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="6.152425202849142" CI_START="-8.152425202849141" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.02" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.7840631891350407" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="43" TOTAL_2="44" UNITS="" WEIGHT="100.0" Z="0.27402788969527564">
<NAME>Mental state: 1. Average scale score by end of trial (PANSS, medium term, high=poor)</NAME>
<GROUP_LABEL_1>E-EPA</GROUP_LABEL_1>
<GROUP_LABEL_2>PLACEBO</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours E-EPA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="6.152425202849142" CI_START="-8.152425202849141" DF="0" EFFECT_SIZE="-1.0" ESTIMABLE="YES" I2="0.0" ID="CMP-004.02.01" NO="1" P_CHI2="1.0" P_Z="0.7840631891350407" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="44" WEIGHT="100.0" Z="0.27402788969527564">
<NAME>E-EPA (&lt;1g/day)</NAME>
<CONT_DATA CI_END="6.152425202849142" CI_START="-8.152425202849141" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="69.0" MEAN_2="70.0" ORDER="233" SD_1="16.0" SD_2="18.0" SE="3.6492635881406796" STUDY_ID="STD-Fenton-2001" TOTAL_1="43" TOTAL_2="44" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-004.03" NO="3" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Mental state: 2. Percentage change in total scores by end of trial (PANSS, medium term, high =good, skewed)</NAME>
<TR>
<TH>
<P>Interventions</P>
</TH>
<TH>
<P>N</P>
</TH>
<TH>
<P>Mean</P>
</TH>
<TH>
<P>SD</P>
</TH>
</TR>
<OTHER_DATA ORDER="103" STUDY_ID="STD-Emsley-2002">
<TR>
<TD>
<P>E-EPA (3g/day)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>12.6</P>
</TD>
<TD>
<P>12.6</P>
</TD>
</TR>
<TR>
<TD>
<P>Placebo<BR/>
</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>3.1</P>
</TD>
<TD>
<P>13.3</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<DICH_OUTCOME CHI2="2.081860820536077" CI_END="1.2329449660574459" CI_START="0.6884632481728634" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9213236652503234" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="48" I2="3.932098617187966" I2_Q="0.0" ID="CMP-004.04" LOG_CI_END="0.09094369178552573" LOG_CI_START="-0.16211923847421672" LOG_EFFECT_SIZE="-0.03558777334434551" METHOD="MH" NO="4" P_CHI2="0.3531261374214826" P_Q="0.0" P_Z="0.5814607734570691" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="91" TOTAL_2="93" WEIGHT="300.0" Z="0.5512522436478544">
<NAME>Adverse events: General 1. Experiencing at least one adverse effect (short term)</NAME>
<GROUP_LABEL_1>E-EPA</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours E-EPA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5750305896542025" CI_START="0.5958465623871103" DF="0" EFFECT_SIZE="0.96875" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="16" I2="0.0" ID="CMP-004.04.01" LOG_CI_END="0.19728899291229568" LOG_CI_START="-0.2248655618835623" LOG_EFFECT_SIZE="-0.013788284485633295" NO="1" P_CHI2="1.0" P_Z="0.8981240427073086" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="31" WEIGHT="100.0" Z="0.12803150264955426">
<NAME>E-EPA (&lt;1g/day)</NAME>
<DICH_DATA CI_END="1.5750305896542025" CI_START="0.5958465623871103" EFFECT_SIZE="0.96875" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="16" LOG_CI_END="0.19728899291229568" LOG_CI_START="-0.2248655618835623" LOG_EFFECT_SIZE="-0.013788284485633295" ORDER="235" O_E="0.0" SE="0.24797567518583546" STUDY_ID="STD-Peet-2002" TOTAL_1="32" TOTAL_2="31" VAR="0.06149193548387097" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1986832358161161" CI_START="0.3700534048448038" DF="0" EFFECT_SIZE="0.666015625" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="16" I2="0.0" ID="CMP-004.04.02" LOG_CI_END="0.07870443154545685" LOG_CI_START="-0.4317355955121229" LOG_EFFECT_SIZE="-0.17651558198333303" NO="2" P_CHI2="1.0" P_Z="0.17524152390776057" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="31" WEIGHT="100.0" Z="1.3555527194517363">
<NAME>E-EPA (2g/day)</NAME>
<DICH_DATA CI_END="1.1986832358161161" CI_START="0.3700534048448038" EFFECT_SIZE="0.666015625" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="16" LOG_CI_END="0.07870443154545685" LOG_CI_START="-0.4317355955121229" LOG_EFFECT_SIZE="-0.17651558198333303" ORDER="236" O_E="0.0" SE="0.2998349986125067" STUDY_ID="STD-Peet-2002" TOTAL_1="32" TOTAL_2="31" VAR="0.08990102639296188" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.8234654570162316" CI_START="0.7229334479705954" DF="0" EFFECT_SIZE="1.1481481481481481" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="16" I2="0.0" ID="CMP-004.04.03" LOG_CI_END="0.26089754063069814" LOG_CI_START="-0.1409016812801274" LOG_EFFECT_SIZE="0.05999792967528537" NO="3" P_CHI2="1.0" P_Z="0.5583217937688578" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="31" WEIGHT="100.0" Z="0.5853360330131491">
<NAME>E-EPA (4g/day)</NAME>
<DICH_DATA CI_END="1.8234654570162316" CI_START="0.7229334479705954" EFFECT_SIZE="1.1481481481481481" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="16" LOG_CI_END="0.26089754063069814" LOG_CI_START="-0.1409016812801274" LOG_EFFECT_SIZE="0.05999792967528537" ORDER="237" O_E="0.0" SE="0.23601885188864455" STUDY_ID="STD-Peet-2002" TOTAL_1="27" TOTAL_2="31" VAR="0.055704898446833934" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.490364232127542" CI_END="1.6439761066488234" CI_START="0.5222700537286499" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9266064372472801" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="21" I2="64.66582683640357" I2_Q="0.0" ID="CMP-004.05" LOG_CI_END="0.21589550126608936" LOG_CI_START="-0.28210487531799944" LOG_EFFECT_SIZE="-0.03310468702595503" METHOD="MH" NO="5" P_CHI2="0.03689337873462306" P_Q="0.0" P_Z="0.794417885475179" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="134" TOTAL_2="137" WEIGHT="300.0" Z="0.2605780932753428">
<NAME>Adverse events: Specific 1a. Gastrointestinal (diarrhoea)</NAME>
<GROUP_LABEL_1>E-EPA</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours E-EPA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.7017185810959035" CI_END="4.537822606726934" CI_START="0.9134529521246579" DF="1" EFFECT_SIZE="2.0359487852921863" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="7" I2="78.73118131696188" ID="CMP-004.05.01" LOG_CI_END="0.6568475143727498" LOG_CI_START="-0.03931381630140952" LOG_EFFECT_SIZE="0.30876684903567014" NO="1" P_CHI2="0.03013255340435894" P_Z="0.08210572354215977" STUDIES="2" TAU2="0.0" TOTAL_1="75" TOTAL_2="75" WEIGHT="100.0" Z="1.738596721951746">
<NAME>E-EPA (&lt;1g/day)</NAME>
<DICH_DATA CI_END="292.1946308338578" CI_START="1.034535233016475" EFFECT_SIZE="17.386363636363637" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="0" LOG_CI_END="2.46567223137702" LOG_CI_START="0.014745285957840753" LOG_EFFECT_SIZE="1.2402087586674302" ORDER="238" O_E="0.0" SE="1.4396866200232725" STUDY_ID="STD-Fenton-2001" TOTAL_1="43" TOTAL_2="44" VAR="2.0726975638740344" WEIGHT="6.500328299409061"/>
<DICH_DATA CI_END="2.440380378946034" CI_START="0.3845615915439031" EFFECT_SIZE="0.96875" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.3874575245363297" LOG_CI_START="-0.4150340935075962" LOG_EFFECT_SIZE="-0.013788284485633295" ORDER="239" O_E="0.0" SE="0.4713875488365774" STUDY_ID="STD-Peet-2002" TOTAL_1="32" TOTAL_2="31" VAR="0.22220622119815667" WEIGHT="93.49967170059094"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.060331473475848" CI_START="0.018062826000420064" DF="0" EFFECT_SIZE="0.13839285714285715" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" I2="0.0" ID="CMP-004.05.02" LOG_CI_END="0.02544165262106961" LOG_CI_START="-1.74321430162085" LOG_EFFECT_SIZE="-0.8588863244998901" NO="2" P_CHI2="1.0" P_Z="0.05696531650654868" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="31" WEIGHT="100.0" Z="1.9035768474884633">
<NAME>E-EPA (2g/day)</NAME>
<DICH_DATA CI_END="1.060331473475848" CI_START="0.018062826000420064" EFFECT_SIZE="0.13839285714285715" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="0.02544165262106961" LOG_CI_START="-1.74321430162085" LOG_EFFECT_SIZE="-0.8588863244998901" ORDER="240" O_E="0.0" SE="1.0389172625098757" STUDY_ID="STD-Peet-2002" TOTAL_1="32" TOTAL_2="31" VAR="1.0793490783410138" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.717863190813961" CI_START="0.14094631139223227" DF="0" EFFECT_SIZE="0.49206349206349204" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" I2="0.0" ID="CMP-004.05.03" LOG_CI_END="0.23498857402350817" LOG_CI_START="-0.8509462852621263" LOG_EFFECT_SIZE="-0.30797885561930904" NO="3" P_CHI2="1.0" P_Z="0.266258802122914" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="31" WEIGHT="100.0" Z="1.1117194735065308">
<NAME>E-EPA 4g/day</NAME>
<DICH_DATA CI_END="1.717863190813961" CI_START="0.14094631139223227" EFFECT_SIZE="0.49206349206349204" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.23498857402350817" LOG_CI_START="-0.8509462852621263" LOG_EFFECT_SIZE="-0.30797885561930904" ORDER="241" O_E="0.0" SE="0.6378835118086296" STUDY_ID="STD-Peet-2002" TOTAL_1="27" TOTAL_2="31" VAR="0.40689537463731007" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.2671191762816626" CI_END="32.87745779466484" CI_START="1.095769063595721" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="6.002174700978615" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-004.06" LOG_CI_END="1.5168982289278357" LOG_CI_START="0.03971903501151611" LOG_EFFECT_SIZE="0.7783086319696758" METHOD="MH" NO="6" P_CHI2="0.8749753363027242" P_Q="0.0" P_Z="0.03888850518463717" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="89" TOTAL_2="93" WEIGHT="300.0" Z="2.065364708357272">
<NAME>Adverse events: Specific 1b. Gastrointestinal (nausea, short term)</NAME>
<GROUP_LABEL_1>E-EPA</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours E-EPA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="68.80620475148235" CI_START="0.12299486576714651" DF="0" EFFECT_SIZE="2.909090909090909" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-004.06.01" LOG_CI_END="1.8376276034655539" LOG_CI_START="-0.9101130171421922" LOG_EFFECT_SIZE="0.4637572931616809" NO="1" P_CHI2="1.0" P_Z="0.5082299471469534" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="31" WEIGHT="100.0" Z="0.6615963569106003">
<NAME>E-EPA (&lt;1g/day)</NAME>
<DICH_DATA CI_END="68.80620475148235" CI_START="0.12299486576714651" EFFECT_SIZE="2.909090909090909" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8376276034655539" LOG_CI_START="-0.9101130171421922" LOG_EFFECT_SIZE="0.4637572931616809" ORDER="242" O_E="0.0" SE="1.6140364420804247" STUDY_ID="STD-Peet-2002" TOTAL_1="32" TOTAL_2="31" VAR="2.6051136363636362" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="126.23619543512021" CI_START="0.3649927683587031" DF="0" EFFECT_SIZE="6.787878787878788" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-004.06.02" LOG_CI_END="2.101183897094496" LOG_CI_START="-0.43771574018194526" LOG_EFFECT_SIZE="0.8317340784562753" NO="2" P_CHI2="1.0" P_Z="0.19908813846518286" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="31" WEIGHT="100.0" Z="1.2841538236128511">
<NAME>E-EPA (2g/day)</NAME>
<DICH_DATA CI_END="126.23619543512021" CI_START="0.3649927683587031" EFFECT_SIZE="6.787878787878788" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.101183897094496" LOG_CI_START="-0.43771574018194526" LOG_EFFECT_SIZE="0.8317340784562753" ORDER="243" O_E="0.0" SE="1.4913622146920764" STUDY_ID="STD-Peet-2002" TOTAL_1="32" TOTAL_2="31" VAR="2.2241612554112553" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="159.3654222570907" CI_START="0.4657525517126623" DF="0" EFFECT_SIZE="8.615384615384615" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-004.06.03" LOG_CI_END="2.2023940977881615" LOG_CI_START="-0.331844757061472" LOG_EFFECT_SIZE="0.9352746703633448" NO="3" P_CHI2="1.0" P_Z="0.14798914777686686" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="31" WEIGHT="100.0" Z="1.44667079510427">
<NAME>E-EPA (4g/day)</NAME>
<DICH_DATA CI_END="159.3654222570907" CI_START="0.4657525517126623" EFFECT_SIZE="8.615384615384615" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.2023940977881615" LOG_CI_START="-0.331844757061472" LOG_EFFECT_SIZE="0.9352746703633448" ORDER="244" O_E="0.0" SE="1.4886244480233244" STUDY_ID="STD-Peet-2002" TOTAL_1="25" TOTAL_2="31" VAR="2.2160027472527473" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="68.80620475148235" CI_START="0.12299486576714651" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.909090909090909" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-004.07" LOG_CI_END="1.8376276034655539" LOG_CI_START="-0.9101130171421922" LOG_EFFECT_SIZE="0.4637572931616809" METHOD="MH" NO="7" P_CHI2="1.0" P_Q="0.0" P_Z="0.5082299471469534" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="96" TOTAL_2="93" WEIGHT="100.0" Z="0.6615963569106003">
<NAME>Adverse events: Specific 2. Liver and biliary tract (short term)</NAME>
<GROUP_LABEL_1>E-EPA</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>FavoursE-EPA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="68.80620475148235" CI_START="0.12299486576714651" DF="0" EFFECT_SIZE="2.909090909090909" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-004.07.01" LOG_CI_END="1.8376276034655539" LOG_CI_START="-0.9101130171421922" LOG_EFFECT_SIZE="0.4637572931616809" NO="1" P_CHI2="1.0" P_Z="0.5082299471469534" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="31" WEIGHT="100.0" Z="0.6615963569106003">
<NAME>E-EPA (&lt;1g/day)</NAME>
<DICH_DATA CI_END="68.80620475148235" CI_START="0.12299486576714651" EFFECT_SIZE="2.909090909090909" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8376276034655539" LOG_CI_START="-0.9101130171421922" LOG_EFFECT_SIZE="0.4637572931616809" ORDER="245" O_E="0.0" SE="1.6140364420804247" STUDY_ID="STD-Peet-2002" TOTAL_1="32" TOTAL_2="31" VAR="2.6051136363636362" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-004.07.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="31" WEIGHT="0.0" Z="0.0">
<NAME>E-EPA (2g/day)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="246" O_E="0.0" SE="0.0" STUDY_ID="STD-Peet-2002" TOTAL_1="32" TOTAL_2="31" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-004.07.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="31" WEIGHT="0.0" Z="0.0">
<NAME>E-EPA (4g/day)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="247" O_E="0.0" SE="0.0" STUDY_ID="STD-Peet-2002" TOTAL_1="32" TOTAL_2="31" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.7236541703498817" CI_END="6.971323967956241" CI_START="0.43765485107081215" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.7467208571956403" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-004.08" LOG_CI_END="0.8433152655261278" LOG_CI_START="-0.35886825334613337" LOG_EFFECT_SIZE="0.24222350608999724" METHOD="MH" NO="8" P_CHI2="0.6964028932667485" P_Q="0.0" P_Z="0.4296377095557916" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="91" TOTAL_2="93" WEIGHT="300.0" Z="0.7898117728161232">
<NAME>Adverse events: Specific 4. Metabolic and nutritional (short term)</NAME>
<GROUP_LABEL_1>E-EPA</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours E-EPA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="14.815825472151083" CI_START="0.0633428467596375" DF="0" EFFECT_SIZE="0.96875" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-004.08.01" LOG_CI_END="1.170725853454479" LOG_CI_START="-1.198302422425746" LOG_EFFECT_SIZE="-0.013788284485633295" NO="1" P_CHI2="1.0" P_Z="0.9817979432457848" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="31" WEIGHT="100.0" Z="0.022814874162185785">
<NAME>E-EPA (&lt;1g/day)</NAME>
<DICH_DATA CI_END="14.815825472151076" CI_START="0.06334284675963754" EFFECT_SIZE="0.96875" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.170725853454479" LOG_CI_START="-1.1983024224257455" LOG_EFFECT_SIZE="-0.013788284485633295" ORDER="248" O_E="0.0" SE="1.3915789361311384" STUDY_ID="STD-Peet-2002" TOTAL_1="32" TOTAL_2="31" VAR="1.936491935483871" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="14.815825472151083" CI_START="0.0633428467596375" DF="0" EFFECT_SIZE="0.96875" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-004.08.02" LOG_CI_END="1.170725853454479" LOG_CI_START="-1.198302422425746" LOG_EFFECT_SIZE="-0.013788284485633295" NO="2" P_CHI2="1.0" P_Z="0.9817979432457848" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="31" WEIGHT="100.0" Z="0.022814874162185785">
<NAME>E-EPA (2g/day)</NAME>
<DICH_DATA CI_END="14.815825472151076" CI_START="0.06334284675963754" EFFECT_SIZE="0.96875" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.170725853454479" LOG_CI_START="-1.1983024224257455" LOG_EFFECT_SIZE="-0.013788284485633295" ORDER="249" O_E="0.0" SE="1.3915789361311384" STUDY_ID="STD-Peet-2002" TOTAL_1="32" TOTAL_2="31" VAR="1.936491935483871" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="31.197546385038354" CI_START="0.38029264816011304" DF="0" EFFECT_SIZE="3.4444444444444446" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" ID="CMP-004.08.03" LOG_CI_END="1.4941204391036795" LOG_CI_START="-0.419882070313784" LOG_EFFECT_SIZE="0.5371191843949479" NO="3" P_CHI2="1.0" P_Z="0.27131717140455114" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="31" WEIGHT="100.0" Z="1.1000343538107806">
<NAME>E-EPA (4g/day)</NAME>
<DICH_DATA CI_END="31.197546385038354" CI_START="0.38029264816011304" EFFECT_SIZE="3.4444444444444446" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4941204391036795" LOG_CI_START="-0.419882070313784" LOG_EFFECT_SIZE="0.5371191843949479" ORDER="250" O_E="0.0" SE="1.124294548497042" STUDY_ID="STD-Peet-2002" TOTAL_1="27" TOTAL_2="31" VAR="1.2640382317801673" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.006917936104957559" CI_END="2.1164580897822667" CI_START="0.05507259670390892" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3414071510957324" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-004.09" LOG_CI_END="0.3256096729723215" LOG_CI_START="-1.2590644458068652" LOG_EFFECT_SIZE="-0.46672738641727174" METHOD="MH" NO="9" P_CHI2="0.9965470072919762" P_Q="0.0" P_Z="0.24828712239016082" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="91" TOTAL_2="93" WEIGHT="300.0" Z="1.154519856336252">
<NAME>Adverse events: Specific 5. Musculoskeletal (short term)</NAME>
<GROUP_LABEL_1>E-EPA</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours E-EPA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.645133861275818" CI_START="0.013666096196349616" DF="0" EFFECT_SIZE="0.32323232323232326" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-004.09.01" LOG_CI_END="0.8833850940262291" LOG_CI_START="-1.8643555265815168" LOG_EFFECT_SIZE="-0.49048521627764385" NO="1" P_CHI2="1.0" P_Z="0.48409817628420715" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="31" WEIGHT="100.0" Z="0.6997264236978039">
<NAME>E-EPA (&lt;1g/day)</NAME>
<DICH_DATA CI_END="7.645133861275818" CI_START="0.013666096196349616" EFFECT_SIZE="0.32323232323232326" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8833850940262291" LOG_CI_START="-1.8643555265815168" LOG_EFFECT_SIZE="-0.49048521627764385" ORDER="251" O_E="0.0" SE="1.6140364420804247" STUDY_ID="STD-Peet-2002" TOTAL_1="32" TOTAL_2="31" VAR="2.6051136363636362" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.645133861275818" CI_START="0.013666096196349616" DF="0" EFFECT_SIZE="0.32323232323232326" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-004.09.02" LOG_CI_END="0.8833850940262291" LOG_CI_START="-1.8643555265815168" LOG_EFFECT_SIZE="-0.49048521627764385" NO="2" P_CHI2="1.0" P_Z="0.48409817628420715" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="31" WEIGHT="100.0" Z="0.6997264236978039">
<NAME>E-EPA (2g/day)</NAME>
<DICH_DATA CI_END="7.645133861275818" CI_START="0.013666096196349616" EFFECT_SIZE="0.32323232323232326" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8833850940262291" LOG_CI_START="-1.8643555265815168" LOG_EFFECT_SIZE="-0.49048521627764385" ORDER="252" O_E="0.0" SE="1.6140364420804247" STUDY_ID="STD-Peet-2002" TOTAL_1="32" TOTAL_2="31" VAR="2.6051136363636362" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.7412933628051654E-33" CI_END="8.98076602622495" CI_START="0.0161595031124857" DF="0" EFFECT_SIZE="0.3809523809523809" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="100.0" ID="CMP-004.09.03" LOG_CI_END="0.9533133819650612" LOG_CI_START="-1.7915719974490127" LOG_EFFECT_SIZE="-0.41912930774197577" NO="3" P_CHI2="0.0" P_Z="0.5494716609018742" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="31" WEIGHT="100.0" Z="0.5985520227550128">
<NAME>E-EPA (4g/day)</NAME>
<DICH_DATA CI_END="8.98076602622495" CI_START="0.0161595031124857" EFFECT_SIZE="0.38095238095238093" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9533133819650612" LOG_CI_START="-1.7915719974490127" LOG_EFFECT_SIZE="-0.4191293077419757" ORDER="253" O_E="0.0" SE="1.61235925926959" STUDY_ID="STD-Peet-2002" TOTAL_1="27" TOTAL_2="31" VAR="2.599702380952381" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.2889853473462567" CI_END="48.61075474351884" CI_START="1.7902419358200488" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="9.328719723183392" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-004.10" LOG_CI_END="1.6867323640986291" LOG_CI_START="0.2529117261148396" LOG_EFFECT_SIZE="0.9698220451067344" METHOD="MH" NO="10" P_CHI2="0.8654612642011809" P_Q="0.0" P_Z="0.008015875999799343" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="91" TOTAL_2="93" WEIGHT="300.0" Z="2.651400362733054">
<NAME>Adverse events: Specific 6. Psychiatric (short term)</NAME>
<GROUP_LABEL_1>E-EPA</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours E-EPA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="155.6245075081896" CI_START="0.489417062105017" DF="0" EFFECT_SIZE="8.727272727272727" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" I2="0.0" ID="CMP-004.10.01" LOG_CI_END="2.192077990066709" LOG_CI_START="-0.31032089430402254" LOG_EFFECT_SIZE="0.9408785478813433" NO="1" P_CHI2="1.0" P_Z="0.14052031019718283" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="31" WEIGHT="100.0" Z="1.4738562098883794">
<NAME>E-EPA (&lt;1g/day)</NAME>
<DICH_DATA CI_END="155.6245075081896" CI_START="0.489417062105017" EFFECT_SIZE="8.727272727272727" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.192077990066709" LOG_CI_START="-0.31032089430402254" LOG_EFFECT_SIZE="0.9408785478813433" ORDER="254" O_E="0.0" SE="1.4699214917536216" STUDY_ID="STD-Peet-2002" TOTAL_1="32" TOTAL_2="31" VAR="2.160669191919192" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="97.10953275882997" CI_START="0.24207515635327403" DF="0" EFFECT_SIZE="4.848484848484849" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-004.10.02" LOG_CI_END="1.9872618645253863" LOG_CI_START="-0.6160497789693115" LOG_EFFECT_SIZE="0.6856060427780373" NO="2" P_CHI2="1.0" P_Z="0.30190864525064987" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="31" WEIGHT="100.0" Z="1.0323490503227704">
<NAME>E-EPA (2g/day)</NAME>
<DICH_DATA CI_END="97.10953275882997" CI_START="0.24207515635327403" EFFECT_SIZE="4.848484848484849" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9872618645253863" LOG_CI_START="-0.6160497789693115" LOG_EFFECT_SIZE="0.6856060427780373" ORDER="255" O_E="0.0" SE="1.5291981459892532" STUDY_ID="STD-Peet-2002" TOTAL_1="32" TOTAL_2="31" VAR="2.3384469696969696" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="252.10693507331786" CI_START="0.8755597850307327" DF="0" EFFECT_SIZE="14.857142857142858" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" I2="0.0" ID="CMP-004.10.03" LOG_CI_END="2.40158479261277" LOG_CI_START="-0.05771419404372279" LOG_EFFECT_SIZE="1.1719352992845236" NO="3" P_CHI2="1.0" P_Z="0.06176595623684364" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="31" WEIGHT="100.0" Z="1.8679721264242253">
<NAME>E-EPA (4g/day)</NAME>
<DICH_DATA CI_END="252.10693507331786" CI_START="0.8755597850307327" EFFECT_SIZE="14.857142857142858" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.40158479261277" LOG_CI_START="-0.05771419404372279" LOG_EFFECT_SIZE="1.1719352992845236" ORDER="256" O_E="0.0" SE="1.4446043984883432" STUDY_ID="STD-Peet-2002" TOTAL_1="27" TOTAL_2="31" VAR="2.086881868131868" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.4097066447857485" CI_END="3.331842931543836" CI_START="0.18500393844839375" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7851140456182474" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-004.11" LOG_CI_END="0.5226845198741179" LOG_CI_START="-0.7328190260391584" LOG_EFFECT_SIZE="-0.10506725308252028" METHOD="MH" NO="11" P_CHI2="0.49418111711809265" P_Q="0.0" P_Z="0.7428810094269562" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="91" TOTAL_2="93" WEIGHT="300.0" Z="0.3280405422455401">
<NAME>Adverse events: Specific 7. Reproductive (short term)</NAME>
<GROUP_LABEL_1>E-EPA</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours E-EPA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.645133861275818" CI_START="0.013666096196349616" DF="0" EFFECT_SIZE="0.32323232323232326" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-004.11.01" LOG_CI_END="0.8833850940262291" LOG_CI_START="-1.8643555265815168" LOG_EFFECT_SIZE="-0.49048521627764385" NO="1" P_CHI2="1.0" P_Z="0.48409817628420715" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="31" WEIGHT="100.0" Z="0.6997264236978039">
<NAME>E-EPA (&lt;1g/day)</NAME>
<DICH_DATA CI_END="7.645133861275818" CI_START="0.013666096196349616" EFFECT_SIZE="0.32323232323232326" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8833850940262291" LOG_CI_START="-1.8643555265815168" LOG_EFFECT_SIZE="-0.49048521627764385" ORDER="257" O_E="0.0" SE="1.6140364420804247" STUDY_ID="STD-Peet-2002" TOTAL_1="32" TOTAL_2="31" VAR="2.6051136363636362" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.645133861275818" CI_START="0.013666096196349616" DF="0" EFFECT_SIZE="0.32323232323232326" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-004.11.02" LOG_CI_END="0.8833850940262291" LOG_CI_START="-1.8643555265815168" LOG_EFFECT_SIZE="-0.49048521627764385" NO="2" P_CHI2="1.0" P_Z="0.48409817628420715" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="31" WEIGHT="100.0" Z="0.6997264236978039">
<NAME>E-EPA (2g/day)</NAME>
<DICH_DATA CI_END="7.645133861275818" CI_START="0.013666096196349616" EFFECT_SIZE="0.32323232323232326" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8833850940262291" LOG_CI_START="-1.8643555265815168" LOG_EFFECT_SIZE="-0.49048521627764385" ORDER="258" O_E="0.0" SE="1.6140364420804247" STUDY_ID="STD-Peet-2002" TOTAL_1="32" TOTAL_2="31" VAR="2.6051136363636362" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="23.94240491598844" CI_START="0.22023588268958144" DF="0" EFFECT_SIZE="2.2962962962962963" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-004.11.03" LOG_CI_END="1.3791677713538726" LOG_CI_START="-0.6571119206753394" LOG_EFFECT_SIZE="0.3610279253392666" NO="3" P_CHI2="1.0" P_Z="0.4870586683305025" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="31" WEIGHT="100.0" Z="0.694994635410848">
<NAME>E-EPA (4g/day)</NAME>
<DICH_DATA CI_END="23.94240491598844" CI_START="0.22023588268958144" EFFECT_SIZE="2.2962962962962963" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3791677713538726" LOG_CI_START="-0.6571119206753394" LOG_EFFECT_SIZE="0.3610279253392666" ORDER="259" O_E="0.0" SE="1.1961207708449988" STUDY_ID="STD-Peet-2002" TOTAL_1="27" TOTAL_2="31" VAR="1.430704898446834" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.024887497858941" CI_END="2.2160410622487916" CI_START="0.603763930742472" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.156704656526485" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="15" I2="57.29468975959621" I2_Q="0.0" ID="CMP-004.12" LOG_CI_END="0.34557780341327116" LOG_CI_START="-0.21913283557825827" LOG_EFFECT_SIZE="0.06322248391750643" METHOD="MH" NO="12" P_CHI2="0.0711088261235574" P_Q="0.0" P_Z="0.6607646871994024" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="134" TOTAL_2="137" WEIGHT="300.0" Z="0.43885764827368196">
<NAME>Adverse events: Specific 8. Infections and respiratory system</NAME>
<GROUP_LABEL_1>E-EPA</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours E-EPA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.37421356580159" CI_END="6.189272739812779" CI_START="0.9501042431589695" DF="1" EFFECT_SIZE="2.4249648022526555" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="5" I2="77.1387476867114" ID="CMP-004.12.01" LOG_CI_END="0.791639620968112" LOG_CI_START="-0.02222874234794635" LOG_EFFECT_SIZE="0.38470543931008283" NO="1" P_CHI2="0.03648669667419746" P_Z="0.0638965308923005" STUDIES="2" TAU2="0.0" TOTAL_1="75" TOTAL_2="75" WEIGHT="100.0" Z="1.8529011316578463">
<NAME>E-EPA (&lt;1g/day)</NAME>
<DICH_DATA CI_END="292.1946308338578" CI_START="1.034535233016475" EFFECT_SIZE="17.386363636363637" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="0" LOG_CI_END="2.46567223137702" LOG_CI_START="0.014745285957840753" LOG_EFFECT_SIZE="1.2402087586674302" ORDER="260" O_E="0.0" SE="1.4396866200232725" STUDY_ID="STD-Fenton-2001" TOTAL_1="43" TOTAL_2="44" VAR="2.0726975638740344" WEIGHT="8.869832330730834"/>
<DICH_DATA CI_END="3.0197853071694567" CI_START="0.31077592180871455" EFFECT_SIZE="0.96875" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.479976067716755" LOG_CI_START="-0.5075526366880215" LOG_EFFECT_SIZE="-0.013788284485633295" ORDER="261" O_E="0.0" SE="0.5800792493132908" STUDY_ID="STD-Peet-2002" TOTAL_1="32" TOTAL_2="31" VAR="0.336491935483871" WEIGHT="91.13016766926917"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5655856317238" CI_START="0.02397764883589748" DF="0" EFFECT_SIZE="0.19375" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" I2="0.0" ID="CMP-004.12.02" LOG_CI_END="0.19467682689898513" LOG_CI_START="-1.6201934045422894" LOG_EFFECT_SIZE="-0.7127582888216522" NO="2" P_CHI2="1.0" P_Z="0.12368652133994165" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="31" WEIGHT="100.0" Z="1.5394826049501378">
<NAME>E-EPA (2g/day)</NAME>
<DICH_DATA CI_END="1.565585631723799" CI_START="0.023977648835897494" EFFECT_SIZE="0.19375" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.19467682689898488" LOG_CI_START="-1.6201934045422892" LOG_EFFECT_SIZE="-0.7127582888216522" ORDER="262" O_E="0.0" SE="1.066063757701138" STUDY_ID="STD-Peet-2002" TOTAL_1="32" TOTAL_2="31" VAR="1.136491935483871" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.6181267325591153" CI_START="0.1812623870849432" DF="0" EFFECT_SIZE="0.6888888888888889" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" I2="0.0" ID="CMP-004.12.03" LOG_CI_END="0.4179906651020441" LOG_CI_START="-0.741692304984186" LOG_EFFECT_SIZE="-0.161850819941071" NO="3" P_CHI2="1.0" P_Z="0.5843212883164938" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="31" WEIGHT="99.99999999999999" Z="0.5470836187741703">
<NAME>E-EPA (4g/day)</NAME>
<DICH_DATA CI_END="2.6181267325591153" CI_START="0.1812623870849432" EFFECT_SIZE="0.6888888888888889" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.4179906651020441" LOG_CI_START="-0.741692304984186" LOG_EFFECT_SIZE="-0.161850819941071" ORDER="263" O_E="0.0" SE="0.6812035171519355" STUDY_ID="STD-Peet-2002" TOTAL_1="27" TOTAL_2="31" VAR="0.46403823178016723" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.055924020678311814" CI_END="22.296342228837712" CI_START="0.6263516180544626" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="3.737024221453287" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-004.13" LOG_CI_END="1.3482336217868367" LOG_CI_START="-0.20318179632603312" LOG_EFFECT_SIZE="0.5725259127304019" METHOD="MH" NO="13" P_CHI2="0.9724253331159477" P_Q="0.0" P_Z="0.14801209413463495" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="91" TOTAL_2="93" WEIGHT="300.0" Z="1.4465889098001365">
<NAME>Adverse events: Specific 9. Skin (short term)</NAME>
<GROUP_LABEL_1>E-EPA</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours E-EPA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="97.10953275882997" CI_START="0.24207515635327403" DF="0" EFFECT_SIZE="4.848484848484849" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-004.13.01" LOG_CI_END="1.9872618645253863" LOG_CI_START="-0.6160497789693115" LOG_EFFECT_SIZE="0.6856060427780373" NO="1" P_CHI2="1.0" P_Z="0.30190864525064987" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="31" WEIGHT="100.0" Z="1.0323490503227704">
<NAME>E-EPA (&lt;1g/day)</NAME>
<DICH_DATA CI_END="97.10953275882997" CI_START="0.24207515635327403" EFFECT_SIZE="4.848484848484849" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9872618645253863" LOG_CI_START="-0.6160497789693115" LOG_EFFECT_SIZE="0.6856060427780373" ORDER="264" O_E="0.0" SE="1.5291981459892532" STUDY_ID="STD-Peet-2002" TOTAL_1="32" TOTAL_2="31" VAR="2.3384469696969696" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="68.80620475148235" CI_START="0.12299486576714651" DF="0" EFFECT_SIZE="2.909090909090909" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-004.13.02" LOG_CI_END="1.8376276034655539" LOG_CI_START="-0.9101130171421922" LOG_EFFECT_SIZE="0.4637572931616809" NO="2" P_CHI2="1.0" P_Z="0.5082299471469534" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="31" WEIGHT="100.0" Z="0.6615963569106003">
<NAME>E-EPA (2g/day)</NAME>
<DICH_DATA CI_END="68.80620475148235" CI_START="0.12299486576714651" EFFECT_SIZE="2.909090909090909" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8376276034655539" LOG_CI_START="-0.9101130171421922" LOG_EFFECT_SIZE="0.4637572931616809" ORDER="265" O_E="0.0" SE="1.6140364420804247" STUDY_ID="STD-Peet-2002" TOTAL_1="32" TOTAL_2="31" VAR="2.6051136363636362" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="80.8268942360246" CI_START="0.14543552801237133" DF="0" EFFECT_SIZE="3.4285714285714284" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-004.13.03" LOG_CI_END="1.9075558914043862" LOG_CI_START="-0.8373294880096878" LOG_EFFECT_SIZE="0.5351132016973491" NO="3" P_CHI2="1.0" P_Z="0.44475593112892875" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="31" WEIGHT="100.0" Z="0.764186811474511">
<NAME>E-EPA (4g/day)</NAME>
<DICH_DATA CI_END="80.8268942360246" CI_START="0.14543552801237133" EFFECT_SIZE="3.4285714285714284" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.9075558914043862" LOG_CI_START="-0.8373294880096878" LOG_EFFECT_SIZE="0.5351132016973491" ORDER="266" O_E="0.0" SE="1.61235925926959" STUDY_ID="STD-Peet-2002" TOTAL_1="27" TOTAL_2="31" VAR="2.599702380952381" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.0737151580154953" CI_END="3.3545894130929543" CI_START="0.17221573659506886" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7600743955362679" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-004.14" LOG_CI_END="0.5256393720340277" LOG_CI_START="-0.7639271664471583" LOG_EFFECT_SIZE="-0.11914389720656525" METHOD="MH" NO="14" P_CHI2="0.5845824793458549" P_Q="0.0" P_Z="0.717228948033678" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="91" TOTAL_2="93" WEIGHT="300.0" Z="0.36216471276874274">
<NAME>Adverse events: Specific 10. Urinary (short term)</NAME>
<GROUP_LABEL_1>E-EPA</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours E-EPA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="20.297315786483008" CI_START="0.18494594504461098" DF="0" EFFECT_SIZE="1.9375" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-004.14.01" LOG_CI_END="1.3074386085439162" LOG_CI_START="-0.7329551861872203" LOG_EFFECT_SIZE="0.2872417111783479" NO="1" P_CHI2="1.0" P_Z="0.5810593566322133" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="31" WEIGHT="100.0" Z="0.5518379934510659">
<NAME>E-EPA (&lt;1g/day)</NAME>
<DICH_DATA CI_END="20.297315786482997" CI_START="0.18494594504461104" EFFECT_SIZE="1.9375" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.307438608543916" LOG_CI_START="-0.7329551861872201" LOG_EFFECT_SIZE="0.2872417111783479" ORDER="267" O_E="0.0" SE="1.1985374151372459" STUDY_ID="STD-Peet-2002" TOTAL_1="32" TOTAL_2="31" VAR="1.436491935483871" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.645133861275818" CI_START="0.013666096196349616" DF="0" EFFECT_SIZE="0.32323232323232326" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-004.14.02" LOG_CI_END="0.8833850940262291" LOG_CI_START="-1.8643555265815168" LOG_EFFECT_SIZE="-0.49048521627764385" NO="2" P_CHI2="1.0" P_Z="0.48409817628420715" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="31" WEIGHT="100.0" Z="0.6997264236978039">
<NAME>E-EPA (2g/day)</NAME>
<DICH_DATA CI_END="7.645133861275818" CI_START="0.013666096196349616" EFFECT_SIZE="0.32323232323232326" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8833850940262291" LOG_CI_START="-1.8643555265815168" LOG_EFFECT_SIZE="-0.49048521627764385" ORDER="268" O_E="0.0" SE="1.6140364420804247" STUDY_ID="STD-Peet-2002" TOTAL_1="32" TOTAL_2="31" VAR="2.6051136363636362" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.7412933628051654E-33" CI_END="8.98076602622495" CI_START="0.0161595031124857" DF="0" EFFECT_SIZE="0.3809523809523809" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="100.0" ID="CMP-004.14.03" LOG_CI_END="0.9533133819650612" LOG_CI_START="-1.7915719974490127" LOG_EFFECT_SIZE="-0.41912930774197577" NO="3" P_CHI2="0.0" P_Z="0.5494716609018742" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="31" WEIGHT="100.0" Z="0.5985520227550128">
<NAME>E-EPA (4g/day)</NAME>
<DICH_DATA CI_END="8.98076602622495" CI_START="0.0161595031124857" EFFECT_SIZE="0.38095238095238093" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9533133819650612" LOG_CI_START="-1.7915719974490127" LOG_EFFECT_SIZE="-0.4191293077419757" ORDER="269" O_E="0.0" SE="1.61235925926959" STUDY_ID="STD-Peet-2002" TOTAL_1="27" TOTAL_2="31" VAR="2.599702380952381" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.3251038981650336" CI_END="2.743265771913421" CI_START="0.09489930915371192" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5102293862368258" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-004.15" LOG_CI_END="0.4382678847769933" LOG_CI_START="-1.0227369491303768" LOG_EFFECT_SIZE="-0.29223453217669165" METHOD="MH" NO="15" P_CHI2="0.8499719561108943" P_Q="0.0" P_Z="0.43299572858799795" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="91" TOTAL_2="93" WEIGHT="300.0" Z="0.7840756509660415">
<NAME>Adverse events: Specific 11. Vision (short term)</NAME>
<GROUP_LABEL_1>E-EPA</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours E-EPA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="14.815825472151083" CI_START="0.0633428467596375" DF="0" EFFECT_SIZE="0.96875" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-004.15.01" LOG_CI_END="1.170725853454479" LOG_CI_START="-1.198302422425746" LOG_EFFECT_SIZE="-0.013788284485633295" NO="1" P_CHI2="1.0" P_Z="0.9817979432457848" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="31" WEIGHT="100.0" Z="0.022814874162185785">
<NAME>E-EPA (&lt;1g/day)</NAME>
<DICH_DATA CI_END="14.815825472151076" CI_START="0.06334284675963754" EFFECT_SIZE="0.96875" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.170725853454479" LOG_CI_START="-1.1983024224257455" LOG_EFFECT_SIZE="-0.013788284485633295" ORDER="270" O_E="0.0" SE="1.3915789361311384" STUDY_ID="STD-Peet-2002" TOTAL_1="32" TOTAL_2="31" VAR="1.936491935483871" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.645133861275818" CI_START="0.013666096196349616" DF="0" EFFECT_SIZE="0.32323232323232326" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-004.15.02" LOG_CI_END="0.8833850940262291" LOG_CI_START="-1.8643555265815168" LOG_EFFECT_SIZE="-0.49048521627764385" NO="2" P_CHI2="1.0" P_Z="0.48409817628420715" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="31" WEIGHT="100.0" Z="0.6997264236978039">
<NAME>E-EPA (2g/day)</NAME>
<DICH_DATA CI_END="7.645133861275818" CI_START="0.013666096196349616" EFFECT_SIZE="0.32323232323232326" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8833850940262291" LOG_CI_START="-1.8643555265815168" LOG_EFFECT_SIZE="-0.49048521627764385" ORDER="271" O_E="0.0" SE="1.6140364420804247" STUDY_ID="STD-Peet-2002" TOTAL_1="32" TOTAL_2="31" VAR="2.6051136363636362" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.7412933628051654E-33" CI_END="8.98076602622495" CI_START="0.0161595031124857" DF="0" EFFECT_SIZE="0.3809523809523809" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="100.0" ID="CMP-004.15.03" LOG_CI_END="0.9533133819650612" LOG_CI_START="-1.7915719974490127" LOG_EFFECT_SIZE="-0.41912930774197577" NO="3" P_CHI2="0.0" P_Z="0.5494716609018742" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="31" WEIGHT="100.0" Z="0.5985520227550128">
<NAME>E-EPA (4g/day)</NAME>
<DICH_DATA CI_END="8.98076602622495" CI_START="0.0161595031124857" EFFECT_SIZE="0.38095238095238093" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9533133819650612" LOG_CI_START="-1.7915719974490127" LOG_EFFECT_SIZE="-0.4191293077419757" ORDER="272" O_E="0.0" SE="1.61235925926959" STUDY_ID="STD-Peet-2002" TOTAL_1="27" TOTAL_2="31" VAR="2.599702380952381" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.21472231190375693" CI_END="28.865541926693727" CI_START="0.9282987937283554" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="5.176470588235294" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-004.16" LOG_CI_END="1.4603797154311633" LOG_CI_START="-0.03231221388737388" LOG_EFFECT_SIZE="0.7140337507718947" METHOD="MH" NO="16" P_CHI2="0.8982012256276124" P_Q="0.0" P_Z="0.06077765597496266" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="91" TOTAL_2="93" WEIGHT="300.0" Z="1.8751095356935057">
<NAME>Adverse events: Specific 12. Other (short term)</NAME>
<GROUP_LABEL_1>E-EPA</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours E-EPA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="97.10953275882997" CI_START="0.24207515635327403" DF="0" EFFECT_SIZE="4.848484848484849" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-004.16.01" LOG_CI_END="1.9872618645253863" LOG_CI_START="-0.6160497789693115" LOG_EFFECT_SIZE="0.6856060427780373" NO="1" P_CHI2="1.0" P_Z="0.30190864525064987" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="31" WEIGHT="100.0" Z="1.0323490503227704">
<NAME>E-EPA (&lt;1g/day)</NAME>
<DICH_DATA CI_END="97.10953275882997" CI_START="0.24207515635327403" EFFECT_SIZE="4.848484848484849" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9872618645253863" LOG_CI_START="-0.6160497789693115" LOG_EFFECT_SIZE="0.6856060427780373" ORDER="273" O_E="0.0" SE="1.5291981459892532" STUDY_ID="STD-Peet-2002" TOTAL_1="32" TOTAL_2="31" VAR="2.3384469696969696" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="68.80620475148235" CI_START="0.12299486576714651" DF="0" EFFECT_SIZE="2.909090909090909" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-004.16.02" LOG_CI_END="1.8376276034655539" LOG_CI_START="-0.9101130171421922" LOG_EFFECT_SIZE="0.4637572931616809" NO="2" P_CHI2="1.0" P_Z="0.5082299471469534" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="31" WEIGHT="100.0" Z="0.6615963569106003">
<NAME>E-EPA (2g/day)</NAME>
<DICH_DATA CI_END="68.80620475148235" CI_START="0.12299486576714651" EFFECT_SIZE="2.909090909090909" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8376276034655539" LOG_CI_START="-0.9101130171421922" LOG_EFFECT_SIZE="0.4637572931616809" ORDER="274" O_E="0.0" SE="1.6140364420804247" STUDY_ID="STD-Peet-2002" TOTAL_1="32" TOTAL_2="31" VAR="2.6051136363636362" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="148.2499707353154" CI_START="0.4317032892658387" DF="0" EFFECT_SIZE="8.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-004.16.03" LOG_CI_END="2.170994616306167" LOG_CI_START="-0.36481464232227967" LOG_EFFECT_SIZE="0.9030899869919435" NO="3" P_CHI2="1.0" P_Z="0.16270761074718232" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="31" WEIGHT="100.0" Z="1.3960228619563566">
<NAME>E-EPA (4g/day)</NAME>
<DICH_DATA CI_END="148.2499707353154" CI_START="0.4317032892658387" EFFECT_SIZE="8.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.170994616306167" LOG_CI_START="-0.36481464232227967" LOG_EFFECT_SIZE="0.9030899869919435" ORDER="275" O_E="0.0" SE="1.489546910976623" STUDY_ID="STD-Peet-2002" TOTAL_1="27" TOTAL_2="31" VAR="2.21875" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.861200787502708" CI_END="2.4653806853384697" CI_START="0.8418178526121198" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4406253761485068" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="20" I2="0.0" I2_Q="0.0" ID="CMP-004.17" LOG_CI_END="0.3918839892427484" LOG_CI_START="-0.07478186831391975" LOG_EFFECT_SIZE="0.1585510604644143" METHOD="MH" MODIFIED="2009-02-02 10:04:21 +0000" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="0.5617346818030913" P_Q="0.0" P_Z="0.18292370119099685" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="278" TOTAL_2="280" WEIGHT="400.0" Z="1.3318067443284045">
<NAME>Leaving the study early</NAME>
<GROUP_LABEL_1>E-EPA</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours E-EPA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.5945118465702963" CI_END="3.6650275676313173" CI_START="0.7089062542278468" DF="1" EFFECT_SIZE="1.611881188118812" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="8" I2="37.28488112829373" ID="CMP-004.17.01" LOG_CI_END="0.564077245668861" LOG_CI_START="-0.14941119212778115" LOG_EFFECT_SIZE="0.20733302677053989" NO="1" P_CHI2="0.2066827493639518" P_Z="0.25466389165624037" STUDIES="2" TAU2="0.0" TOTAL_1="77" TOTAL_2="76" WEIGHT="100.0" Z="1.139094184990168">
<NAME>E-EPA (&lt;1g/day)</NAME>
<DICH_DATA CI_END="2.886194343367041" CI_START="0.4525414069850424" EFFECT_SIZE="1.1428571428571428" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.46032557118235495" LOG_CI_START="-0.34434167722698156" LOG_EFFECT_SIZE="0.05799194697768673" ORDER="276" O_E="0.0" SE="0.4726655248827636" STUDY_ID="STD-Fenton-2001" TOTAL_1="45" TOTAL_2="45" VAR="0.2234126984126984" WEIGHT="87.32673267326733"/>
<DICH_DATA CI_END="39.13964079309497" CI_START="0.5994412208974373" EFFECT_SIZE="4.84375" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.5926168355710224" LOG_CI_START="-0.22225339587025156" LOG_EFFECT_SIZE="0.6851817198503856" ORDER="277" O_E="0.0" SE="1.066063757701138" STUDY_ID="STD-Peet-2002" TOTAL_1="32" TOTAL_2="31" VAR="1.136491935483871" WEIGHT="12.673267326732674"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.4849531662262976" CI_END="2.550586355413766" CI_START="0.5393737875397466" DF="2" EFFECT_SIZE="1.1729106628242074" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="11" I2="19.515585759016847" ID="CMP-004.17.02" LOG_CI_END="0.4066400320604193" LOG_CI_START="-0.2681101631917268" LOG_EFFECT_SIZE="0.0692649344343463" MODIFIED="2009-02-02 10:04:21 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.28866850839477676" P_Z="0.6873961321660621" STUDIES="3" TAU2="0.0" TOTAL_1="154" TOTAL_2="153" WEIGHT="100.00000000000001" Z="0.4023912192633491">
<NAME>E-EPA (2g/day)</NAME>
<DICH_DATA CI_END="2.6203861225065315" CI_START="0.2650160747226723" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.41836529075425605" LOG_CI_START="-0.5767277828495057" LOG_EFFECT_SIZE="-0.07918124604762482" MODIFIED="2009-01-29 11:03:23 +0000" MODIFIED_BY="[Empty name]" ORDER="141" O_E="0.0" SE="0.5845225972250061" STUDY_ID="STD-Berger-2007" TOTAL_1="80" TOTAL_2="80" VAR="0.3416666666666667" WEIGHT="54.46685878962536"/>
<DICH_DATA CI_END="3.148306452599371" CI_START="0.1786674863038117" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.49807699947966155" LOG_CI_START="-0.7479544726962613" LOG_EFFECT_SIZE="-0.12493873660829993" ORDER="77" O_E="0.0" SE="0.7319250547113998" STUDY_ID="STD-Emsley-2006" TOTAL_1="42" TOTAL_2="42" VAR="0.5357142857142856" WEIGHT="36.31123919308357"/>
<DICH_DATA CI_END="39.13964079309497" CI_START="0.5994412208974373" EFFECT_SIZE="4.84375" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.5926168355710224" LOG_CI_START="-0.22225339587025156" LOG_EFFECT_SIZE="0.6851817198503856" ORDER="278" O_E="0.0" SE="1.066063757701138" STUDY_ID="STD-Peet-2002" TOTAL_1="32" TOTAL_2="31" VAR="1.136491935483871" WEIGHT="9.221902017291066"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="69.5152908317231" CI_START="0.12946791838627933" DF="0" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-004.17.03" LOG_CI_END="1.84208034406391" LOG_CI_START="-0.8878378346245852" LOG_EFFECT_SIZE="0.47712125471966244" NO="3" P_CHI2="1.0" P_Z="0.49327758741034355" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.6851051308492763">
<NAME>E-EPA (3g/day)</NAME>
<DICH_DATA CI_END="69.5152908317231" CI_START="0.12946791838627933" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.84208034406391" LOG_CI_START="-0.8878378346245852" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="279" O_E="0.0" SE="1.6035674514745464" STUDY_ID="STD-Emsley-2002" TOTAL_1="20" TOTAL_2="20" VAR="2.5714285714285716" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="23.94240491598844" CI_START="0.22023588268958144" DF="0" EFFECT_SIZE="2.2962962962962963" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-004.17.04" LOG_CI_END="1.3791677713538726" LOG_CI_START="-0.6571119206753394" LOG_EFFECT_SIZE="0.3610279253392666" NO="4" P_CHI2="1.0" P_Z="0.4870586683305025" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="31" WEIGHT="100.0" Z="0.694994635410848">
<NAME>E-EPA (4g/day)</NAME>
<DICH_DATA CI_END="23.94240491598844" CI_START="0.22023588268958144" EFFECT_SIZE="2.2962962962962963" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3791677713538726" LOG_CI_START="-0.6571119206753394" LOG_EFFECT_SIZE="0.3610279253392666" ORDER="280" O_E="0.0" SE="1.1961207708449988" STUDY_ID="STD-Peet-2002" TOTAL_1="27" TOTAL_2="31" VAR="1.430704898446834" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2009-02-25 12:50:56 +0000" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2009-02-25 12:50:56 +0000" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Methodological quality graph: review authors' judgments about each methodological quality item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAfMAAADnCAMAAAA94U9AAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2009-02-25 12:50:56 +0000" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological quality summary: review authors' judgments about each methodological quality item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAARUAAAHaCAIAAAChMkrUAAAUr0lEQVR42u3dvY4cxxWG4QGcONiA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2009-02-25 16:39:50 +0000" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2009-02-25 13:14:21 +0000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2009-01-14 12:24:54 +0000" MODIFIED_BY="[Empty name]">Original search</TITLE>
<APPENDIX_BODY MODIFIED="2009-02-25 13:14:21 +0000" MODIFIED_BY="[Empty name]">
<P>1. Search for the original review<BR/>1.1 Biological Abstracts on Silver Platter (1985 to February 1998)<BR/>We used the Cochrane Schizophrenia Group's terms for randomised controlled trials and for schizophrenia combined with the phrase:</P>
<P>[and (phospholip* or EFA or EPA or MaxEPA or DHA or ALA or omega*) or (acid near1 (arachi* or docosahex* or fatty)) or (fish near3 oil*) or (fatty near3 acid* near3 (n-3 or n-6)) or (membran* near2 (hypothes* or neuronal*)) or (evening near3 primrose) or (oil near3 (flax or linseed))]</P>
<P>1.2 CINAHL on Silver Platter (1982 to February 1998)<BR/>We used the Cochrane Schizophrenia Group's terms for randomised controlled trials and for schizophrenia combined with the phrase:</P>
<P>[and (phospholip* or EFA or EPA or MaxEPA or DHA or ALA or omega*) or (acid near1 (arachi* or docosahex* or fatty)) or (fish near3 oil*) or (fatty near3 acid* near3 (n-3 or n-6)) or (membran* near2 (hypothes* or neuronal*)) or (evening near3 primrose) or (oil near3 (flax or linseed)) or explode "FISH-OILS"/ all topical subheadings / all age subheadings or explode "FATTY-ACIDS"/ all topical subheadings / all age subheadings or explode "FATTY-ACIDS,-ESSENTIAL"/ all topical subheadings / all age subheadings or explode "FATTY-ACIDS,-OMEGA-3"/ all topical subheadings / all age subheadings or explode "ARACHIDONIC-ACIDS"/ all topical subheadings / all age subheadings or explode "PLANT-OILS"/ all topical subheadings / all age subheadings or explode "PHOSPHOLIPIDS"/ all topical subheadings / all age subheadings]</P>
<P>1.3 The Cochrane Library (Issue 4, 1999)<BR/>We used the Cochrane Schizophrenia Group's terms for randomised controlled trials and for schizophrenia combined with the phrase:</P>
<P>[and (phospholip* or EFA or EPA or MaxEPA or DHA or ALA or omega*) or (acid near1 (arachi* or docosahex* or fatty)) or (fish near3 oil*) or (fatty near3 acid* near3 (n-3 or n-6)) or (membran* near2 (hypothes* or neuronal*)) or (evening near3 primrose) or (oil near3 (flax or linseed)) or LIPIDS-AND-ANTILIPEMIC-AGENTS*:ME or FATTY-ACIDS*:ME or FATTY-ACIDS-OMEGA-3*:ME or PHOSPHOLIPIDS*:ME or<BR/>NEUROTRANSMITTERS-AND-NEUROTRANSMITTER-AGENT*:ME or MEMBRANE-LIPIDS*:ME]</P>
<P>1.4 The Cochrane Schizophrenia Group's Register (June 1998)<BR/>We used the phrase:</P>
<P>[(phospholip* or EFA or EPA or MaxEPA or DHA or ALA or omega*) or (acid and (arachi* or docosahex* or fatty)) or (fish and oil*) or (fatty and acid* and (n-3 or n-6)) or (membran* and (hypothes* or neuronal*)) or (evening and primrose) or (oil and (flax or linseed))]</P>
<P>1.5 EMBASE (January 1980 to February 1998)<BR/>We used the Cochrane Schizophrenia Group's terms for randomised controlled trials and for schizophrenia combined with the phrase:</P>
<P>[and (phospholip* or EFA or EPA or MaxEPA or DHA or ALA or omega*) or (acid near1 (arachi* or docosahex* or fatty)) or (fish near3 oil*) or (fatty near3 acid* near3 (n-3 or n-6)) or (membran* near2 (hypothes* or neuronal*)) or (evening near3 primrose) or (oil near3 (flax or linseed)) or explode "FISH-OIL"/ all subheadings or explode "LINSEED-OIL"/ all subheadings or explode "PRIMROSE-OIL"/ all subheadings or explode "ARACHIDONIC-ACID"/ all subheadings or explode "DOCOSAHEXAENOIC-ACID"/ all subheadings or explode "OMEGA-3-FATTY-ACID"/ all subheadings or explode "LIPID-MEMBRANE"/ all subheadings or explode "NERVE-CELL-MEMBRANE"/ all subheadings or explode "FATTY-ACID"/ all subheadings or explode "ESSENTIAL-FATTY-ACID"/ all subheadings or explode "MEMBRANE-PHOSPHOLIPID"/ all subheadings or explode "PHOSPHOLIPID"/ all subheadings]</P>
<P>1.6 MEDLINE on Silver Platter (January 1966 to February 1998)<BR/>We used the Cochrane Schizophrenia Group's terms for randomised controlled trials and for schizophrenia combined with the phrase:</P>
<P>[and (phospholip* or EFA or EPA or MaxEPA or DHA or ALA or omega*) or (acid near1 (arachi* or docosahex* or fatty)) or (fish near3 oil*) or (fatty near3 acid* near3 (n-3 or n-6)) or (membran* near2 (hypothes* or neuronal*)) or (evening near3 primrose) or (oil near3 (flax or linseed)) or explode "FISH-OILS"/ all subheadings or explode "LINSEED-OIL"/ all subheadings or explode "FATTY-ACIDS"/ all subheadings or explode "FATTY-ACIDS,-ESSENTIAL"/ all subheadings or explode "FATTY-ACIDS,-OMEGA-3"/ all subheadings or explode "DOCOSAHEXAENOIC-ACIDS"/ all subheadings or explode "ARACHIDONIC-ACIDS"/ all subheadings or explode "ARACHIDONIC-ACID"/ all subheadings or explode "MEMBRANE-LIPIDS"/ all subheadings or explode "CELL-MEMBRANE"/ all subheadings or explode "SYNAPTIC-MEMBRANES"/ all subheadings or explode "PHOSPHOLIPIDS"/ all subheadings]</P>
<P>1.7 PsycLIT on Silver Platter (January 1974 to February 1998)<BR/>We used the Cochrane Schizophrenia Group's terms for randomised controlled trials and for schizophrenia combined with the phrase:</P>
<P>and (phospholip* or EFA or EPA or MaxEPA or DHA or ALA or omega*) or (acid near1 (arachi* or docosahex* or fatty)) or (fish near3 oil*) or (fatty near3 acid* near3 (n-3 or n-6)) or (membran* near2 (hypothes* or neuronal*)) or (evening near3 primrose) or (oil near3 (flax or linseed)) or explode "FATTY-ACIDS"or explode "PHOSPHATIDES" or explode "LIPIDS" or explode "MEMBRANES" or explode NEUROTRANSMITTERS"]</P>
<P>We also inspected citations for additional terms, and if found we added these to the above searches and repeated the process.</P>
<P>1.8 Cited reference searching<BR/>1.8.1 ISI database - Science Citation Index and Social Science Citation Index<BR/>We sought each of the included studies as a cited reference on the above databases. We then inspected reports of articles that had cited these studies in order to identify further trials.</P>
<P>1.8.2 Reference lists<BR/>We examined the references cited in all included trials in order to identify any missing studies.</P>
<P>1.9 Personal contact<BR/>We contacted the authors of all studies initially selected for inclusion in order to identify further relevant trials.</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2009-02-25 13:14:54 +0000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2009-02-10 12:11:06 +0000" MODIFIED_BY="[Empty name]">Previous update searches</TITLE>
<APPENDIX_BODY MODIFIED="2009-02-25 13:14:54 +0000" MODIFIED_BY="[Empty name]">
<P>1. The update of 2002 and 2005<BR/>1.1 Electronic searches<BR/>We searched the Cochrane Schizophrenia Group's Register (July 2002 and July 2005) with the phrase:</P>
<P>[(*phospholip* or * EFA* or * EPA* or * MaxEPA* or * DHA* or * ALA* or * omega* or *arachi* or *docosahex* or *fish oil* or *fatty acid* or *evening primrose* or *flax* or *linseed* or *eicosapentaenoic* in title, abstract, index terms of REFERENCE)]</P>
<P>The Schizophrenia Groups trials register is based on regular searches of BIOSIS Inside; CENTRAL; CINAHL; EMBASE; MEDLINE and PsycINFO; the hand searching of relevant journals and conference proceedings, and searches of several key grey literature sources. A full description is given in the Group's module.</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2009-02-25 16:39:50 +0000" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2009-01-14 12:52:59 +0000" MODIFIED_BY="[Empty name]">Cochrane Schizophrenia Group trials register search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-02-25 16:39:50 +0000" MODIFIED_BY="[Empty name]">
<P>[(*phospholip* or * EFA* or * EPA* or * MaxEPA* or * DHA* or * ALA* or *omega* or *arachi* or *docosahex* or *fish oil* or *fatty acid* or *evening primr* or *flax* or *linseed* or *eicosapentaenoic* or *polyunsaturat* in title, abstract, index terms of REFERENCE) or (*phospholip* or *docosahex* or *fish o* or *fatty a* or *evening p* or *eicosap* or *polyu* in intervention field in STUDY)]</P>
<P> This register is compiled by systematic searches of major databases, hand searches and conference proceedings (see <A HREF="http://mrw.interscience.wiley.com/cochrane/cochrane_clsysrev_crglist_fs.html">Group Module</A>). The Cochrane Schizophrenia Group Trials Register is maintained on Meerkat 1.5.1. This version of Meerkat stores references as studies. When an individual reference is selected through a search, all references which have been identified as the same study are also selected.  </P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>